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ABSTRACT 
 
Three separate recent publications used genome-wide RNA interference (RNAi) to screen 
for novel host factors that are required for HIV-1 infection and replication. This was 
achieved using small interfering RNAs (siRNAs) to silence the expression of ~21 000 
human genes and determining the effect of each gene’s loss of function on HIV-1 
replication. Collectively, several hundred genes have now been implicated as novel HIV-1 
host factors (termed HIV-1 Dependency Factors, HDFs). However, differences in study 
design resulted in little overlap and limited interpretive value from the three published 
datasets. To identify novel HDFs that are potential targets for anti-HIV therapy, five 
putative HDFs (SPTBN1, TMED2, KIAA1012, PRDM14 and SP110) were chosen for 
validation. RNAi effecters (both siRNAs and expressed short hairpin RNAs) were used to 
silence the selected genes. Gene suppression was measured by quantitative RT-PCR 
assay and two candidate genes were studied further (SPTBN1 and SP110) based on 
efficient mRNA inhibition (over 90%).  As efforts to deliver the RNAi effecters to a T-cell 
line were unsuccessful, the effect of this knockdown on HIV-1 replication (both early- and 
late-stage) was assessed in cultured TZM-bl cells, a HeLa-derived cell line that expresses 
HIV-1 entry receptors and an integrated luciferase reporter for HIV-1 transcriptional 
activity (also used in the first genome-wide RNAi screen). An initial viral challenge assay 
with Subtype C-enveloped pseudovirus showed a 60% decrease in TZM-bl luciferase 
reporter activity in cells with suppressed SPTBN1 function, while knockdown of SP110 
showed no effect on reporter activity. The final experiment, using fully-replicating Subtype 
B virus, showed a 75% decrease in late-stage viral replication when SPTBN1 expression 
was suppressed. In addition, SP110 suppression was confirmed to have no effect on 
TZM-bl reporter activity during any stage of HIV-1 replication. In conclusion, SPTBN1, but 
not SP110, is required for late-stage HIV-1 replication, though these results need to be 
confirmed in CD4+ T-cells. The absence of several important viral accessory factors from 
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the virus used in the genome-wide screen may explain these findings and emphasises the 
need for using physiologically representative viral and cellular models to study the 
viral/cellular interactome. 
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CHAPTER 1 : INTRODUCTION 
 
1.0 Chapter summary 
Acquired Immune-Deficiency Syndrome (AIDS) is an infectious disease caused by 
the Human Immunodeficiency Virus (HIV) that is now a pandemic affecting 33.4 million 
people worldwide, with 5.7 million of these living in South Africa. HIV-1 is a retrovirus that 
makes extensive use of its host cell’s pathways during its replication cycle in cells of the 
immune system. Antiretroviral (ARV) therapies targeting various steps in the HIV-1 
replication cycle can suppress viral activity in infected patients and prevent the onset of 
AIDS (Palella et al., 1998). However, these therapies are not without adverse side effects 
and cannot eradicate latent viral reservoirs. Alternative antiviral strategies include gene 
therapy approaches, the most promising of which uses RNA (ribonucleic acid)  
interference (RNAi) to specifically and potently silence gene expression and thereby 
suppress criticial viral and/or cellular gene functions that are required for efficient HIV-1 
replication (Barichievy et al., 2009). RNAi-based silencing of viral genes has suppressed 
HIV-1 infection in several cellular and animal models. However, the error-prone Reverse 
Transcriptase enzyme of HIV-1 leads to the rapid evolution of mutant strains, resulting in 
resistance developing to both ARVs and RNAi-based therapies in the long term. By 
targeting HIV-1 host factors the risk of viral mutational escape can be alleviated. However, 
several concerns exist regarding the possible side-effects of inhibiting a cellular gene 
function, as well as the existence of functional redundancy in the pathways used by the 
virus.  
Apart from gene therapy applications, RNAi is widely used as a tool to explore 
gene function [reviewed by (Castanotto and Rossi 2009)]. RNAi has been widely used to 
reveal the complex interplay that occurs between cellular and viral gene products during 
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HIV-1 infection and replication. The advent of high-throughput technology has allowed 
RNAi to be used at a genome-wide scale and has resulted in the identification of hundreds 
of novel HIV-1 host factors. However, as the cellular and viral models used in these 
studies do not represent a natural infection validation of these candidate host factors is 
required.  
 
1.1 HIV-1/AIDS 
 
1.1.1 Global and local burden of the AIDS pandemic  
The HIV/AIDS pandemic is placing an increasingly heavy burden on global health, with 
33.4 million people living with the disease worldwide (see Figure 1-1). Over two thirds of 
these people (22.4 million) are living in Sub-Saharan Africa. This region also accounts for 
32% of all new HIV infections and 72% of global AIDS-related deaths (1.9 million and 1.4 
million people, respectively) (UNAIDS 2009). South Africa’s population has the largest 
number of infections in the world (5.7 million people) (UNAIDS 2008). 
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Figure 1-1: The number of people living with HIV/AIDS in each country worldwide 
Just over thirty-three million people are living with HIV/AIDS world-wide. Sub-Saharan Africa’s 
infected population stands at 22.4 million people (UNAIDS 2009). 
 
1.1.2 AIDS pathogenesis 
AIDS is a complex and variable syndrome whose pathogenesis is not yet 
completely understood. However, it is generally characterized by progressive immune 
deficiency that results in susceptibility to viral, bacterial and fungal opportunistic infections 
[reviewed by (El-Atrouni et al., 2006; Martinez and Temesgen 2006; Tsigrelis et al., 
2006)]. AIDS patients also have increased risk of developing tumours of the 
gastrointestinal tract, lungs or skin that are mostly caused by co-infections with oncogenic 
(cancer-causing) viruses like Epstein-Barr Virus, EBV [reviewed by (Angeletti et al., 
2008)]. Finally, neurological symptoms (including encephalopathies, meningitis and AIDS 
dementia complex) often develop in late-stage AIDS patients [reviewed by (Levy et al., 
1985; Navia et al., 1986)], as well as non-specific symptoms like weight-loss, diarrhea and 
fevers.  
The course of the disease begins with an acute stage following HIV-1 infection, 
progresses to a chronic asymptomatic stage that can last for 10 years or more and 
culminates in the clinical symptoms of AIDS and subsequent death. During the acute 
stage, high levels of virus target the T-helper lymphocytes that express the CD4 (cluster of 
differentiation 4) surface marker and cause them to undergo apoptosis (programmed cell 
death) (Laurent-Crawford et al., 1991; Lu et al., 1994). The immune system is in a 
chronically activated state throughout the course of the infection, contributing to the virus-
mediated depletion of CD4+ T-cell numbers (Hazenberg et al., 2003), especially those 
bearing the CCR5 (C-C chemokine receptor type 5) marker that are concentrated in the 
gut mucosal lining, but also newly generated in the thymus and circulating in peripheral 
blood (Brenchley et al., 2004). As the T-helper cells are critical for an effective immune 
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response, their loss is directly involved in the progression of the disease. When the CD4+ 
T-cell count becomes lower than 200 cells per microlitre of blood, signs and symptoms of 
AIDS generally ensue (Hogg et al., 2001).  
 
1.1.3 The HIV-1 replication cycle 
HIV-1 is a retrovirus (i.e. a virus with an RNA genome that is converted to DNA 
(deoxyribonucleic acid) by its Reverse Transcriptase (RT) enzyme during replication) that 
was discovered over 25 years ago (Barre-Sinoussi et al., 1983) and associated with 
causing AIDS not long after (Gallo et al., 1984). A brief summary of the HIV-1 replication 
cycle follows: Firstly, the enveloped virus recognizes and binds to entry receptors on its 
target cells, which include T-helper lymphocytes, macrophages, dendritic cells and 
microglial cells of the neural system (Klatzmann et al., 1984; Macatonia et al., 1990; 
Watkins et al., 1990; Kalter et al., 1991). This leads to fusion of the viral envelope with the 
cell membrane and subsequent entry (Stein et al., 1987). Once inside the cell, the virus 
sheds its coat (made of capsid, CA, proteins) and forms a reverse transcription complex 
(RTC) to convert the two copies of its single-stranded RNA genome into double-stranded 
DNA by viral RT (Bukrinsky et al., 1993). The resulting pre-integration complex (PIC) is 
then trafficked towards the nucleus where import of the PIC occurs for subsequent 
integration (mediated by viral Integrase, IN) of the viral DNA into the host genome (Farnet 
and Haseltine 1991; Bukrinsky et al., 1992; Bukrinskaya et al., 1996).  
Viral gene expression requires the initial transcription and translation of the Tat 
regulatory protein, which then causes transactivation (via the transactivation response, 
TAR, loop) for high-level long terminal repeat (LTR)-driven transcription  of the viral genes 
encoding the accessory factors Vif (viral infectivity factor), Vpu (viral protein U), Vpr (viral 
protein R) and Nef (negative regulatory factor), the Env (envelope) and Gag (group-
specific antigen) structural proteins and the Pol-encoded RT / ribonuclease (RNase) H 
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integrase (IN) and protease (PR) enzymes (see Figure 1-2) (Sodroski et al., 1985; Fisher 
et al., 1986). The Rev regulatory protein plays an important role in allowing partially 
spliced and unspliced viral transcripts to exit the nucleus for subsequent translation and 
processing of viral proteins (Malim et al., 1989; Kjems et al., 1991). The Gag and Env 
proteins are transported to the membrane where the RNA genome and other viral factors 
are encapsulated. As the assembled viral components bud outward from the host 
membrane (which has viral Env proteins embedded in it) a new virion is formed (Bugelski 
et al., 1995). During budding, virion maturation occurs when the PR enzyme cleaves the 
Pol and Gag precursor proteins into their subunits, readying the virus for infection of a 
new cell (Peng et al., 1989).  
 
 
Figure 1-2: HIV-1 genome structure. 
Depiction of HIV-1’s nine open reading frames (ORFs) — Gag, Env, Pol, Tat, Rev, Vpu, Vif, Vpr 
and Nef — flanked by long terminal repeats (LTRs) in the HIV-1 genome. Group-specific antigen 
(Gag) polyprotein is cleaved to form MA (p17 matrix protein), CA (p24 capsid protein), NC (p7 
nucleocapsid protein) and p6. Pol encodes the viral enzymes protease (PR), reverse transcriptase 
(RT)/RNase H and integrase (IN). The envelope protein (Env) has surface (SU, gp120) and 
transmembrane (TM, gp41) subunits); Vif, Vpr, Vpu and Nef are viral accessory proteins while Tat 
and Rev are viral regulatory proteins (Robinson 2002). 
 
1.2 Host factors required for HIV-1 replication 
Apart from the viral gene functions decribed above, several host factors have been 
shown to be involved in each stage of HIV-1 infection and replication (Goff 2007). An 
overview of these factors is given below as a background to the novel host factors that 
were validated in this study. While small RNA species (microRNAs, miRNAs) of viral and 
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cellular origin, as well as dozens of cellular and humoral immune system factors, have 
been shown to be involved in regulating viral replication (Kaur and Mehra 2009; Mothe et 
al., 2009; Ouellet et al., 2009), these factors are not included in this overview, as they are 
not the focus of this study. 
 
1.2.1 Entry  
During cellular entry of HIV-1, the viral Env glycoprotein, gp120, binds to host 
receptor CD4 and a chemokine co-receptor, mostly CCR5 or CXCR4 (C-X-C chemokine 
receptor 4) (Doranz et al., 1997), which are brought into close proximity by F-actin 
(Iyengar et al., 1998), whose movement is regulated by moesin of the exrin-radixin-
moesin protein family (Barrero-Villar et al., 2009), within cholesterol-rich lipid 
microdomains (Manes et al., 2000; Liao et al., 2001). Actin and myosin drives the 
movement of CD4-bound virus particles along filopodia from the cell periphery to the cell 
body where fusion occurs between the lipid bilayers of the viral envelope and the plasma 
membrane (Lehmann et al., 2005). The viral fusion protein (gp41) recruits a guanine 
nucleotide exchange factor (GEF) for the Rho GTPase, which together with CXCR4-
activated cofilin (actin depolymerizing factor), acts to remodel the cortical actin barrier 
beneath the plasma membrane at the fusion site (Zhang et al., 1999; Yoder et al., 2008). 
The viral accessory protein, Nef, also appears to enable the entering viral capsid to cross 
this actin barrier (Campbell et al., 2004). In addition, histone deacetylase (HDAC) 6 is 
activated that stabilizes microtubules, possibly for anchoring the fusion pore (Westermann 
and Weber 2003; Valenzuela-Fernandez et al., 2005).  
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1.2.2 Uncoating and Reverse Transcription 
Uncoating of the viral capsid after entry is mediated by cyclophilin A (CypA) and 
Tripartite motif-containing (TRIM) 5α. These host factors recognize and bind viral CA 
protein and promotes its premature disassembly ((Luban et al., 1993; Braaten et al., 1996; 
Sokolskaja et al., 2004; Chatterji et al., 2006; Stremlau et al., 2006). While human TRIM5α 
weakly affects HIV-1, other species’ orthologues have more potent effects (Stremlau et 
al., 2005). It appears that activation of the actin polymerization nucleator, Arp2/3 (Komano 
et al., 2004) is required for subsequent short-range actin-driven transport of the viral 
capsid to microtubule tracks where the RTC is formed (Bukrinskaya et al., 1998). 
Subsequently, viral nucleocapsid (NC) protein (which coats the RNA) recruits the cellular 
tRNALys primer to the viral primer binding site for initiation of cDNA synthesis (Chan and 
Musier-Forsyth 1997).  
Reverse transcription is downregulated by APOBEC3G/F (apolipoprotein B 
mRNA-editing enzyme, catalytic polypeptide-like 3G and F). This cytidine deaminase 
converts cytosines to uracils during reverse transcription, resulting in DNA that is either 
degraded by cellular uracil-DNA glycosidases and repair enzymes (Mangeat et al., 2003) 
or has G-A hypermutations (Lecossier et al., 2003). In addition, APOBEC3G is 
incorporated into virions where it hinders subsequent rounds of infection. However Vif 
(viral infectivity factor) counteracts this action by binding it, inducing its degradation and 
preventing incorporation into virions (Sheehy et al., 2002; Stopak et al., 2003). 
 
1.2.3 Inward trafficking and nuclear import  
Trafficking of the PIC to the nuclear pore appears to occur by retrograde 
microtubule transport, probably using dynein motors (McDonald et al., 2002). 
Subsequently, the PIC is actively transported across the nuclear envelope, an aspect that 
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enables HIV-1 (and other lentiviruses) to infect non-dividing cells where the nuclear 
envelope is not fragmented during mitosis. Several host factors have been suggested as 
being required for nuclear import, including importin 7, a nuclear import receptor for 
ribosomal RNA and histones (Fassati et al., 2003), Nup98, a component of the nuclear 
pore complex (Ebina et al., 2004), as well as transfer RNAs (tRNAs) and their precursors 
(Zaitseva et al., 2006), which may act as transport carriers. 
 
1.2.4 Integration  
Integration comprises processing of the 3’ ends of the viral DNA just after reverse 
transcription, followed by strand transfer in the nucleus and subsequent repair of the 
recombination intermediate. Integration is mainly controlled by viral IN via its interaction 
with host LEDGF (lens epithelium-derived growth factor)/p75 and BAF (barrier to auto-
integration factor). Other IN-interacting host factors include INI1 (integrase interactor 1) 
(Kalpana et al., 1994) and hRAD18 (Mulder et al., 2002). 
LEDGF is a nuclear transcriptional co-activator that acts as a chromatin-
associated receptor for the PIC (Emiliani et al., 2005; Llano et al., 2006b). It interacts with 
IN (thereby preventing its degradation by the proteasome – (Llano et al., 2004) and directs 
proviral integration to active transcription units (Cherepanov et al., 2003; Ciuffi et al., 
2005). RNAi-mediated knockdown studies, as well as knockout mutant and 
overexpression studies, show an essential role for LEDGF in HIV-1 infection (Llano et al., 
2006a; Vandekerckhove et al., 2006; Shun et al., 2007). 
BAF prevents intramolecular integration of the viral DNA by compacting the cDNA 
and forming DNA-protein structures on the HIV-1 long terminal repeat (LTR) ends for 
insertion of the provirus into the host chromosome (Lee and Craigie 1994; Chen and 
Engelman 1998). LAP2α, a laminin-associated component of nuclear membrane, binds to 
BAF. Both are components of the PIC and are required for productive integration 
9 
 
(Shumaker et al., 2001; Lin and Engelman 2003). In addition, emerin (a component of the 
inner nuclear membrane that interacts with BAF) seems to mediate association of the PIC 
with chromatin thus promoting integration (Lee et al., 2001; Bengtsson and Wilson 2006). 
 
1.2.5 Transcription 
A vast network of 183 nuclear proteins that interact with the HIV-1 Tat 
transcriptional activator protein in vitro (i.e. in cultured cells) has recently been described 
(Gautier et al., 2009). This Tat interactome could be subdivided into functional modules 
including transcriptional activators, transcriptional repressors, replication and chromosome 
organization factors and nuclear structure components. Several transcription factor 
binding sites occur in the integrated viral DNA that modify the surrounding chromatin to 
control transcriptional activity by recruiting HATs (histone acetyltransferases) and HDACs. 
Some of the most well-known factors are members of the Sp1 (Harrich et al., 1989) and 
NF-κB signaling pathways (Kawakami et al., 1988).  
PCAF (p300/CBP-associated factor) (Deng et al., 2000) and TRBP (TAR RNA 
binding protein) (Gatignol et al., 1991) recruit Tat and bind the HIV-1 TAR loop, 
respectively. Cyclin T1 and cyclin-dependant kinase 9, CDK9 (subunits of the positive 
transcriptional elongation factor b complex, P-TEFb) (Bieniasz et al., 1998) are recruited 
by Tat to relieve RNA Polymerase II stalling for the production of full-length viral 
transcripts (Yankulov and Bentley 1998). Recently, integrase interactor 1 (INI1), the key 
subunit of the SWI/SNF (switch/sucrose non-fermentable) chromatin remodeling complex, 
was found to downregulate basal LTR promoter activity and may induce one of two states 
post-integration: either latency or high-level, Tat-dependant gene expression (Boese et 
al., 2009). 
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1.2.6 RNA processing and export 
The transcribed 9 kb viral RNA encoding the Gag and Gag-Pol precursor protein 
can be spliced to a 4 kb RNA encoding Vif, Vpr, Vpu and Env or further spliced to a 2 kb 
RNA encoding Tat, Rev and Nef (Schwartz et al., 1990; Purcell and Martin 1993). HIV-1 
RNA splicing is controlled by viral exonic splicing silencers (ESS) and an intronic splicing 
silencer (ISS) that are bound by the cellular hnRNP (heterogeneous nuclear 
ribonucleoprotein) A/B family (Bilodeau et al., 2001) or by hnRNP H. In addition, viral 
exonic splicing enhancers (ESE) are bound by the host SR (serine-arginine) proteins 
(Stoltzfus and Madsen 2006). HIV-1 Tat-specific factor 1 (HTATSF1), previously defined 
as a Tat regulatory factor (Zhou and Sharp 1996) has recently been shown not to function 
in stimulation of transcription but rather in regulating the relative levels of spliced and 
unspliced viral transcripts ((Miller et al., 2009). 
The fully-spliced 2 kb RNA encoding Rev is exported to the cytoplasm for 
translation, after which Rev shuttles back to the nucleus and binds the Rev-responsive 
element (RRE) in the introns of the 9 kb and 4 kb RNAs. The nuclear export signal of Rev 
then allows the bound RNA to be exported via the Ran-CRM1 (exportin 1) pathway 
(Fridell et al., 1996), involving host factors Rev-interacting protein, hRIP (Bogerd et al., 
1995), Ran binding protein 1, RanBP1 (Zolotukhin and Felber 1997) and Sam68 (Reddy 
et al., 1999). A Rev-independent RNA export pathway using the constitutive transport 
element (CTE) can also be used (Bray et al., 1994) that relies on host factors Sam68, 
transcytosis-associated protein (TAP) and RNA helicase A (Tang et al., 1997; Li et al., 
1999; Reddy et al., 2000).  
 
11 
 
1.2.7 Translation, processing and trafficking 
HIV-1 can use cap-independent translation by means of an internal ribosomal 
entry site (IRES) in its 5’ untranslated region (UTR) (Brasey et al., 2003) and in the Gag 
ORF (Buck et al., 2001). This appears to be the favoured mode of translation as the viral 
PR inhibits a crucial host factor for cap-dependant translation, eukaryotic translation 
initiation factor 4GI, eIF4GI (Ventoso et al., 2001). Finally, for Gag-Pol translation to occur, 
an RNA pseudoknot forms that allows for read-through of the Gag stop codon by inducing 
a translational frameshift (Kang 1998). 
The viral structural protein precursors, Gag and GagPol are translated in the 
cytoplasm on soluble polysomes and then directly transported to the membrane where 
multimerization (promoted by host ATP-binding cassette, sub-family E (OABP), member 1 
- HP68/ABCE1 (Zimmerman et al., 2002)) causes a conformational change that increases 
its affinity for the membrane (Lindwasser and Resh 2001; Lingappa et al., 2006). 
Membrane trafficking of Gag is inhibited by TRIM22 that is induced by the Type I 
Interferon response (Barr et al., 2008). In addition, Gag appears to bud into intracellular 
vesicles for release from the cell by budding exosomes (Gould et al., 2003; Perlman and 
Resh 2006). This pathway is especially important in macrophages (Nguyen et al., 2003, 
Pelchen-Matthews et al., 2003) and requires the adaptor protein AP-3 for sorting into 
endosomes (Dong et al., 2005). Recently, the role of dynein motor complexes and late 
endosomes in trafficking the viral RNA genome and Gag for virion production has been 
shown (Lehmann et al., 2009). 
Although Env and Gag trafficking to the membrane can occur independently, when 
co-expressed they affect each other’s localization (Lodge et al., 1997; Bhattacharya et al., 
2006). The Env protein is trafficked via the Golgi body after translation by ribosomes 
bound to the endoplasmic reticulum (ER). During transit, it forms a trimer, is processed 
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into its subunits (gp120 and gp41) by cellular endoproteases and is modified by 
glycosylation (Earl et al., 1991).  
 
1.2.8 RNA encapsulation and assembly 
Virion assembly and release is driven by the viral NC protein that stabilizes and 
encapsulates the RNA genome during virion formation. Incorporation of the Env proteins 
and assembly at the membrane occurs on cholesterol-enriched microdomains or lipid rafts 
(Ono and Freed 2001) and requires the 47-kDa tail interacting protein, TIP47 (Blot et al., 
2003). As the entry receptor CD4 inhibits Env incorporation, it is down-modulated by viral 
Nef, Vpu and Env soon after entry (Chen et al., 1996). Several host proteins are also 
incorporated into the virion: These include cyclophilin A, CypA (Franke et al., 1994), 
APOBEC3G (Mariani et al., 2003), tumour susceptibility gene 101, TSG101 (Garrus et al., 
2001) and vacuolar protein sorting 28, Vps28 (Hammarstedt and Garoff 2004), immune 
molecules HLA-DR (human leukocyte antigen DR), β2-microglobulin and MHC (major 
histocompatibility complex) class I proteins (Orentas and Hildreth 1993; Tremblay et al., 
1998), as well as heat shock protein 70, Hsp70 (Gurer et al., 2002), INI1/SNF5 (Yung et 
al., 2001) and lysyl-tRNA synthetase (Kleiman et al., 2004). These factors are either 
passively incorporated (by being embedded in the part of the plasma membrane that buds 
off) or included due to functional interactions with various viral products. 
 
1.2.9 Virion budding  
Budding is mediated by the endosomal sorting complex required for transport 
(ESCRT) components I, II and III (Usami et al., 2009). Briefly, this machinery is recruited 
to the plasma membrane by Gag, which is ubiquitylated at low frequency (Gottwein and 
Krausslich 2005), via its associations with AIP1 (atrophin-interacting protein 1) (Strack et 
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al., 2003) and TSG101, a component of the Class E vacuolar protein sorting (VPS) 
machinery (Garrus et al., 2001; VerPlank et al., 2001). Several other VPS proteins, as well 
as the charged multivesicular body (MVB) proteins, CHMPs, that form the ESCRT III 
complex are involved in mediating efficient viral budding (Zamborlini et al., 2006).  
Other host factors involved in the process include Gag-interacting annexin II 
(Ryzhova et al., 2006) and endophilins that interact with the ESCRT machinery and 
induce membrane curvature for virion budding (Farsad et al., 2001). Tetherin (BST-2) has 
recently been shown to inhibit the spreading and release of budding viral particles. One of 
the membrane-spanning domains of this protein is embedded in the viral envelope while 
the other is anchored in the host cell membrane, effectively ―tethering‖ the virions to the 
host cell. This action is countered by viral Vpu that causes proteasomal degradation of 
tetherin, as well as CD4 (Bour et al., 1999; Levesque et al., 2003), via the β-TrCP2-
dependent pathway (Neil et al., 2008; Douglas et al., 2009; Mangeat et al., 2009).  
 
1.2.10 Virus transfer 
Mature virus passes between cells mainly by the formation of virological synapses 
(Jolly and Sattentau 2004) that are induced by Env-CD4-coreceptor interactions and Env-
induced activation of lymphocyte function-associated antigen 1, LFA1 (Arthos et al., 
2008). Other requirements include actin and tubulin cytoskeletal rearrangements, 
polarization of the microtubule organizing centre (MTOC) and junction stabilization by 
cellular adhesion molecules (Chen et al., 2007; Jolly et al., 2007). These can form 
between T-cells (Jolly et al., 2004) and T-cells and dendritic cells (Stoll et al., 2002; 
McDonald et al., 2003).  
Viral transfer between HIV-1 CD4+ T-cells is promoted by trafficking of Env and 
Gag to tetraspanin-enriched membrane domains for assembly and budding (Jolly and 
Sattentau 2007). Dendritic cells can take up virus particles by the C-type lectin, DC-SIGN 
14 
 
(dendritic cell-specific ICAM3 (intercellular adhesion molecule 3)-grabbing non-integrin) 
(Geijtenbeek et al., 2000) that internalizes the virus into endocytic vesicles without 
becoming infected. When contact is made with a CD4+ T-cell, the virus is passed to the T-
cell across a virological synapse mimicking the process of antigen presentation across an 
immunological synapse (McDonald et al., 2003). Polysynapses have also been described 
whereby virus is passed from one infected T-cell to multiple target cells (Rudnicka et al., 
2009). Other modes of virus transport across cell-to-cell contacts use tunneling nanotubes 
(Sherer and Mothes 2008; Sowinski et al., 2008) and filopodial bridges (Sherer et al., 
2007) as physical cellular extensions for virus transfer. 
 
1.3 Current approaches to managing HIV-1/AIDS 
 
The last 25 years have seen the development of several classes of ARV therapies 
that target various steps of the HIV-1 lifecycle. These include eight nucleoside/nucleotide 
analogues that inhibit viral RT activity [reviewed by (Cihlar and Ray 2010)], four non-
nucleoside RT inhibitors [reviewed by (de Bethune 2010)] and nine approved PR inhibitors 
[reviewed by (Wensing et al., 2010)]. In addition, inhibitors of viral entry and fusion (by 
maraviroc and enfuvirtide, respectively) [reviewed by (Tilton and Doms 2010)] and one 
targeting integration (raltegravir) have recently been approved, while another IN strand-
transfer inhibitor (called elvitegravir) [reviewed by (McColl and Chen 2010)] is currently 
undergoing clinical trials. ARVs are the only available treatment options at present. These 
drugs effectively suppress HIV-1 replication when their regimen is adhered to consistently. 
However, adverse reactions in some patients, as well as poor access to the drugs in 
developing countries, often results in non-compliance to treatment (Deeks 2006).  
HIV-1’s relatively short lifecycle (1.5 days) and low-fidelity RT enzyme contribute to 
an uncommonly high viral mutation rate of ~2 x 10-5 mutations per base per replication 
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cycle (Huang and Wooley 2005). This leads to rapid evolution of viral escape mutations 
during single-drug therapy resistance to all known ARVs. In response, a highly active 
antiretroviral therapy (HAART) treatment programme was developed, in which two or 
more drugs (usually from different classes) are combined. HAART has been very 
successful, particularly in developed countries, at reducing the morbidity and mortality of 
HIV/AIDS (Palella et al., 1998). The extensive development of ARVs has provided both 
first-line therapies (for previously untreated, ARV-naïve, patients) and second-line options 
for those that develop resistance or do not respond to initial therapy, while new drugs 
continue to be tested for efficacy from each ARV class (McColl and Chen 2010). However, 
as HAART cannot prevent viral resistance developing (particularly in non-compliant 
patients) nor eradicate latent reservoirs of transcriptionally silent integrated provirus 
(Pierson et al., 2000) novel approaches are constantly being sought.   
While the United States Food and Drug Administration (US FDA) have yet to 
approve a single vaccine for clinical use (AIDSinfo 2008), there are currently around 30 
vaccine candidates being tested for clinical efficacy (IAVI 2010). In November 2007, the 
field was dealt a major blow when advanced clinical trials (Human Phase 2b) of the Merck 
vaccine (based on Ad5 – Adenovirus Type 5) were halted. The vaccine could neither 
prevent infection nor lower viral load in infected patients, while potentially increasing the 
risk of infection (Watkins et al., 2008). As a result, the focus has shifted to basic research 
of alternative strategies, including gene therapy. While catalytic ribozymes, antisense 
molecules, aptamers and RNA decoys have all been used to good effect to target HIV-1 
[reviewed by (Sherer et al., 2007; Reyes-Darias et al., 2008)], the most exciting advances 
have been in using the molecular tool RNA interference (RNAi) for the specific silencing 
(termed knockdown) of any gene of choice.  
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1.4 RNA interference (RNAi) 
 
1.4.1 The endogenous RNAi pathway  
The Nobel prize-winning discovery of gene silencing in nematode worms mediated 
by double-stranded RNA, termed RNAi (Fire et al., 1998), was followed by the finding that 
21-base pair (bp) small RNA duplexes (termed small interfering RNAs, siRNAs) could 
direct sequence-specific inhibition of mammalian genes with complementary sequences 
(Elbashir et al., 2001). Subsequently, this inhibition was found to occur via the same 
pathway that generates 21-23 nt microRNAs (miRNAs), of which more than 700 have now 
been cloned, according to miRBase (Griffiths-Jones et al., 2008). These sequences have 
diverse functions in development and cellular physiology [reviewed by (Bala et al., 2009; 
Coolen and Bally-Cuif 2009; Iorio and Croce 2009; Liang and Qin 2009; Yang et al., 
2009)].  
Both siRNAs and miRNAs are processed by RNAse III-like endonucleolytic 
complexes in the multi-step RNAi pathway (Figure 1-3). Genome-encoded long RNA Pol 
II-derived primary miRNA (pri-miRNA) transcripts fold into an imperfect hairpin structure 
that is cleaved by the Micro-processor complex comprising of the Drosha nuclease and its 
cofactor, DGCR8 (DiGeorge critical region-8) (Lee et al., 2003; Gregory et al., 2004; Han 
et al., 2004; Lee et al., 2004). The mechanism by which Drosha ―measures‖ the duplex 
before cleavage is still under debate (Han et al., 2006; Zeng and Cullen 2006), but this 
process has recently been shown to occur during transcription in association with 5'-3' and 
3'-5' exonucleases that degrade intronic sequences before splicing occurs (Morlando et 
al., 2008). In addition, mirtrons (a subclass of miRNAs within intronic sequences) are not 
processed by Drosha at all but are rather generated during the splicing reaction (Okamura 
et al., 2007; Ruby et al., 2007).  
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Figure 1-3: The mammalian RNAi pathway.  
Long primary microRNA (pri-miRNA) transcripts form hairpin structures that are recognised and 
cleaved by the nuclease Drosha and its cofactor DGCR8. The resulting pre-miRNAs are exported 
from the nucleus and subsequently processed by Dicer/TRBP (HIV TAR RNA binding protein) into 
~22-nt mature miRNAs with 5’ phosphates and 2 nucleotide overhangs on the 3’ end. The strand 
with the thermodynamically most unstable 5’ end is incorporated into an RNA-induced silencing 
complex (RISC) as a guide strand, leading the complex to target mRNAs of complementary 
sequence for cleavage by Ago2 (in the case of perfect complementarity) or translational 
suppression (imperfect binding).  
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The ~70 nucleotide (nt) pre-miRNAs generated by Drosha processing are exported 
from the nucleus by G protein-coupled Exportin 5 (Yi et al., 2003; Lund et al., 2004). In the 
cytoplasm, these pre-miRNAs are further processed by Dicer and its cofactors TRBP, a 
factor that provides an interesting link between HIV-1 and RNAi, which may be used by 
the virus to subvert the RNAi machinery and prevent downregulation of viral gene 
expression (Bennasser et al., 2006), and the protein, PACT (Kok et al., 2007). Dicer 
―measures‖ 21-22-nt from the Drosha cleavage site to create mature miRNAs with 5’ 
phosphates and 3’ 2-nt overhanging ends (Bernstein et al., 2001; Hutvagner et al., 2001). 
Double-stranded RNA is similarly processed into 21-25 nt siRNAs. Subsequently, the 
duplex is unwound (by an unknown helicase) and one strand (the mature miRNA or guide 
strand) is incorporated into the RNA-induced silencing complex, RISC (Gregory et al., 
2005), selected based on the relative thermodynamic stability of the duplex ends 
(Khvorova et al., 2003; Schwarz et al., 2003).  
Perfect complementarity with the guide sequence results in target mRNA cleavage 
by the Argonaute (Ago) 2 component of the RISC (Chendrimada et al., 2005), while 
imperfect binding mediates translational suppression and mRNA destabilization [reviewed 
by (Ma et al., 2009)]. The most important sequence in the latter mechanism is the ―seed‖ 
or ―nucleus‖, a seven base-pair region at the 5’ end of the guide strand extending from 
nucleotides 2 to 8 (Doench and Sharp 2004). miRNA seed region matching allows a 
single miRNA to potentially target hundreds of genes, usually in their 3’ untranslated 
regions (Grimson et al., 2007). When these genes are regulators of transcription or 
alternative splicing themselves, the compound effect of the miRNA on gene regulation can 
become complex [reviewed by (Makeyev and Maniatis 2008)]. The exact mechanism of 
miRNA translational suppression is incompletely understood  but seems to include 
deadenylation of poly-A tails and decapping (or inhibiting 5’ cap recognition) of mRNA that 
leads to destabilisation and exonuclease degradation, respectively, as well as inhibition of 
the translation initiation machinery [reviewed by (Ma et al., 2009)]. 
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The mechanisms described above mediate post-transcriptional gene silencing by 
the RNAi pathway. Recently, a novel transcriptional gene silencing process in the nucleus 
has been described, whereby promoter-targeted siRNAs induce chromatin modifications 
associated with transcriptional silencing, including histone 3 lysine 9 (H3K9) dimethylation 
and H3K27 trimethylation (Mette et al., 2000; Morris et al., 2004; Strunnikova et al., 2005; 
Weinberg et al., 2006). Although the exact mechanisms are still unclear, Ago1, DNA 
methyltransferase 3a (DNMT3a) and HDAC1 appear to initiate siRNA-mediated 
transcriptional gene silencing, TGS, while DNMT1 is necessary for maintaining the 
silencing effect (Hawkins et al., 2009). In addition, Ago1 and the Polycomb group 
component, EZH2, were associated with miRNA-mediated TGS of the polymerase (RNA) 
III (DNA directed (POLR3D) cell cycle gene promoter [reviewed by (Kim et al., 2008)]. 
There is some controversy as to whether TGS targets the DNA or associated RNA of the 
promoter (Verdel et al., 2004; Han et al., 2007). Finally, as the silencing mediated by TGS 
is stabler than PTGS and also heritable, the prospect of its application in gene therapies is 
great. Recently, prolonged TGS of a sequence within the HIV-1 LTR promoter has been 
reported in a T-cell line model using a retrovirally delivered shRNA (Turner et al., 2009). 
 
1.4.2 RNAi as a reverse genetics tool 
The RNAi pathway can be harnessed for use as a molecular tool by exogenously 
introducing synthetic siRNAs or vectors that express short hairpin RNAs (shRNAs) that 
enter the miRNA pathway post- and pre-Dicer processing, respectively. These 
shRNAs/siRNAs can be engineered for targeting specific genes for knockdown, which has 
rapidly become the most popular reverse genetic approach to studying gene function. 
Some of the organisms in which this approach has recently been used include: mammals 
(in vitro) (Chen et al., 2010; Shahbazian et al., 2010; Zalckvar et al., 2010), invertebrates 
(Posnien et al., 2009; Rehm et al., 2009; Yang et al., 2010), yeast (Hoffmann et al., 2009; 
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Bolz et al., 2010), plants (Petsch et al., 2009; Zhang et al., 2009), protoplasts (Zhai et al., 
2009), parasites (Stephens et al., 2007; de la Fuente et al., 2010; Verner et al., 2010) and 
viruses (Heikkila et al., 2010; Hirsch 2010; Karlas et al., 2010). The advantage of RNAi 
over previous approaches like mutagenesis screens and mouse knock-out models is that 
it is far simpler, quicker and less costly to implement (even at a genome-wide scale) while 
providing potent gene inhibition to study loss-of-function effects.  
 
1.4.3 RNAi as an exciting and powerful new gene therapy 
Apart from functional studies, novel gene therapy strategies based on RNAi have 
been developed and even patented  for a wide range of diseases [reviewed by (Grinberg 
2008)]. These include neurodegenerative diseases [reviewed by (Farah 2007)], cancers 
[reviewed by (Ashihara et al., 2009)], respiratory disorders like asthma [reviewed by 
(Huang and Chiang 2009)], cardiovascular disease (Hu et al., 2009; Qiu et al., 2009) and 
infectious diseases (Yokota et al., 2007; Gao et al., 2008; Lambeth et al., 2009). Because 
of the ease with which RNAi effectors can be designed (using bioinformatic approaches) 
to target any gene, it is now possible to develop therapeutics for targets that have before 
now been declared ―undruggable‖, as well as for diseases that are rare or newly 
emerging. Moreover, diseases that manifest early or are heritable can be addressed by 
the advent of delivery of RNAi to human embryonic stem cells (HESCs) [reviewed by 
(Rassouli and Matin 2009)]. These cells are not only pluripotent (i.e. differentiate into 
every cell type during development) but also self-renewable (Thomson et al., 1998), 
making RNAi-modified HESCs an attractive prospect for treating degenerative disorders.  
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1.5    RNAi approaches targeting HIV-1 
 
There have been numerous studies using RNAi to silence HIV-1 gene expression, 
including the gag, pol, vif, tat, rev, env and nef genes and the LTR promoter region 
(Coburn and Cullen 2002; Hu et al., 2002; Jacque et al., 2002; Park et al., 2003; Boden et 
al., 2004; Das et al., 2004). However, the high viral mutation rate makes it difficult to 
develop antiviral RNAi therapies with long-lasting efficacy. As with antiretroviral drug 
resistance, escape mutants arise rapidly to evade RNAi-mediated targeting, via single 
base changes within the target region or by evolving secondary structures that render the 
target region inaccessible (Boden et al., 2003; Das et al., 2004; Westerhout et al., 2005). 
In response, researchers have combined shRNAs targeting several highly conserved viral 
regions simultaneously (ter Brake et al., 2006), while multiple siRNAs targeting gag, pol, 
int and vpu conserved sequences have been shown to effectively inhibit various strains of 
HIV-1, as well as viral replication in a chronically infected cell line and in primary human 
peripheral blood lymphocytes (Chang et al., 2005). Finally, a combination of three potent 
shRNA sequences that target highly conserved HIV-1 sequences was recently shown to 
inhibit replication of a HIV-1 molecular clone in shRNA vector-transduced T-cells without 
viral escape for more than three months (von Eije et al., 2009).  
The relative advantages and disadvantages of using siRNAs versus shRNA 
expression vectors in this setting are well reviewed (Subramanya et al., 2010). The main 
issues raised are that siRNAs mediate transient knockdown (a few days), are not 
effectively delivered to T-cell or macrophage primary cells and cannot be incorporated into 
combinatorial therapies, while shRNAs are more time-, cost- and labour-intensive to 
produce and when stably expressed from lentiviral (HIV-derived) vectors pose safety 
concerns. 
 
22 
 
1.5.1 Viral versus cellular targets 
An alternative strategy to prevent viral escape from RNAi is to target cellular genes 
that HIV-1 requires for efficient replication. While HIV-1 can evade RNAi effectors 
targeting its own genome with relative ease, targeting essential HIV-1 host factors would 
require the virus to evolve a novel or alternate method of exploiting the host cellular 
pathways. Another advantage to this approach is that the problem of eradicating latent 
integrated provirus may be overcome by targeting host factors involved in pre-integration 
stages of the replication cycle. Disadvantages of targeting host factors include HIV-1’s 
ability to exploit multiple cellular pathways in parallel. This redundancy that has evolved 
between host and pathogen creates networks of interactions that are difficult to define and 
interrupt via therapeutic means. Targeting host genes may also have detrimental side-
effects on normal cellular function: while knockdown of both CD4 and CXCR4 have been 
shown to inhibit HIV-1 replication (Martinez et al., 2002; Novina et al., 2002; Park et al., 
2002), CD4 is essential to immune function while CXCR4 is important for hematopoietic 
stem cell function and differentiation, thus limiting these factors’ value as good therapeutic 
targets (Moore 1997; Lapidot and Kollet 2002). In contrast, the CCR5 entry co-receptor 
poses an attractive target for several reasons: 1) it is not essential for immune function, 2) 
individuals with a 32 base-pair genetic deletion (CCR5Δ32) are healthy and 3) these 
individuals either resist HIV-1 infection (if homozygous for the deletion) or progress much 
slower to AIDS (heterozygous carriers) (Samson et al., 1996; Eugen-Olsen et al., 1997; 
Garred et al., 1997). Indeed, a recent report shows that transplantation of CCR5Δ32 stem 
cells to an HIV-1 infected patient inhibited the virus to undetectable levels for 20 months 
after the transplant, without HAART (Hutter et al., 2009). The only apparent drawback of 
targeting this factor is that HIV-1 switches tropism during infection from using CCR5 as 
coreceptor to CXCR4 (Arien et al., 2006). In addition, a recent study in South Africa has 
shown a concerning increase in primary HIV-1 strains that use CXCR4 as entry co-
receptor (Connell et al., 2008). However, by targeting conserved viral sequences in 
23 
 
addition to such cellular factors a more potent and durable therapy is made possible. As 
more host factors are identified and characterised, a greater diversity of such therapies 
can be developed.  
 
1.6 Genome-wide siRNA screens for novel HIV-1 host factors 
 
Before the development of genome-wide libraries of RNAi effectors approximately 
50 host factors were known to be involved in regulating HIV-1 replication [reviewed by 
(Goff 2007)]. Since then, high-throughput technology and robotic systems have developed 
that have been used in several genome-wide siRNA screens in the last two years. These 
screens have collectively implicated several hundred novel host factors that appear to be 
involved in HIV-1 replication, effectively leap-frogging our understanding of this process. 
The first published study (Brass et al., 2008) used a genomic siRNA screen to determine 
which of ~21,000 human genes HIV-1 needs to replicate. The authors discovered 273 
host genes that could be classified by their criteria as HIV-1 dependency factors (HDFs), 
of which 237 were novel (see Figure 1-4, pg 27). Two independent research teams (Konig 
et al., 2008; Zhou et al., 2008) closely followed with reported discoveries of 213 and 267 
novel HDFs respectively.  
A meta-analysis comparing these three datasets, as well as several other studies’ 
datasets (Chertova et al., 2006; Hao et al., 2008; Krishnan et al., 2008; Studamire and 
Goff 2008) showed limited overlaps from individual pairwise comparisons (Bushman et al., 
2009). However, network analysis of the novel genes recovered formed several densely 
connected cellular-viral gene clusters representing cellular subsystems involved in HIV-1 
replication. These include the proteasome, various subunits and factors of RNA 
Polymerase II, the Mediator complex, various transcription factors required for Tat 
activation and elongation of transcription, RNA binding and splicing proteins, protein 
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chaperones involved in protein folding and sorting, Tat activation and budding and finally 
factors involved in tRNA synthase functioning and transport (Bushman et al., 2009).  
The small overlap between these datasets mostly reflects fundamental differences 
in study design. All three groups used cell lines engineered to allow artificial infection by 
HIV-1. The pattern of gene expression in these cells differs greatly from CD4+ T-cells and 
macrophages (HIV-1 natural host cell types). This implies that gene expression products 
in these cell lines may allow interactions with viral proteins that do not represent true host-
virus interactions occurring during a natural infection. In addition, viruses used were either 
lab-adapted strains or molecular clones missing several important viral accessory proteins 
(including Nef, Vpu and Vpr) or pseudotyped with the envelope protein of Vesicular 
Stomatitis Virus (VSV-G) that uses a different mode of entry to HIV-1. Screening for host 
factors using such virus models could thus mask many important viral/host interactions.  
 
1.6.1 Selection of novel host factors for validation in this study 
To address the need to validate these candidate factors, five of the novel HDFs 
implicated by Brass et al. (2008) as being required for HIV-1 infection were selected: 
SPTBN1 (spectrin beta non-erythrocytic 1), TMED2 (transmembrane emp24 domain 
trafficking protein 2), KIAA1012 (a gene of relatively unknown function), PRDM14 (PR 
domain containing 14) and SP110 (SP110 nuclear body protein), using unbiased criteria 
as described in Section 3.1. According to Brass et al., SPTBN1, TMED2 and KIAA1012 
are involved in the early phase (pre-Gag translation) of the HIV-1 lifecycle, while PRDM14 
and SP110 are required for later stages involving assembly and budding of virions (see 
Figure 1-4, pg 27). 
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1.6.1.1  SPTBN1 
SPTBN1 is one member of a family of beta-spectrin genes. Spectrin is an actin-
crosslinking and molecular scaffold protein and functions in determining cell shape, 
arranging transmembrane proteins and organelle organization (Taylor-Harris et al., 2005). 
In addition, it appears to play a role in regulating T-lymphocyte function via ankyrin, which 
binds directly to CD45, sequestering it from being recruited to the cell surface and 
abrogating Jurkat T-cell activation (Pradhan and Morrow 2002). Finally, this spectrin is 
directly cleaved by HIV-1 protease, along with other focal adhesion plaque proteins. Brass 
et al. hypothesize that SPTBN1 may be involved in inward trafficking of the virus via its 
interaction with the actin network. 
 
1.6.1.2  TMED2 
TMED2 (p24A) is part of the p24 cargo receptor family. This family has been 
shown to form complexes with GRASP55 and -65, peripheral membrane components of 
the Golgi matrix, which sequesters the p24 cargo receptors in the Golgi apparatus. In 
addition, p24A interacts with both ARF1 and ARFGAP (Majoul et al., 2001), with studies 
implicating it as an integral receptor for the coatomer protein 1 (COP1) vesicle coat, 
cycling continuously between the intermediate compartments of the Golgi and the cis-
Golgi network (Blum et al., 1999). Recently, p24A has had a novel function described as a 
regulator of signal-dependent trafficking during the life cycle of PAR-2 (Protease-activated 
receptor 2) (Luo et al., 2007). Thus this gene may play a role in retrograde Golgi-to-ER 
trafficking of virus.  
 
26 
 
1.6.1.3  KIAA1012 
KIAA1012 is highly expressed in immune cells, both B- and T-lymphocytes, as well 
as NK (natural killer) cells. With three transcripts expressing five proteins, its function is 
still uncharacterised. Its homologue, TRS85, is a component of the transport protein 
particle complex (TRAPP) (Sacher et al., 2000) and is involved in selective autophagy via 
the Cvt (cytoplasm to vacuole targeting) pathway, for the biogenesis of  double 
membrane-layered Cvt vesicles (Meiling-Wesse et al., 2005). A putative involvement in 
viral transport via these vesicles has still to be explored. 
1.6.1.4  PRDM14 
PRDM14, apart from containing a PR-domain, a subtype of the SET domain that 
catalyzes histone methylation, also has several zinc finger conserved domains. Recently, 
upregulation of this gene was found in two-thirds of all breast cancers, while an effect of 
reducing cancer cell sensitivity to chemotherapeutics was also described (Nishikawa et 
al., 2007). Interestingly, PRDM14 is specifically expressed in undifferentiated human ES 
(embryonic stem) cells (Tsuneyoshi et al., 2008). Taken together, these findings indicate a 
potential role in transcriptional regulation of viral gene expression.  
1.6.1.5  SP110 
SP110 acts as a nuclear hormone receptor transcriptional co-activator and is 
associated with the nuclear body complex. This gene is induced by the Interferon 
response (Regad and Chelbi-Alix 2001), offering immunoprotection against pathogens 
(Everett and Chelbi-Alix 2007). In contrast, it has also been found to be recruited by 
several pathogens, specifically Epstein Barr Virus (Nicewonger et al., 2004) and 
Anaplasma phagocytophilium (de la Fuente et al., 2007) where it modulates retinoid 
signalling and stabilises pathogenic gene expression. Thus a potential role in regulation of 
viral gene expression and/or the Interferon response is intriguing.  
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The functions and molecular interactions of these genes, as well as the findings 
published by Brass et al. (2008), support their putative role as novel HDFs. However, a 
robust, individual approach is required for careful validation of these genes’ role in HIV-1 
infection and replication. Validating each of the several hundred candidate HDFs that 
have been implicated recently will vastly accelerate our understanding of the way in which 
complex retroviruses like HIV-1 adapt to use their cellular environment for efficient 
replication. In addition, such HDFs will potentially provide a large array of novel targets for 
conventional drug-targeting and newer gene therapy approaches, thereby making an 
effective anti-HIV treatment a more feasible goal.  
  
Figure 1-4: Model of putative HDF roles in the HIV lifecycle.  
The function and sub-cellular location of HDFs was determined using multiple databases (Table S4 
of Brass et al., 2008). Proteins in multiple locations represent more than one possible role in the 
HIV lifecycle. The HDFs selected for this study are circled in red. Newly identified HDFs (red or 
blue, the latter late-acting); previously implicated HDFs detected (green), or not detected but with a 
relevant interaction (grey); HIV protein (black): matrix, MA, reverse transcriptase, RT, integrase, IN, 
envelope (gp41, gp120), ENV. Unfolded protein response, UPR. (Brass et al., 2008) 
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1.7 Aims and Objectives 
 
The overall aim of this project was to validate the role that SPTBN1, TMED2, 
KIAA1012, PRDM14 and SP110 play in HIV-1 infection and replication. The specific 
objectives were to: 
 
1) Use expressed shRNAs and siRNAs to silence the expression of these genes by 
the RNA interference (RNAi) pathway.  
2) Quantify the ability of these RNAi effecters to suppress their target sequences in (i) 
a minimal target/reporter system and (ii) at the endogenous mRNA level using a 
dual luciferase reporter assay and quantitative RT-polymerase chain reaction 
(qRT-PCR) assays, respectively. The latter would require optimisation and 
validation to ensure that the results are accurate and reproducible. 
3) Determine if gene loss-of-function, as well as the RNAi process or cellular delivery 
method, had any detrimental effects on cell viability using a colorimetric assay for 
metabolic enzyme activity. 
4) Optimise delivery of DNA- and RNA-based fluorescent reporters to a T-cell line 
using electroporation and lipid-based transfection reagents. 
5) Determine the effect of each gene's knockdown on HIV-1 replication kinetics in (i) 
a single infection cycle pseudoviral challenge and (ii) a two-part challenge with 
fully-replicating virus.  
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CHAPTER 2 : METHODS AND MATERIALS 
 
2.1 RNAi effecters 
 
2.1.1 shRNA-encoding sequences 
The original set of shRNAs was designed based on the sequences available in the 
Broad Institute/The RNAi Consortium (TRC) MISSION™ shRNA library (Moffat et al., 
2006; TRC 2008). This library consists of shRNA sequences designed to specifically 
target the transcripts of a large number of NCBI (National Centre for Biotechnology 
Information) human and mouse genes and can be accessed online at the following URL: 
http://www.broadinstitute.org/rnai/trc/lib. The 21-mer candidate shRNA sequences 
(typically five per gene) span the length of the coding region (25 bp after the initiation of 
transcription until 150 bp before the end of the transcript) and usually include one 
targeting the 3’ untranslated region. They are sorted according to a score that is based on 
siRNA sequence criteria (Elbashir et al., 2001; Reynolds et al., 2004). These include 
strong base-pairing at the 5’ end, weak base-pairing at the 3’ end, no internal loop 
formations, a preferred GC-content of 60-70%, no single nucleotide polymorphisms 
(SNPs) or ambiguous bases, relatively AT-rich sequences from positions 6-11 and 
avoidance of seven consecutive GC bases or four of the same bases in a row. After 
sorting the candidates are further selected to avoid overlaps with each other and matches 
with other human gene sequences.  
The TRC 21-nucleotide sense and antisense sequences were joined with a nine-
nucleotide loop sequence (5’-CCT GAC CCA-3’) (see Figure 2-1 for an example). A 
guanine residue (G) at the 5’ end (the same first nucleotide as in the native U6 small 
nuclear RNA) and six T-residues at the 3’ end ensured efficient initiation and termination 
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of transcription respectively. Where three or more T-residues occurred in the sense (anti-
guide) strand, mismatches were introduced to avoid premature termination of 
transcription. If three or more T-residues occurred in the antisense (guide) sequence that 
is important for target sequence recognition, a different shRNA sequence was designed 
using the HPCDispatcher siRNA site selector application (Heale et al., 2005). This is an 
online application available at the following universal resource locator (URL): 
http://www1.infosci.coh.org/hpcdispatcher/siRNA.aspx (HPCDispatcher) that calculates 
the difference in thermodynamic stability between the ends of a siRNA duplex. Duplexes 
with the greatest thermodynamic difference were chosen while incorporating the same 
design rules and modifications described above.  
 
 
 
 
 
 
Figure 2-1: Example of shRNA design approach.  
The top panel shows the duplex sequence from the online TRC MISSION shRNA library. The 
bottom panel shows 21 base-pairs of the duplex connected by a 9-nucleotide loop, including single-
stranded end modifications and mismatches induced (bold) to remove triple uridine residues in the 
sense strand (anti-guide). 
 
2.1.2 Specificity and structure of shRNA sequences 
The specificity of all shRNA sequences was assessed using NCBI’s online BLAST 
(basic local alignment and search tool) (Altschul et al., 1990; BLASTn 1990) to detect off-
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target matches with other gene sequences. This search tool can be found online at the 
following URL: http://blast.ncbi.nlm.nih.gov/Blast. The shRNA sequence was compared 
with the human genomic and transcript database using the megablast program of BLASTn 
(for nucleotide sequences) that optimises the search for highly similar sequences. In 
addition, the secondary structure of the shRNA sequence was assessed using the RNA 
mfold v 3.2 server (Zuker 1995-2010; Mathews et al., 1999; Zuker 2003) using the default 
parameter settings. This program is available at the following URL: 
http://mfold.bioinfo.rpi.edu/cgi-bin/rna-form1.cgi. 
 
2.1.3 siRNA SMARTpools 
siRNA ON-TARGETplus™ SMARTpools were ordered from Dharmacon® 
(Thermo Fisher Scientific, Lafayette, CO, USA) targeting SP110 (target transcript 
NM_004510, catalogue number L-011875-00-0005) and SPTBN1 (target transcript 
NM_178313, catalogue number L-018149-01-0005). As a non-targeting control, a siRNA 
targeting the HBx sequence of Hepatitis B Virus, HBV (designed by Prof Piet Herdewijn of 
the Rega Institute for Medical Research Laboratory of Medicinal Chemistry / Katholieke 
Universiteit Leuven in Leuwen, Belgium and Prof Joachim Engels of Wolfgang Goethe 
University in Frankfurt, Germany) was used that comprised a Cy3 fluorescent dye-labelled 
antisense strand and a sense strand that were annealed together before use (see Table 
A-8 of Appendix A). All siRNAs were resuspended in buffer (60 mM KCl (Burani Design 
Holding, BDH, Chemicals, Poole, England), 6 mM HEPES (pH7.5), 0.2 mM MgCl2 
(Saarchem Merck Chemicals, Gauteng, South Africa)) and stored as 20 µM aliquots at -
70°C.  
Subsequently, new shRNAs were designed based on the individual siRNA target 
sequences of each SMARTpool. The same nine-nucleotide loop sequence was used to 
join the 19 bp sense/antisense (antiguide/guide) duplex, with six terminating T-residues at 
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the 3’ end and a G-residue as the first nucleotide to be transcribed. Three or more T-
residues were again avoided by introducing mismatches (if occurring in the sense strand). 
Where these occurred within the antisense (guide) strand the sequence was synthesized 
so that ~50% of the oligonucleotides would have a T-residue at that point and ~50% 
would have a C-residue (as both these nucleotides have pyrimidine bases, they have 
similar ability to bind the sense strand). Thus a single clone produced from these 
oligonucleotides would have either a T- or a C-residue. The genomic locations targeted by 
the shRNAs and siRNAs described above are listed in Tables A-1 and A-2, respectively, 
of Appendix A. 
 
2.2 Previously constructed plasmids used in this study 
 
Several plasmids were used routinely in cloning or in transfections that were not 
created during this study: pTZ57R (provided with the PureExtreme® InsTAclone™ PCR 
cloning kit from MBI Fermentas, MD, USA) was used in T/A cloning - this method exploits 
the fact that Taq polymerase adds an A-residue to the 3’ end of amplicons (Clark 1988; 
Hu 1993). PCR products can easily be inserted into the linearised vector, pTZ57R/T, by 
ligating to the flanking T-residue of the T/A cloning site (Holton and Graham 1991; 
Marchuk et al., 1991; Mead et al., 1991).  
psiCHECK-2.2 was created by Dr M S Weinberg of our laboratory: an 
oligonucleotide encoding several restriction sites was inserted into psiCHECK-2™ 
(Promega, WI, USA), thereby creating a new multiple cloning site. This vector encodes 
both Renilla luciferase and Firefly luciferase and is useful for rapidly assessing RNAi 
knockdown efficacy. 
pCI-EGFP is a useful reporter plasmid expressing enhanced Green Fluorescent 
Protein (eGFP) from the Cytomegalovirus (CMV) immediate early enhancer/promoter. It 
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was constructed by cloning the EGFP ORF into the mammalian expression vector pCI 
Neo (Promega, WI, USA) (Passman et al., 2000).  
phRL-CMV (Promega, WI, USA) is a reporter plasmid that expresses Renilla 
luciferase from a CMV promoter. This plasmid was used to control for transfection 
efficiency and variation in cell density during experiments in TZM-bl cells that stably 
express integrated Firefly luciferase (Section 2.4). 
All shRNAs used and created in this study are expressed from the pTZU6+1 vector 
(kindly provided by Dr David Engelke of the University of Michigan). To control for 
background activity from the U6 promoter, experiments always included this empty vector 
as a Mock control. To control for non-specific knockdown effects, several plasmids 
expressing shRNAs targeted to other sequences were tested for use in knockdown 
experiments. Two shRNAs targeted to HBV, U6 shRNA 5 and U6 shRNA 10 (Carmona et 
al., 2006), renamed shHBx-5 and shHBx-10 here, as well as shLacZ (constructed in our 
laboratory to target the lacZ gene of E. coli) were tested for their ability to knockdown 
each of the genes targeted in this study. 
Two shRNAs that have been shown previously to knock down HIV-1 were included 
as positive controls in virus knockdown experiments: shLTR was constructed in our 
laboratory by S Barichievy and targets the HIV-1 long terminal repeat (LTR) promoter. 
U6+1 tat/rev shRNA (Scherer et al., 2004) was renamed shTat in this study and targets 
the viral tat/rev ORF. Two shRNAs targeting confirmed HIV-1 host factors were used: 
shPL3 (renamed shLEDGF in this study) was created by V Green of our laboratory to 
target LEDGF (lens epithelium-derived growth factor) (Section 1.2.4); shHTATSF-2 (also 
created by V Green) targets HTATSF1 (Section 1.2.6). The sequences of these shRNA 
controls are given in Table A-8 of Appendix A. 
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2.3 Molecular cloning  
 
2.3.1 Cloning of shRNA expression cassettes  
Sequences encoding the first set of shRNAs were designed as two overlapping 
oligonucleotides. They were synthesized in reverse primer orientation to allow for two-step 
PCR-amplification of the U6 promoter template, similar to the approach used by 
Castanotto et al. (2002). Figure 2-2 shows a schematic of the PCR/cloning approach and 
Tables A-3 and A-4 (Appendix A) list the primer sequences used.  
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Figure 2-2: Schematic of two-step PCR approach used in construction of shRNA cassettes.  
Two-step PCR amplification of the U6 promoter using a universal U6 forward primer and two 
reverse primers successively resulted in a final product comprising the U6 Pol III promoter, 
beginning with BamHI and EcoRI restriction sites and ending in a Guanine residue (important for 
initiation of transcription), followed by the sense, loop and antisense sequences of the shRNA and 
ending with a poly-T termination signal of 6 Thymine residues. This PCR product (with 3’ adenine 
residues added by Taq polymerase) could be cloned into T/A vector pTZ57R/T. 
 
First-round PCR amplification of 10 pmol of U6 promoter template was performed 
using 10 pmol each of forward and reverse primer (R1) and 1 × PCR Master Mix 
(Promega, WI, USA) (25 U/ml Taq polymerase in a proprietary buffer at pH 8.5; 200 µM of 
each dNTP and 1.5 mM MgCl2) in a 20 µl reaction volume. Thermal cycling parameters 
were as follows: initial denaturation at 95°C for 5 minutes, followed by 30 cycles of 
denaturation (95°C for 30 seconds), primer annealing (58°C for 45 seconds) and 
elongation (72°C for 30 seconds) and a 15 minute extension step (at 72°C). 
Approximately 10 ng of the product was used as template for the second round of PCR, 
using the same conditions as above with R2 reverse primer and the final step extended to 
20 minutes at 72°C. 
The PCR-amplified shRNA cassettes were then ligated with pTZ57R/T using the 
InsTAclone PCR cloning kit. After PCR, 5 µl of the reaction volume was analyzed by gel 
electrophoresis (2% agarose, stained with ethidium bromide (Sigma-Aldrich Corp., MO, 
USA) (see Appendix B for safety precautions) and run at 5 V/cm in 1 × Tris-borate-EDTA 
(TBE) buffer (45 mM Tris-borate, 1mM EDTA (ethylenediaminetetraacetic acid), pH 8.3) 
(Saarchem Merck). When a single clear band was visible under UV light, 540 ng of the 
~300 bp PCR product was used directly in the ligation reaction with 150 ng of pTZ57R/T 
(corresponding to a 3:1 ratio of insert:vector), 5 U T4 DNA Ligase and 1 × ligation buffer 
(40 mM Tris-HCl, 10 mM MgCl2, 10 mM dithiothreitol (DTT), 0.5 mM ATP, pH 7.8) made 
up to a 20 µl reaction volume. When non-specific bands were visible, gel extraction of the 
correct-sized band was done (using the KOMA EzWay Gel Extraction Kit (KOMA Biotech, 
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Seoul, Korea) according to the instructions of the supplier) before ligation. Quantification 
of the DNA used in the ligation was done using the NanoDrop™ 1000 spectrophotometer 
(Thermo Scientific) at 260 nm relative to 280 nm. 
  Cloning of the second set of shRNAs, shSPTBN-A, shSPTBN-B, shSPTBN-C, 
shSPTBN-D, shSP110-A, shSP110-B, shSP110-C and shSP110-D, was done using the 
pooled siRNA sequences (see Section 2.1.3) and used a slightly different approach (also 
described by Castanotto et al., 2002): a single round of PCR was performed using one 
long reverse primer (encoding a portion complementary to the 3’ end of the U6 promoter, 
followed by the entire shRNA sequence) and a U6 forward primer with four upstream 
restriction sites: BamHI, XhoI, NotI and NheI. The sequences of these primers are given in 
Table A-5 (Appendix A). 
 
2.3.2 Cloning of target reporter plasmids 
Target reporter plasmids (corresponding to the first set of shRNAs) were 
constructed so that the three shRNA target sites for each gene were cloned in tandem 
downstream of the Renilla luciferase ORF (see Figure 2-3, pg 38), expressed from the 
dual luciferase reporter plasmid, psiCHECK-2.2. A set of four oligonucleotides was 
designed to encode the various target sequences (Table A-6 of Appendix A and Figure 2-
3). The F1 and R1 oligonucleotides were designed to anneal as double stranded DNA 
sequences encoding the first half of the three target sites and an overhang containing 
XhoI and EcoRV restriction sites at the 5’ end. Similarly, the F2 and R2 oligonucleotides 
were designed to anneal as double stranded DNA sequences encoding the second half of 
the three target sites and a NotI overhang at the 3’ end. The annealed F1/R1 and F2/R2 
sequences would also have overhangs at their 3’ and 5’ ends respectively, that would 
allow them to be ligated together. psiCHECK-2.2 backbone was prepared for directional 
cloning by digesting 2 µg of plasmid with 2 U XhoI and 1 U NotI restriction enzymes using 
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Buffer O (MBI Fermentas, Ontario, Canada) (50 mM Tris-HCl, 10 mM MgCl2, 100 mM 
NaCl, 0.1 mg/ml bovine serum albumin (BSA), pH 7.5) in a 30 µl reaction volume. This 
was followed by agarose gel electrophoresis (0.8% agarose, stained with ethidium 
bromide and run at 5 V/cm in 1 × TBE buffer) and extraction of the digested product with 
the KOMA EzWay Gel Extraction Kit (KOMA Biotech, Seoul, Korea). The four 
oligonucleotides for each target sequence were joined to form one double-stranded 
oligonucleotide by the following steps: First, the 5’ ends of the F2 and R1 oligonucleotides 
were phosphorylated - 200 pmol of oligonucleotide was incubated with 2 µl of 10 mM ATP 
(Sigma-Aldrich) and 5 U of T4 Polynucleotide Kinase (PNK) (New England Biolabs, NEB) 
in 1 × T4 Polynucleotide Kinase Reaction Buffer (NEB) (70 mM Tris-HCl, 10 mM MgCl2, 5 
mM DTT, pH 7.6) in a 20 µl reaction volume at 37°C for 1 hour. Next, the F1/R1 and 
F2/R2 pairs were annealed to form two double-stranded oligonucleotides: 100 pmol each 
of the oligonucleotides were incubated at 80°C for 5 minutes, followed by slow cooling to 
~25°C. Finally, these were three-way ligated into the prepared backbone: 60 fmol of 
vector backbone was added to 180 fmol each of insert and incubated with 5 U of T4 DNA 
Ligase and 1 × ligation buffer (composition described above) in a 20 µl reaction volume for 
1 hour at 16°C.  
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Figure 2-3: Reporter target cloning strategy.  
The oligonucleotides encoding the shRNA target sequences for TMED2. After ligating the 
oligonucleotide pairs, they were positionally cloned into psiCHECK2.2 digested with XhoI and NotI. 
 
2.3.3 Transformation and verification of clones 
Chemically competent DH5α Escherichia coli (E. coli) cells (see Appendix B) were 
transformed with the ligation mixes by incubating 100 μl cells with 10 μl of the ligation 
reaction for 30 minutes on ice, heat-shocking at 42°C for 90 seconds, followed by further 
incubation on ice for 5 minutes. Transformed cells were plated onto sterile Agar (see 
Appendix B) containing  ampicillin (100 µg/ml) and spread with 40 μl X-Gal (20 mg/ml,    
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5-bromo-4-chloro-3-indolyl b-D-galactopyranoside) and 8 μl IPTG (100 mg/ml, Isopropyl β-
D-1-thiogalactopyranoside) and grown overnight at 37°C. In recombinant clones, the lacZ 
gene is interrupted by the ligation reaction and thus white colonies are formed (Sambrook 
and Russell 2001). White colonies were selected and used to inoculate 4 ml Luria-Bertani 
broth supplemented with ampicillin for overnight culture (see Appendix B). Subsequent 
plasmid preparation was done using the High Pure Plasmid Isolation kit (Roche Applied 
Science, Mannheim, Germany) as described in Appendix B. Target clones were screened 
by EcoRV (MBI Fermentas) digestion (10 U in Buffer R (MBI Fermentas) (10 mM Tris-HCl,  
10 mM MgCl2, 100 mM KCl, 0.1 mg/ml BSA, pH 8.5) for 1 hour at 37°C) and shRNA 
clones with XbaI/HindIII double digestion (2 U of HindIII, 1 U of XbaI and 1 × Tango buffer 
(MBI Fermentas) (33 mM Tris-acetate, 10 mM Mg-acetate, 66 mM K-acetate, 0.1 mg/ml 
BSA, pH 7.5) in a 30 µl reaction volume for 1 hour at 37°C), followed by agarose (stained 
with ethidium bromide) gel electrophoresis and visualization under UV light. 
Positive clones were verified using automated sequencing with the BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). The 
cycle sequencing reaction was set up with 100 ng of template plasmid, 2 µl Ready 
Reaction Mix (Applied Biosystems), 1 × BigDye Terminator v3.1 Sequencing Buffer 
(Applied Biosystems) and   10 pmol primer, made up to 10 µl with distilled water (dH2O). 
Sequencing of pTZU6-shRNA clones was done with M13 reverse primer (5’-CAG GAA 
ACA GCT ATG AC-3’) or the U6 forward primer; target primer (5’-CGA CGA TCT GCC 
TAA GAT GT-3’) was used for psiCHECK-target clones. Thermal cycling conditions were 
as follows: 96°C for 1 minute, followed by 25 cycles of: 96°C for 10 seconds, 50°C for 5 
seconds and 60°C for 4 minutes. The reaction product was purified by ethanol/EDTA 
precipitation (see Appendix B) and the pellet resuspended in Hi-Di™ Formamide (Applied 
Biosystems) for subsequent electrophoresis performed by Inqaba Biotec (Pretoria, SA) or 
internally on the ABI Prism 3100-Avant Genetic Analyzer (Applied Biosystems). Sequence 
data analysis was performed using the Sequencing Analysis V3.3 programs (Applied 
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Biosystems) and FinchTV v 1.4.0 (Geospiza, Seattle, WA, USA). Bulk preparations were 
made of all sequence-verified plasmids for use in molecular cloning and transfections. 
These preparations were made using the QIAGEN® Plasmid Maxi Kit (QIAGEN, Hilden, 
Germany) as detailed in Appendix B.  
 
2.4 Mammalian cell culture 
 
116 cells (human embryonic kidney cells expressing the T-antigen of SV40 virus 
and Cre Recombinase) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with  4.5 g/L Glucose and 2 mM L-Glutamine (BioWhittaker®, Lonza, 
Walkersville, Maryland, USA) and 10% heat-inactivated fetal bovine serum, FBS (Gibco®, 
Invitrogen, CA, USA), referred to as complete medium. Cells were incubated at 37°C with 
5% CO2 and passaged at 80% confluency as described in Appendix B. TZM-bl cells 
(HeLa-derived cells expressing CD4, CCR5 and CXCR4 HIV receptors, as well as 
luciferase and lacZ reporter genes under control of the HIV Tat-inducible LTR promoter) 
were obtained through the NIH AIDS Research and Reference Reagent Program 
(NARRRP), Division of AIDS, NIAID, NIH (Catalogue number 8129) from Dr. John C. 
Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. TZM-bl cells were also cultured in complete 
medium (10% FBS) and passaged with 0.25% Trypsin / 1 mM EDTA (Gibco) (see 
Appendix B). SupT1 cells (NARRRP Catalogue Reagent 100, obtained from Dr. James 
Hoxie (Smith et al., 1984)), were grown in suspension in complete medium (10% FBS). 
Their passaging is also described in Appendix B.  
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2.5 Transfection of DNA and RNA into cultured cells 
 
For all transfections cells seeded the previous day were transfected at 50-80% 
confluency. The following protocols are for 24-well culture plates (2 cm2 culture surface 
area). Transfections in 96-well culture plates (0.4 cm2 surface area) were carried out in the 
same way but scaled down by a factor of 0.2.  
 
2.5.1 Lipofectamine™ 2000 transfections 
A maximum amount of 1 µg DNA was diluted with OptiMEM® Medium to a 50 µl 
volume. The required volume of Lipofectamine™ 2000 (Invitrogen, CA, USA) (using a 
ratio of 1 µl Lipofectamine™ 2000 to 1 ug DNA) was similarly diluted into 50 µl OptiMEM® 
Medium (Invitrogen). After five minutes incubation at room temperature, the dilutions were 
mixed and allowed to incubate for 20 minutes at room temperature to allow lipoplexes 
(DNA-lipid complexes) to form. Thereafter the total volume (100 µl) was added drop-wise 
to the cell culture medium (500 µl). The culture plate was gently rocked to distribute the 
complexes evenly and incubated for the required length of time at 37⁰C. 
 
2.5.2 ESCORT™ V transfections 
For this reagent, the culture medium was replaced with fresh medium (without 
antibiotics) from 30 minutes to two hours before the transfection. A maximum amount of 
700 ng DNA was diluted with 60 µl ESCORT V Transfection Buffer (Sigma-Aldrich). As a 
ratio of 3 µl ESCORT V Transfection Reagent (Sigma-Aldrich) to 1 µg DNA was used, 2.1 
µl of Transfection Reagent was diluted with 60 µl Transfection Buffer. The dilutions were 
mixed gently, combined and mixed again before incubating at room temperature for 20 
minutes. The rest of the procedure is the same as described in Section 2.5.1. 
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2.5.3 DharmaFECT®-4 transfections 
Transfections with this reagent were carried out using the same procedures 
described in Section 2.5.1, except that a 96-well format was used. siRNAs were used 
instead of DNA and precautions were therefore taken to avoid RNase contamination of 
the samples and the siRNAs were stored on ice when not being handled. Moreover, 
dilutions of the siRNA stocks to required final concentrations were done using the buffer 
described in Section 2.1.3. Transfections were optimised as explained in Section 2.9 and 
thereafter 0.4 µl of the transfection reagent was used per 100 nM siRNA, unless otherwise 
specified. 
 
2.6 Dual-Luciferase reporter assays 
 
To evaluate the ability of the shRNA expression cassettes to knock down their 
reporter targets, a dual luciferase reporter assay was performed. Because each shRNA’s 
target sequence was cloned into the 3’ UTR of the Renilla (Renilla reniformis) luciferase 
reporter gene, the level of knockdown could be determined by measuring Renilla 
Luciferase activity relative to that of control Firefly (Photinus pyralis) Luciferase 
(expressed separately on the same plasmid). The 116 cells were seeded 24 hours prior to 
transfection at 1.2 × 105 cells per well in 24-well culture plates (Nunclon™ Δ Surface, 
Thermo Fisher Scientific, Rochester, NY, USA). Cells were then transfected at 10:1 and 
5:1 ratios of shRNA:target using Lipofectamine™ 2000 (see Section 2.5.1). In both cases 
a total of 1 µg of DNA was transfected, comprising: 800 ng shRNA with 80 ng target (for 
10:1 ratio) and 750 ng shRNA with 150 ng target (5:1), as well as 100 ng of pCI-EGFP 
reporter plasmid (to monitor transfection efficiency). Mock (pTZU6+1) and non-specific 
controls (U6 shRNA 5, renamed shHBx-5) were included in both experiments.  
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Forty-eight hours post-transfection, a Dual-Luciferase® Reporter Assay (Promega, 
WI, USA) was performed. After aspirating the culture medium, cells were lysed in the 
recommended volume of 1 × passive lysis buffer (PLB) (Promega, proprietary formulation) 
and incubated at 37°C for 15-20 minutes. After resuspending the lysates to remove 
clumps, 12 µl of each sample were transferred to the wells of  a white-walled 96-well plate 
(Corning® Costar®, Corning Inc., MA, USA) and loaded into the Veritas dual-injection 
luminometer (Turner Biosystems, CA, USA). Sufficient volumes (i.e. 50 µl per sample plus 
500 µl for injector priming) of 1 × Luciferase Assay Reagent II (LAR II) and Stop & Glo® 
Reagent (Promega, proprietary formulations) were made up according to the instructions 
of the supplier. Luciferase activity readings were then taken (in relative light units, RLU): 
first Firefly luciferase, after addition of LAR II, followed by Renilla luciferase after Stop & 
Glo Reagent addition. The protocol used for measurements was adapted for 50 µl from 
the Promega protocol for 100 µl of reagent per sample. 
 
2.7 qRT-PCR assays 
 
Quantitative real-time reverse-transcription PCR (qRT-PCR) was performed in 
order to verify the knockdown efficacy of the shRNA constructs against their endogenous 
mRNA targets. qRT-PCR primers (see Table A-7 of Appendix A) were designed to amplify 
each of the 5 genes, as well as housekeeping genes glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and β-actin. TZM-bl, HEK293T and 116 cells were seeded in 
12-well (2.5 × 105 cells per well) or 24-well (1.2 × 105 cells per well) tissue culture plates 
(Nunclon™ Δ Surface, Thermo Fisher Scientific). Twenty-four hours later, the maximum 
amount of DNA was transfected for each well format (i.e. 24-well plates: 950 ng of 
shRNA-expressing plasmid or control plasmid and 50 ng pCI-EGFP; 12-well plates: 1.9 µg 
shRNA or control plasmid with 100 ng pCI-EGFP). Lipofectamine™ 2000 was used for 
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116 and HEK293T cells (as described in Section 2.5.1), while ESCORT™ V transfection 
reagent (Sigma-Aldrich) was used to transfect TZM-bl cells (see Section 2.5.2).  
RNA was extracted 48 hours post-transfection using TRI-Reagent® (Sigma-
Aldrich). Culture medium was aspirated and the cells lysed using the recommended 
amount of TRI-Reagent   (1 ml per 10 cm2 of culture dish area). After resuspension and 5 
minutes incubation at room temperature, chloroform (200 µl per ml TRI-Reagent) was 
added to the homogenate, vortexed until thoroughly mixed and the phases allowed to 
separate before centrifugation at 12 000 × g for 15 minutes at 4°C. The upper aqueous 
phase (containing the RNA) was then transferred to a clean microfuge tube and 
isopropanol added (500 µl per ml TRI-Reagent) before storing at -70°C overnight. The 
following day (or when needed) the RNA was pelleted by centrifugation at 12 000 × g for 
30 minutes at 4°C. The supernatant was discarded, 75% ethanol added (1 ml per ml TRI-
Reagent) and the RNA washed by brief vortexing. After centrifugation at 7 500 × g for 5 
minutes, the pellet was allowed to air-dry for ~5 minutes before resuspension in diethyl 
pyrocarbonate (DEPC)-treated water (Sigma-Aldrich) and incubation at 55°C for 10 
minutes. Thereafter the RNA was stored on ice and used directly in reverse transcription 
before long-term storage at -70°C. 
The QuantiTect® Reverse Transcription kit (QIAGEN, Hilden, Germany) was used 
for reverse transcription of RNA to cDNA. The reaction was scaled down so that 500 ng or    
1 µg of RNA was incubated with 1 µl gDNA Wipeout buffer in a 7 µl reaction volume at 
42°C for two minutes and then placed on ice. Thereafter 0.5 µl Quantiscript® Reverse 
Transcriptase (a proprietary mixture of the QIAGEN® products Omniscript® Reverse 
Transcriptase and Sensiscript® Reverse Transcriptase that also contains RNase 
inhibitor), 0.5 µl RT Primer mix (a blend of oligo-dT and random hexamer primers 
including Mg2+ ions and dNTPs) and 1 × Quantiscript RT buffer were added to the first 
reaction to a final volume of 10 µl and incubated at 42°C for 20 minutes before heat-
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inactivation at 95°C for three minutes and placing on ice. The resulting cDNA (4 µl) was 
used in subsequent qPCR with 10 pmol of the designed primers (Table A-7, Appendix A) 
and 1 × LightCycler® FastStart DNA MasterPLUS SYBR Green I (Roche Applied Science, 
Mannheim, Germany) (proprietary formulation comprising FastStart Taq DNA 
Polymerase, reaction buffer, MgCl2, SYBR Green I dye and dNTP mix) in a 20 µl reaction 
volume. The Roche LightCycler® 2.0 instrument was used for the PCR using the following 
parameters: a hotstart at 95°C for 10 minutes was followed by 35-50 cycles of 
denaturation (95°C for 10 seconds), annealing (60°C for 10 seconds) and elongation 
(72°C for 10 seconds). Quantification occurred during the elongation stage, while melting 
curve analysis (95°C for 30 seconds, 65°C for 30 seconds, followed by slow (ramp of 0.2) 
heating to 95°C with continuous quantification) ensured PCR product specificity. After 
PCR, the Relative Quantification (Monocolour) module of the LightCycler® LCS4 v 
4.0.0.23 software (Roche Applied Science, Mannheim, Germany) was used for data 
analysis. 
 
2.8 Electroporation 
 
Electroporation of SupT1 cells with pCI-EGFP, was done on the CE Module of a 
GenePulser Xcell apparatus (Bio-Rad Laboratories Inc., Hercules, CA, USA) using 
variations of several protocols as outlined in Tables B-1 and B-2 of Appendix B. Buffers 
used included DMEM, with or without FBS (10%) and DMSO (1.25%) (Invitrogen), 
OptiMEM (Invitrogen), Gene Pulser® electroporation buffer (Bio-Rad) (patented 
formulation, International Publication Number WO 2008/134 200 A1, World Intellectual 
Property Organization), phosphate-buffered (PB) sucrose (272 mM sucrose (Saarchem 
Merck), 7 mM K3PO4 (pH 7.4) (Sigma-Aldrich), 1 mM MgCl2) and HEPES-buffered (HB) 
dextrose (20 mM HEPES (pH 7.3) (BDH Chemicals), 137 mM NaCl (Saarchem Merck), 
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0.7 mM Na2HPO4 (Saarchem Merck) and 6 mM dextrose (Saarchem Merck)) (Chu et al., 
1987; Baum et al., 1994). Transfection efficacy (i.e. the proportion of cells that fluoresce 
green) was assessed by fluorescence microscopy (Axiovert 100 M, Carl Zeiss AG, 
Germany) after 24 hours of outgrowth post-electroporation. The total number of cells and 
the number of fluorescing cells were counted in a field of view approximately 2 cm × 2 cm 
under 200 × magnification. The viability of the cells was also assessed using 0.4% 
Trypan-blue stain (Biowhittaker). While dead or dying cells are permeable to the blue dye 
and thus stain blue, viable cells exclude it and appear colourless. To stain the cells, they 
were resuspended in an equal volume of the stain and loaded onto a haemocytometer 
slide for counting (see Appendix B). 
 
2.9 Delivery of DNA and RNA to SupT1 cells by cationic lipid-based 
transfection reagents  
 
Two siRNA pools and a recommended reagent for siRNA transfection, 
DharmaFECT® 4, were purchased from Thermo Scientific Dharmacon® (Thermo Fisher 
Scientific Inc., Lafayette, CO, USA). Delivery of siRNA to SupT1 cells using 
DharmaFECT® 4 transfection reagent was optimised as follows: SupT1 cells were seeded 
in 100 µl of medium at 5 × 103,   1 × 104 and 2.5 ×104 cells per well of a 96-well tissue 
culture plate (Techno Plastic Products AG, TPP®, Switzerland). Twenty-four hours later, 
100 nM siRNA was transfected in duplicate with 0.05, 0.1, 0.2, 0.3, 0.4 or 0.5 µl 
DharmaFECT®-4 (20 µl volume transfection mix). Forty-eight hours later, cells were 
examined using a fluorescence microscope (Axiovert 100 M, Carl Zeiss AG, Germany) for 
detection of the siRNAs (labelled with the sulfoindocyanine fluorescent probe, Cy3) within 
cells. Delivery of the siRNAs to TZM-bl cells using DharmaFECT®-4 was assessed 
similarly: cells were seeded in 100 µl of medium at 10 000 and 25 000 cells per well of a 
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96-well tissue culture plate (TPP®). Twenty-four hours later, 100 nM Cy3-labelled siRNA 
was transfected in duplicate with 0.2, 0.4 or 0.6 µl DharmaFECT®-4 (20 µl volume 
transfection mixes) or 0.4 µl Lipofectamine™ 2000. Forty-eight hours later, cells were 
examined by fluorescence microscopy for Cy3 fluorescence within cells. shRNAs were 
transfected into SupT1 cells and TZM-bl cells using ESCORT™ V transfection reagent 
(Sigma-Aldrich) as explained in Section 2.5.2. 
  
2.10 Cytotoxicity assays 
 
Various assays exist for determining the metabolic and physical condition of cells. 
A colorimetric assay was used here that measures the ability of mitochondrial Reductase 
enzymes to convert the yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, a tetrazole) substrate to purple Formazan (Mosmann 1983). The activity of these 
enzymes is reduced in cells that are experiencing metabolic dysfunction - for example, as 
a result of treatment with a cytotoxic agent like Trichostatin A, TSA. This organic 
compound selectively inhibits the class I and II mammalian HDAC enzyme families 
(Yoshida et al., 1990) and activates expression of apoptotic genes (Henderson et al., 
2003). 
 
For the MTT assay, 5 × 103 TZM-bl cells per well were seeded in DMEM 
containing 10% FBS in a 96-well tissue culture plate (TPP®). Eighteen hours later, cells 
were treated with 0.4 µl ESCORT™ V for shRNA transfections (100 ng of shRNA or 
control plasmid and   10 ng pCI-EGFP) or 0.4 µl DharmaFECT® 4 for 100 nM siRNA 
transfections. Controls wells (in triplicate) included untransfected and untreated cells, as 
well as cells treated with three concentrations (1000 nM, 500 nM and 100 nM) of TSA 
(Sigma-Aldrich). Culture medium was replaced after 5 hours of transfection (siRNA- and 
48 
 
shRNA-treated wells). After 48 hours of transfection, 10 µl of MTT (5 mg/ml in PBS, 0.2 
µm filter-sterilised) (Sigma-Aldrich) was added per well containing 100 µl and incubated at 
37°C with 5% CO2 in the dark for 1 hour. Thereafter, the medium was removed and the 
black formazan precipitate dissolved by addition of 200 µl dimethyl sulfoxide (DMSO). 
After mixing by gentle shaking for 2 minutes, the light absorbance of each well was 
measured at two wavelengths (570 nm, with 655 nm as the reference) using a Microplate 
reader (model 680, BioRad). 
 
2.11 Virus production 
 
Most of the viral work was done in the HIV Pathogenesis Research Laboratory 
with permission of Dr Maria Papathanasopoulos, while later work was carried out in our 
laboratory. For the initial challenge assay in TZM-bl cells, CAP210.2.00.E8 Env-
pseudotyped virus was used (a gift from Maria Papathanasopoulos). The CAP210.2.00.E8 
plasmid (NARRRP Catalogue Reagent 11317, available from Drs. L. Morris, K. Mlisana 
and D. Montefiori (Li et al., 2006)) expresses HIV-1 Subtype C env/rev. The env--/rev-- 
backbone plasmid, pSG3∆env (NARRRP Catalogue Reagent 11051, available from Drs. 
John C. Kappes and Xiaoyun Wu  (Wei et al., 2002; Wei et al., 2003)), contains a 
defective vpu gene. 
For the final challenge assay, HIV-1p81A-4 virus was used. The p81A-4 plasmid 
(NARRRP Catalogue Reagent 11440, available from Dr. Bruce Chesebro (Toohey et al., 
1995)) is a full length HIV-1 infectious molecular clone containing the V1-V3 envelope 
regions of the Ba-L HIV-1 strain in an NL4-3 (Subtype B) strain background. Infectious 
virions were produced by transfecting the plasmid into HEK293T cells, seeded the 
previous day at 2 × 106 cells in a 25 cm2 flask (Corning® flask, Corning, NY, USA) in 5 ml 
medium. Four micrograms of p81A-4 plasmid was suspended in 150 µl serum-free 
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DMEM, mixed with 40 µl PolyFect® transfection reagent (QIAGEN, Hilden, Germany), left 
at room temperature for five minutes and then added to the seeded cells' medium. Cells 
were incubated at 37°C with 5% CO2 and medium changed 24 hours after transfection. A 
further 24 hours later, virus-containing supernatant was collected, centrifuged briefly   
(200 × g for five minutes) to remove cellular debris and filtered through a 0.2 µm sterile 
filter. Serum concentration was adjusted to 20% FBS and aliquots frozen at -70°C. 
 
2.12 Viral titration 
 
An end-point titration technique was used for viral titering, i.e. the TCID50 (50% 
tissue culture infectious dose) was determined based on the protocol published by the 
ACTG Laboratory Technologist Committee of the HIV/AIDS Network Co-ordination (2004). 
Previous data from our laboratory has shown that the TCID50 determined from LTR-
luciferase activity does not differ greatly from the TCID50 obtained by p24 ELISA 
(enzyme-linked immunosorbent assay). Thus, the TCID50 was only determined by 
luciferase assay in this study. A more accurate titre involves calculating the multiplicity of 
infection (m.o.i.), which measures the average number of viral particles present per cell. 
However, as this was not technically feasible in this study, the TCID50 method was used. 
A dosage of 500TCID50 was used in all challenge assays as this dose did not cause cell 
death and yielded LTR-luciferase activity values within a reliable detection range. 
Cells were seeded at 5 × 104 cells per well of a 96-well tissue culture plate 
(TPP®). The following day, the culture medium was removed and replaced with 50 µl 
DMEM containing 10% FBS and 15 µg/ml DEAE-dextran (GE Healthcare Life Sciences, 
Uppsala, Sweden). The virus stock was initially diluted in seven serial three-fold dilutions, 
using DEAE/dextran-containing medium (described above), a total volume of 750 µl and 
250 µl transfers. To each column of three wells containing 50 µl medium, 150 µl of the 
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corresponding virus dilution was added per well (i.e. a 3:4 dilution). Thus the final titration 
consisted of seven serial four-fold dilutions (i.e. 4-2; 4-3; 4-4; ...; 4-8). One column of wells 
served as a control and was treated with DEAE/dextran-containing medium without any 
added virus. The data obtained from the TCID50 Luciferase assay were analyzed using 
the Spearman-Kärber formula detailed in Appendix B.    
 
2.13 Viral challenge assays 
 
The viral challenge assays were performed in TZM-bl cells as they are permissive 
for infection with viruses that are tropic for both T-cells and macrophages. In addition, 
TZM-bl cells support a full viral lifecycle while their integrated reporter genes provide a 
convenient and simple means of assessing changes in viral transcriptional activity. The 
Subtype C-enveloped pseudovirus (Section 2.11) was used as an initial screen for the 
effects of each gene’s suppression during a single round of infection. This was followed by 
a challenge assay consisting of two parts that was based on the approach of Brass et al., 
(2008) (Figure 2-4). In the first part, fully infectious virus (i.e. capable of generating virions 
that can infect new cells) was used to challenge cells in which SPTBN1, SP110 and the 
control genes had been inhibited. The virus used was Subtype B virus produced from a 
full-length infectious molecular clone (p81A-4) that is similar to the NL4-3 strain except for 
the V1-V3 envelope region, which is of the macrophage-tropic BaL strain (Section 2.11). 
In the second part of the assay, the culture medium from the infected cells was transferred 
to uninfected, untransfected cells to assess the effect of knockdown on infectivity (i.e. 
virion production and infection of new cells). 
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Figure 2-4: Schematic of two-part viral challenge assay 
The schematic for the two-part viral challenge assay was based on the approach used by Brass et 
al. (2008), with Part 1 measuring early-stage viral replication and Part 2 measuring later stages 
(assembly and budding). TZM-bl cells were transfected with pooled siRNAs and, after 72 hours of 
gene knockdown, infected with HIV-1. After 48 hours, integrated LTR-luciferase reportergene 
expression was measured (Part 1) and the virus-containing supernatant transferred to fresh TZM-bl 
cells. After 24 hours infection, luciferase reporter activity was again measured for Part 2 of the 
assay. Figure adapted from Brass et al. (2008). 
 
2.13.1 Env-pseudotyped viral challenge 
For the CAP210.2.00.E8 Env-pseudotyped viral challenge assay, TZM-bl cells 
were seeded at 5 × 103 cells per well of a 96-well tissue culture plate (TPP®). The RNAi 
effecters were transfected the following day, using  0.4 µl or 0.2 µl DharmaFECT® 4 for 
siRNA transfections (for 100 nM and 50 nM siRNA, respectively) and 0.4 µl ESCORT™ V 
for shRNA transfections (120 ng DNA : 100 ng of the relevant shRNA or control plasmid, 
10 ng pCI-EGFP and 10 ng phRL-CMV). The Virus Control and No Virus control wells 
were not transfected. Medium (100 µl) was replenished 30 minutes to two hours prior to 
ESCORT™ V transfection and  again 4-6 hours after DharmaFECT® 4 and ESCORT™ V 
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transfections. After 72 hours of transfection (when knockdown is still operative), the cells 
were infected with 500TCID50 of pseudovirus (i.e. 50 TCID50’s in 100 µl) in medium 
containing 5% FBS and DEAE-dextran at a final concentration of 10 µg/ml. After 48 hours 
of infection, a luciferase assay was carried out (see Section 2.6), measuring Firefly (LTR) 
luciferase relative to Renilla luciferase activity for the shRNA-transfected wells and LTR-
luciferase activity only for the siRNA-transfected wells. Data were normalised to the mean 
of the Non-specific control (siHBV). 
 
2.13.2 Replication-competent viral challenge 
As a result of several practical issues, Part 1 in this study was measured using 
LTR-Luciferase activity as opposed to p24 Gag production. For Part 1, cells were seeded 
and transfected with siRNA as was carried out for the pseudovirus challenge assays, with 
untransfected infected (Virus Control) and untransfected uninfected (No Virus) control 
wells included. After 72 hours of transfection, cells were infected with p81 virus at a 
TCID50 of 500/ml in 200 µl medium containing 10% FBS and 15 µg/ml DEAE-dextran. 
The No Virus control wells received the same medium without virus added.  After two 
hours incubation, the medium was removed and replaced with fresh complete medium 
before further incubation at 37 °C with 5% CO2. After 48 hours of infection, Part 2 of the 
assay was initiated by transferring 80 µl of virus-containing supernatant to the wells of a 
replica plate seeded the previous day with 5.4 × 103 TZM-bl cells per well. These cells 
were cultured in medium containing 15 µg/ml DEAE-dextran to facilitate infection. A Dual-
Luciferase reporter assay was performed (as described in Section 2.6) on the Part 1 cells 
after remaining supernatant had been discarded. After 20 hours of infection, the Part 2 
cells were lysed for an assay of LTR-Luciferase activity (also using the Dual-Luciferase 
reporter assay, with only Firefly Luciferase activity measured for siRNA-treated wells).  
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2.14 Statistical analyzes 
 
All data were analyzed using GraphPad Prism version 4.03 for Windows 
(GraphPad Software, San Diego, CA, USA, www.graphpad.com). Non-parametric one-
way analysis of variance (ANOVA) was used to assess the statistical significance of data. 
The post-tests performed are described with each reported result in Chapter 3.  
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CHAPTER 3 : RESULTS 
 
This study aimed to verify whether several genes that have recently been 
implicated as being novel HIV-1 host factors are required for viral infection and replication. 
Five genes were selected from the published dataset (Brass et al., 2008) as it was 
expected that some of these would be false positives (i.e. not true HIV-1 host factors) and 
also that some difficulties might arise during experiments to assess their effect on the 
virus and to inhibit their function by RNAi. Their selection was specifically made in an 
unbiased way, using criteria that would select for genes whose effect on HIV-1 replication 
was supported by good evidence and that could potentially be developed as novel 
drug/gene therapy targets. 
 
3.1 Criteria-based selection of five genes 
 
The five genes that were selected from the list of 237 novel HDFs published by 
Brass et al. (2008), as well as the criteria supporting their selection, are summarised in 
Table 3-1. A full portrayal of the selection process is shown in Appendix C. The first stage 
selected genes that caused a 75% or greater reduction in HIV-1 replication (see Table C-
1). This cut-off value was high enough to narrow down the original gene list while ensuring 
a selection of genes remained that had scored in both early (Part 1) and late (Part 2) 
stages of the HIV-1 lifecycle.  
The second stage selected for genes for which more than one siRNA caused a 
reduction in viral activity (Table C-2). The greater the number of individual siRNAs 
targeting the same gene that cause a significant decrease in viral activity, the more likely 
that the effect is gene-specific. From this stage onwards, the list of genes scoring in Part 1 
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and Part 2 were processed separately. The next stage considered the functional 
importance of the Part 1 genes. Six genes (see Table C-3) were excluded from the 
selection based on their biological function as recorded in the curated UniProt database. 
For example, WNT1 is a member of the Wnt signalling pathway, while NUP107 is an 
essential component of the nuclear pore complex. Knockdown of such genes would likely 
be toxic to the cell and thus not optimal target genes.  
Of the five genes to be studied, three were chosen from the Part 1 list (involved in 
viral entry up until Gag translation) and two from the Part 2 list (involved in later stages 
such as assembly and budding). The final three Part 1 genes were chosen as the first 
three on the remaining sorted list (see Table C-4). The Part 2 genes were processed in 
the same way as explained above, with six genes being excluded based on functional 
importance (Table C-5). As the remaining list contained several more genes than the Part 
1 list, an additional criterion was introduced to further focus the list: the number of gene 
homologues in other species (i.e. orthologues) was considered, as genes that are highly 
conserved across many species are more likely to have essential functions. A cut-off of 
five homologues was chosen that served to shorten the Part 2 gene list by ~30% (see 
Table C-6). The final selection (Table C-7) included one gene with three individual scoring 
siRNAs (PRDM14) and one with a published reference to interaction with pathogens 
(SP110) (see section 1.6.1.5). Thus, these two genes were selected to represent the late 
stage of HIV-1 replication in this study.  
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Table 3-1: The final five putative HDFs selected for validation in this study 
Gene 
NCBI 
GeneID 
Extent of virus 
knockdown 
Number of 
siRNAs  
Involvement in 
protein complexes 
and/or molecular 
pathways 
Function 
References 
to HIV-1 
interaction 
SPTBN1  
(spectrin, beta, 
non-erythrocytic 1) 
6711 76% 3 (Part 1) None 
May be involved in calcium-
dependant movement of the 
cytoskeleton at the membrane, 
through its interaction with 
calmodulin 
(Shoeman et 
al., 2002) 
TMED2  
(transmembrane 
emp24 domain 
trafficking protein 2) 
10959 82% 
3 (Part 1);  
1 (Part 2 ) 
Interacts with 
ARFGAP1 
May be involved in the budding 
of coatomer-coated and other 
coated vesicles. Could bind and 
collect cargo molecules into 
budding vesicles. 
None 
KIAA1012 22878 89% 4 (Part 1) 
Part of the multisubunit 
TRAPP (transport 
protein particle) 
complex. 
May be involved in vesicular 
transport from endoplasmic 
reticulum to Golgi. 
None 
PRDM14  
(PR-domain 
containing 14) 
63978 81% 3 (Part 2) None 
May be involved in 
transcriptional regulation. 
None 
SP110  
(SP110 nuclear 
body protein) 
3431 84% 2 (Part 2) None 
Transcription factor. May be a 
nuclear hormone receptor co-
activator. Enhances 
transcription of genes with 
retinoic acid response elements 
(RARE). 
(Izmailova et 
al., 2003) 
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3.2 Gene-specific knockdown by Pol III-expressed shRNAs 
 
3.2.1 Design of shRNA expression cassettes 
In order to validate the classification of SPTBN1, TMED2, KIAA1012, PRDM14 
and SP110 as HDFs, as well as their role in early versus late stages of HIV-1 replication, 
their function was inhibited using RNAi effecters targeted to the coding region of each 
gene. Because gene knockdown using siRNAs is transient, shRNA expression cassettes 
were designed that would provide a constant supply of RNAi effecters for stabler 
suppressive effects. The U6 Pol III promoter is useful in this regard: shRNA-encoding 
sequences that have a G-residue at the 5’ end and at least four terminating T-residues are 
efficiently expressed to form shRNAs with two-nucleotide 3’ overhangs that allow Dicer 
processing into siRNAs (Paule and White 2000; Brummelkamp et al., 2002; Paddison et 
al., 2002; Paul et al., 2002). 
Initially, shRNAs targeting three different regions of each of the five genes 
(SPTBN1, TMED2, KIAA1012, PRDM14 and SP110) were designed. Their design was 
based on the Broad Institute’s online TRC MISSION shRNA Library (Section 2.1.1). 
However, several candidate sequences available on this database contained three or 
more T-residues in the guide sequence (which cannot be altered without affecting its 
targeting efficacy). To avoid risking premature termination of Pol III transcription, another 
approach was used for the design of these shRNA sequences. The difference in 
thermodynamic stability between the 5’ and 3’ ends of a siRNA duplex is largely 
responsible for ensuring correct selection of the guide strand for loading into the RISC 
(Khvorova et al., 2003; Schwarz et al., 2003) and an effective predictor of siRNA efficacy 
(Heale et al., 2005). An online application which ranks candidate siRNA duplexes based 
on this difference was used to design the sequences encoding shTMED-2, shKIAA-3 and 
shPRDM-3 (Section 2.1.1). 
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The specificity of all shRNA sequences was assessed using BLAST (see Section 
2.1.2) to detect off-target matches with other gene sequences. While partial matches were 
found in some instances (data not shown), no matches with the full seed region 
(nucleotides 2-8 of the guide strand) were found that might cause miRNA-like off-target 
translational suppression (Jackson et al., 2003; Jackson et al., 2006). Finally, the 
secondary structure of the shRNA sequences was assessed using the RNA Mfold 
program (Mathews et al., 1999; Zuker 2003) (Section 2.1.2). This algorithm uses free 
energy predictions to calculate the hybridization and folding of a linear RNA sequence at 
37⁰C. In all cases, the desired hairpin structure was most thermodynamically favourable 
and thus most likely to form under physiological conditions. This is important for efficient 
Dicer processing and subsequently effective RNAi silencing (Siolas et al., 2005). 
 
3.2.2 Cloning of shRNA expression cassettes and reporter targets 
For each gene a set of three U6 Pol III shRNA expression cassettes and one 
plasmid consecutively encoding each shRNA’s minimal target sequence were designed. 
Cloning of the shRNA cassettes used a rapid and simple PCR-based approach that is 
described in Section 2.3.1. The minimal target sequences were inserted by positional 
cloning into the 3’ UTR of the Renilla luciferase reporter gene expressed from the 
psiCHECK-2.2 plasmid (see Sections 2.2 and 2.3.2). This plasmid separately expresses 
Firefly luciferase, providing a useful dual-reporter system whereby knockdown of the 
minimal target RNA can be detected by measuring Renilla luciferase activity relative to 
background Firefly luciferase.  
Restriction digestions were performed with XbaI and HindIII, restriction enzymes 
whose sites flank the T/A cloning site of pTZ57R/T, to verify that individual clones had 
inserts of the correct size. Figure 3-1a (pg 60) shows the digestion products after gel 
electrophoresis: correctly inserted clones produced two bands, one of size 368 bp (the 
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insert) and another of 2840 bp (the backbone of pTZ57R/T). Insertion of the correct 
sequence was subsequently verified by sequencing the insert as shown in the partial 
electrophoretogram in Figure 3-1b. All five of the reporter target plasmids were correctly 
cloned (data not shown). Likewise, of the 15 designed shRNAs, 10 cloned correctly 
(verified by sequencing): shSPTBN-1, shSPTBN-2, shSPTBN-3, shTMED-2 (which was 
subsequently used as a positive control), shKIAA-1, shKIAA-2, shPRDM-1, shPRDM-3, 
shSP110-1 and shSP110-2. The five remaining shRNAs (shTMED-1, shTMED-3, shKIAA-
3, shPRDM-2 and shSP110-3) proved difficult to clone, specifically at the second round of 
PCR-amplification. Nevertheless, sufficient shRNA expression cassettes were correctly 
cloned to continue.  
 
3.2.3 Knockdown of luciferase reporter targets 
The ability of each expressed shRNA to inhibit its respective target sequence was 
assessed by co-transfecting each shRNA (or a non-targeting control, shHBx-5 or an 
empty vector, Mock) with its respective reporter target plasmid into HEK293T cells. After 
48 hours to allow for knockdown to occur, the cells were lysed and the relative 
luminescence of Renilla (reporter) versus Firefly luciferase activity measured (see Section 
2.6). Figure 3-2 (pg 61) shows these ratios normalised to the Mock control, empty 
pTZU6+1 (see Section 2.2). 
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Figure 3-1: Example of restriction digest and sequence data used to verify correct clones. 
a) Digestion of correctly inserted clones (lanes 2-17) with XbaI and HindIII restriction enzymes 
produced products of size 368 bp and 2840 bp after separation by ethidium bromide-stained 
agarose gel electrophoresis and visualisation under UV light. A previously sequence-verified 
shRNA clone, shTMED-2 was used as a positive control (when digested) (lane 19) and as a size 
reference for the larger digestion product when undigested (3208 bp) (lane 20). A molecular weight 
marker, O'GeneRuler™ 100 bp Plus DNA Ladder (Fermentas), was used as an additional band-
size reference in lanes 1 and 21. b) Part of an electrophoretogram showing the sequence of the 3’ 
end of the U6 promoter and the shRNA sequence for correctly cloned shTMED-2. 
 
As shown in Figure 3-2, the non-specific shRNA control (shHBx-5) did not cause 
unwanted off-target knockdown of any of the reporter target sequences relative to the 
Mock control, which serves to normalise for effects of the Pol III promoter. Moreover, all 
correctly cloned shRNAs yielded highly effective knockdown (75% or more, P < 0.01) of 
the reporter targets. This indicates that these shRNAs are being correctly expressed and 
processed by the RNAi pathway for recognition and action on their target sequences.  
 
Individual clones being verified 
500bp 
300bp 
Undigested plasmid 
Positive control 
 
b 
1     2    3     4     5     6    7     8     9    10   11  12  13   14   15   16  17  18    19   20    21 
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1000bp 
3000bp 
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Figure 3-2: Knockdown efficiency of shRNAs against luciferase reporter targets.  
Dual Luciferase Reporter Assay data compiled from several experiments. Data represent Renilla Luciferase activity relative to background Firefly Luciferase. 
The percentage target knockdown relative to Mock is indicated above each shRNA column. The x-axis is divided into 5 groups: one for each gene’s reporter 
target. Key to symbols: M is Mock; 1, 2 and 3 refer to the shRNAs targeting each gene (e.g. 2 in the TMED2 group is shTMED-2); NS is non-specific shRNA, 
shHBx-5. Sample values (n=3) were normalised to the Mock control, with error bars representing the standard error of the mean (SEM). ANOVA with 
Dunnett’s post-test comparison with Mock: ns (p > 0.05); ** (p < 0.01). 
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3.3 Accurate detection of mRNA by quantitative RT-PCR 
The ability of the shRNAs to suppress minimal target sequences does not 
necessarily translate into effective inhibition of the endogenous mRNA target. Frequently, 
secondary structure within the mRNA prevents effective RNAi knockdown (see Section 
4.6.2). To accurately detect the level of mRNA suppression by each shRNA, qRT-PCR 
assays were set up for specific target RNA quantification relative to a stably expressed 
housekeeping gene.  
 
3.3.1 Testing of non-targeting controls 
qRT-PCR is an extremely sensitive technique that requires testing with several 
controls to ensure amplification is occurring correctly. Three non-targeting shRNAs 
(shHBx-5 and shHBx-10, both targeting HBV, and shLacZ, targeting the lacZ gene of E. 
coli) (see Section 2.2) were tested to ensure that non-specific knockdown effects were not 
detected for each gene. Knockdown of SPTBN1 by shHBx-5, shHBx-10 and shLacZ is 
shown in Figure 3-3a. Figures 3-3b and c show knockdown of TMED2, KIAA1012 and 
SP110 by shHBx-5 and shLacZ. GAPDH was used as the reference gene for relative 
mRNA quantification in Figure 3-3a and b, while β-Actin was used in Figure 3-3c. Based 
on these data, shHBx-5 (from here on referred to as shHBx) was used as a non-specific 
control in subsequent experiments as it consistently showed no significant knockdown of 
the various genes tested.  
Amplification of PRDM14 showed extremely low expression levels in several cell 
lines tested (data not shown). The cycle threshold values (i.e. the point at which the PCR 
amplification rate becomes exponential) for amplification of cDNA and water blank 
samples with PRDM14-specific primers were indistinguishable. Since normal expression 
levels of this gene could not be accurately detected, it is unlikely that product would be 
detected in RNAi-suppressed samples. For this reason, this gene was not studied further. 
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Figure 3-3: Testing knockdown of SPTBN1, TMED2, KIAA1012 and SP110 by non-specific shRNA controls. 
Non-specific knockdown of SPTBN1: a) shHBx-5, shHBx-10 and shLacZ were tested for non-specific knockdown of SPTBN1 by qRT-PCR assay using 
GAPDH as housekeeping gene. Sample values (n=3, SEM) were normalised to Mock. One-way ANOVA with Dunnett’s post-test comparison with Mock: 
Not significant, ns (p > 0.05). Non-specific knockdown of TMED2, KIAA1012 and SP110: b) shHBx-5, shHBx-10 and shLacZ were tested for non-specific 
knockdown of TMED2, KIAA1012 and SP110 by qRT-PCR assay. GAPDH was used as housekeeping gene with values normalised to Mock (n=2, SEM). 
Two-way ANOVA with Bonferroni’s post-test comparison with Mock: ns (p > 0.05). c) As in b) with β-Actin used as housekeeping gene and shHBx-10 not 
tested.  
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3.3.2 Testing of positive controls 
As a positive control, shHTATSF-2, a verified shRNA targeting the HTATSF1 gene 
involved in regulating HIV-1 transcript splicing (Section 1.2.6) was tested. As shown in 
Figure 3-4a, quantification of HTATSF1 mRNA levels relative to GAPDH failed to show 
the expected knockdown. When repeated using β-actin as the reference gene (Figure 3-
4b), the expected level of knockdown (50%, P < 0.01) was obtained. This effect was seen 
in several experiments (Figure 3-3b): where GAPDH was used as the reference gene 
there was high variability between triplicate sample values and between successive 
experiments; this was overcome by using β-actin instead (Figure 3-3c). Thus, subsequent 
experiments quantified gene expression relative to β-actin.  
 
 
Figure 3-4:  Knockdown of positive control HTATSF1.  
Knockdown of positive control HTATSF1 by qRT-PCR assay using GAPDH (a) and β-actin (b) as 
housekeeping genes. Sample values (n = 3, SEM) were normalised to Mock. ANOVA with 
Dunnett’s post-test comparison with Mock: ns (p > 0.05); ** (p < 0.01). 
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Two more positive controls were tested that target viral genetic elements. The 
TZM-bl cell line contains a stably integrated Firefly luciferase reporter gene that is 
expressed by the HIV-1 LTR promoter. By transfecting these cells with a Tat expression 
cassette, transactivation of the Tat-responsive LTR promoter can be induced (Section 
1.1.3), which in turn increases reporter gene expression several fold. As shown in Figure 
3-5a and b, verified U6 promoter-expressed shRNAs targeting the LTR and Tat RNA of 
HIV-1 (shLTR and shTat, respectively - Section 2.2) were tested relative to a Mock control 
(an empty vector containing the U6 promoter). In addition, the experiment was tested in 
the presence and absence of Tat (expressed from a CMV promoter), with an empty vector 
containing the CMV promoter added in Tat’s absence to control for promoter activity.  
shLTR was designed to target a Subtype C virus LTR sequence. When this 
shRNA was tested previously as part of a long hairpin RNA (lhRNA) construct to knock 
down a Subtype C LTR-driven luciferase reporter (Barichievy et al., 2007) it yielded 90% 
knockdown in the presence of Tat (which upregulates LTR expression). When tested 
using the same conditions against a Subtype B LTR-driven reporter, it yielded only 50% 
knockdown in the presence of Tat. The data obtained here for shLTR is comparable: 
Figure 3-5a shows the effect of Tat on upregulating luciferase levels. shLTR knockdown is 
only significant in the presence of Tat (representing an infection), matching the expected 
value of 50% knockdown (P < 0.001) of this integrated Subtype B LTR-driven reporter. 
Figure 3-5b shows similar results for the second positive control, shTat. This shRNA 
yielded ~30% knockdown (P < 0.001) when its target (Tat) was added. This is lower than 
expected (Scherer et al., 2004), but may be due to higher target concentration in this 
system, where Tat was strongly expressed from a plasmid.  
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Figure 3-5: Knockdown of LTR-driven luciferase by positive controls shLTR and shTat.  
Knockdown of integrated LTR-luciferase expression in TZM-bl cells by shLTR (a) and shTat (b), 
respectively, in the presence (+) or absence (-) of the HIV-1 transcriptional transactivator protein 
Tat. Luciferase expression was quantified by qRT-PCR assay using β-Actin as housekeeping gene. 
Values were normalised to Mock (the first column) with n=3, SEM. ANOVA with Bonferroni’s post-
test comparisons (see arrows): ns (p > 0.05); *** (p <0.0001). 
 
3.3.3 Other controls used in optimising qRT-PCR assays 
Negative controls (without cDNA template) were included in every qRT-PCR assay 
for each primer set to control for contamination in the reaction. In addition, negative-RT 
controls (without Reverse transcriptase) were included regularly to check for DNA 
contamination during reverse transcription of RNA samples. Finally, the PCR product 
amplified by each set of primers (i.e. for GAPDH, SPTBN1, TMED2, KIAA1012 and 
SP110) was cloned into T/A vector pTZ57R/T to create target plasmid standards. A log10 
dilution (from 0.1 pg to10 ng) of each plasmid was then amplified by qPCR to create 
standard curves for each gene (Figure 3-6). As 10 ng of each target plasmid was 
amplified with a cycle threshold (Ct) value of 12, this amount was regularly included in 
assays as a standard to detect inter-assay variation. The standards continued to amplify 
a b 
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at this Ct value (even using β-Actin as reference gene), giving support for the reliability 
and consistency of the assays. With the necessary controls in place, verification of shRNA 
knockdown of the four remaining genes could be done. 
 
 
 
 
 
 
Figure 3-6: Standard curve of plasmid standards for each primer set 
The PCR product amplified by each gene’s primer set was cloned into a T/A plasmid and used to 
create a log standard curve for each primer set. The Ct value represents the cycle threshold, the 
number of PCR cycles at which amplification becomes exponential. 
 
3.4 shRNA-mediated knockdown of endogenous mRNA targets 
 
The ability of the designed shRNAs to knock down their endogenous mRNA 
targets was verified in both 116 cells and TZM-bl cells by qRT-PCR. Representative data 
are shown in Figures 3-7a and b, 3-8, 3-9a and b and 3-10. Figure 3-7 shows knockdown 
of SPTBN1 endogenous mRNA. Although the sample means of shSPTBN-1 and shHBx in 
Figure 3-7a show almost a two-fold decrease from the Mock, statistical analysis of intra- 
and inter-group variation made it clear that there is no significant knockdown (p > 0.05). 
Figure 3-7b (using GAPDH as housekeeping gene) provides support for the lack of 
significant knockdown of SPTBN1. Retrospective analysis of the sequences encoding 
shSPTBN-2 and shSPTBN-3 showed an error in design. As the luciferase reporter targets 
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were thus designed and cloned based on incorrect shRNA sequence information, 
knockdown of these targets could be obtained but not the endogenous mRNA.  
 
Figure 3-7: Knockdown of endogenous SPTBN1 mRNA by shRNAs.  
a) SPTBN1 knockdown in 116 cells by qRT-PCR assay using β-Actin as housekeeping gene. b) 
SPTBN1 knockdown in TZM-bl cells by qRT-PCR assay using GAPDH as housekeeping gene. 
Data normalised to Mock (n=3, SEM). ANOVA with Dunnett’s post-test comparison: ns (p > 0.05); _ 
(single data point, no statistical analysis done). 
 
As shown in Figures 3-8 and 3-9a and b, statistically significant (i.e. P < 0.05) 
knockdown of TMED2 and KIAA1012 mRNA could not be achieved, though the shRNA 
design and sequence was correct. In all cases, the maximum amount of shRNA was 
transfected with good efficiency in either 116 cells or TZM-bl cells. SP110 was the only 
gene that could be suppressed by a shRNA. SP110 mRNA was decreased relative to 
controls by ~60% by shSP110-2 (Figure 3-10, pg 70). This was the only functional shRNA 
that could be taken forward. 
 
 
 
a b 
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Figure 3-8: Knockdown of endogenous TMED2 mRNA by shRNAs.  
TMED2 knockdown in 116 cells by qRT-PCR assay using β-Actin as housekeeping gene. Data 
normalised to Mock (n=3, SEM). ANOVA with Dunnett’s post-test comparison: ns (p > 0.05). 
 
 
 
Figure 3-9: Knockdown of endogenous KIAA1012 mRNA by shRNAs.  
a) KIAA1012 knockdown in 293T cells by qRT-PCR assay using β-actin as housekeeping gene. b) 
KIAA1012 knockdown in TZM-bl cells by qRT-PCR assay using GAPDH as housekeeping gene. 
Data normalised to Mock (n=3, SEM). ANOVA with Dunnett’s post-test comparison: ns (p > 0.05). 
 
 
a b 
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Figure 3-10: Knockdown of endogenous SP110 mRNA by shRNAs.  
SP110 knockdown in TZM-bl cells by qRT-PCR assay using β-actin as housekeeping gene. Data 
normalised to Mock (n=3, SEM). ANOVA with Dunnett’s post-test comparison: ns (p > 0.05); ** (p< 
0.01). 
 
3.5 Knockdown of endogenous mRNA by siRNA SMARTpools 
 
As the majority of the designed shRNAs failed to effect significant knockdown of 
their endogenous targets, a different approach was required. Commercially available 
siRNA SMARTpools (Dharmacon, CO, USA) comprising four individual siRNAs per gene 
were purchased that are specially designed and modified for enhanced target specificity 
and are guaranteed to effect specific target knockdown of 75% or more (Section 4.6.4). 
Only siRNAs targeting SPTBN1 and SP110 were selected, as these genes seemed the 
most promising of the five originally chosen (Table 3-1). Figure 3-11 shows the 
knockdown efficacy of the SMARTpool siRNAs targeting SPTBN1 (a) and SP110 (b) over 
a range of siRNA concentrations, in comparison to a non-specific siRNA control (targeting 
HBV) (Section 2.1.3). The SMARTpool siRNAs successfully knocked down both genes by 
90% or more (at 100 nM concentration). Moreover, knockdown efficacy decreased in 
proportion to the amount of siRNA transfected. This dosage response supports RNAi as 
being the mechanism for the observed silencing.  
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Figure 3-11: Knockdown of endogenous SPTBN1 mRNA by siRNA SMARTpools. 
a) Knockdown of SPTBN1 (a) and SP110 (b), respectively, by qRT-PCR assay using β-actin as 
housekeeping gene. b) TZM-bl cells were transfected with Dharmacon® SMARTpool siRNAs at 
100, 50, 25, 10 and 5 nM concentrations. Data normalised to Non-specific control siHBV (n=3, 
SEM). ANOVA with Dunnett’s post-test comparison: ns (p > 0.05); * (p < 0.05); ** (p < 0.01).  
a 
b 
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3.6 Knockdown efficacy of shRNAs derived from pooled siRNAs 
 
The knockdown described above was mediated by siRNAs that were introduced 
into the cell cytoplasm. The activity of siRNAs is typically potent but short-lived: they are 
diluted during cell division and degraded over time. In contrast, shRNAs can be 
constitutively expressed from plasmids at a high rate (e.g. using the U6 Pol III promoter). 
This ensures a constant, large supply of RNAi effecters that can mediate longer-lasting 
knockdown than siRNAs can. For this reason, new shRNAs were designed based on the 
sequences of the siRNA pools (designated with the suffixes A-D). Because of the 
difficulties encountered during cloning of the original shRNAs, reverse primers were 
designed that incorporated the entire shRNA sequence upstream of the primer binding 
site. All the shRNAs could be cloned correctly, except for shSP110-D that had a single 
incorrect base in the promoter region. The knockdown efficacy of these shRNAs is shown 
in Figure 3-12. Though knockdown of their endogenous targets was statistically highly 
significant (P < 0.01), the difference in efficacy (approximately two-fold less) between the 
pooled siRNAs and their individual shRNA versions is striking. The inability of shSPTBN-A 
to knock down its target mRNA may be a result of target site accessibility (Section 4.6.2) 
or inefficient processing by Dicer. 
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Figure 3-12: Knockdown of SPTBN1 and SP110 by shRNAs derived from SMARTpool 
siRNAs 
Knockdown of SPTBN1 (a) and SP110 (b), respectively, by shRNAs derived from pooled siRNA 
target sequences. Gene expression quantified by qRT-PCR assay using B-actin as housekeeping 
gene. Data normalised to Mock (n=3, SEM). ANOVA with Dunnett’s post-test comparison: ns (p > 
0.05); ** (p < 0.01). 
 
a 
b 
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3.7 Delivery to SupT1 cells by electroporation 
 
One of the objectives of this project involved optimising delivery of RNAi effecters 
to SupT1 cells, a T-cell line that grows in suspension. Suspension cells are notoriously 
difficult to transfect using conventional transfection reagents. Viral vectors offer one 
alternative for delivering shRNAs to T-cells. Various types of viral vectors, their 
advantages and drawbacks are discussed in Sections 4.6.7.2 and 4.6.7.3. Another 
delivery method is electroporation. This well-characterised technique is simple and rapid 
and widely used for introducing nucleic acids and protein molecules into primary cells, 
suspension cells and other cell types that are refractory to transfection. Electroporation 
entails delivering a pulsed electrical field across the cellular membrane, creating water-
filled pores that rapidly open to allow a highly charged molecule like DNA a short period of 
time (~ 20 ms) to enter the cell before resealing (Langridge et al., 1987). 
Electroporation of SupT1 cells was attempted with eGFP-expressing plasmid using 
various protocols as outlined in Section 2.8 and Tables B-1 and B-2 (Appendix B). The 
efficacy of each experiment is summarised in Table 3-2, with values representing the 
average of three data points. The number of dead cells (staining blue) and the number of 
transfected cells (expressing GFP) are shown as a proportion of the total number of cells. 
In some cases very few cells survived the procedure – even after 24 hours outgrowth their 
numbers were too few for accurate quantification of cell viability or electroporation 
efficacy. While the different protocols tested resulted in varying levels of cell toxicity, the 
overall efficacy of the technique was disappointingly low. Thus, this technique was not be 
used in this study. 
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Table 3-2: Results of electroporation experiments (average of data in triplicate) 
Protocol Average cell death Average transfection efficacy 
Jurkat/1 Accurate quantifications not possible – cells too sparse. 
Jurkat/2 
Jurkat/3 17% 2.6% 
Jurkat/4 24% 2.5% 
Jurkat/5 0 % 0% 
Jurkat/6 0% 0% 
1/1 91% 5 % 
1/2 100% 0% 
2/1 47% 1% 
2/2 45% 2% 
3 
Accurate quantifications not possible.  
4 
5 
 
 
3.8 Delivery to SupT1 cells by transfection reagents 
 
When DharmaFECT-4 transfection reagent was tested for its ability to deliver a 
Cy3 fluorescently-labelled siRNA to SupT1 cells at three different cell densities (Section 
2.9), a moderate fluorescent signal could be observed that co-localised with individual 
cells (Figure 3-13b). Moreover, ESCORT-V transfection reagent could deliver GFP-
expressing plasmid DNA to SupT1 cells, as shown in Figure 3-13a.  
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Figure 3-13: Delivery of plasmid DNA and siRNA to SupT1 cells 
SupT1 cells transfected with GFP-expressing plasmid by ESCORT-V transfection reagent (a) and 
with Cy3-labelled siRNA by DharmaFECT-4 transfection reagent (b) were visualised by 
fluorescence microscopy 48 hours after transfection. The images represent 100 × magnification, 
except for the first picture in a) at 200 × magnification, with scale bars indicated in white for each 
magnification. 
 
 
Though the viability of the samples was not directly measured, there were no 
visible detrimental effects compared to untreated cells. The functionality of the siRNAs 
a 
b 
a 
ESCORT-V 
DharmaFECT 4 
b 
50 µm 100 µm 
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and shRNAs transfected into SupT1 cells was subsequently tested by qRT-PCR. Neither 
the siRNA SMARTpools (that had yielded impressive knockdown in TZM-bl and 293T 
cells), nor the two best shRNAs targeting each gene gave any significant knockdown in 
the SupT1 cell line (Figures 3-14 and 3-15). This indicates that the intracellular delivery of 
both RNAi effecters by transfection reagent is not high enough to yield functional 
knockdown. 
 
 
Figure 3-14: Knockdown by siRNA SMARTpools in SupT1 cells 
Knockdown of SPTBN1 (a) and SP110 (b), respectively, in SupT1 cells transfected with siRNA 
SMARTpools at 100 nM and 50 nM concentrations using DharmaFECT-4 transfection reagent. 
Gene expression quantified by qRT-PCR assay using B-actin as housekeeping gene. Data 
normalised to siHBV non-specific control (n=2, SEM). ANOVA with Dunnett’s post-test comparison: 
ns (p > 0.05). 
 
 
 
b a 
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Figure 3-15: Knockdown of SPTBN1 and SP110 by siRNA-derived shRNAs in SupT1 cells. 
The best shRNAs targeting SPTBN1 (shSPTBN-D) and SP110 (shSP110-2) were tested for their 
knockdown ability after delivery to SupT1 cells by ESCORT-V transfection reagent. Gene 
expression quantified by qRT-PCR assay using B-actin as housekeeping gene and normalised to 
Mock (n=3, SEM). ANOVA with Dunnett’s post-test comparison: ns (p > 0.05). 
 
As the RNAi effecters could not be functionally introduced (by either 
electroporation or transfection reagent) into a cell line that can be infected by HIV-1 and 
that is also closely related to the virus’ natural host cell type (CD4+ T helper cells), the rest 
of this study focused on validating the data produced by Brass et al. (2008) in TZM-bl 
cells. However, before proceeding with viral challenges of the transfected cells, it was 
important to ascertain whether the shRNAs and siRNAs developed produced any 
cytotoxic effects when introduced into cells.  
 
3.9 Cytotoxicity assay 
All the functional RNAi effecters used in this study, as well as their respective 
controls, were transfected into TZM-bl cells and the resultant cytotoxicity measured 
relative to untreated cells (Section 2.10). In addition, cells were treated with several 
concentrations of TSA as a positive control.  As shown in Figures 3-16, none of the 
shRNAs nor their controls showed significant toxicity when compared to untreated 
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controls. However, the siRNA non-specific control (siHBV) showed highly significant 
toxicity (P < 0.01), comparable to the lowest concentration of the positive control (TSA 100 
nM). As the siRNA SMARTpools do not show a significant difference in toxicity to siHBV, 
this implies that siRNA treatment in general is causing cytotoxicity. This is further 
supported by the qualitative observation that the cells transfected with siRNAs appeared 
to grow slower (data not shown) than those transfected with shRNAs. As the toxicity 
associated with siRNA transfection appeared to be slight and not specific to an individual 
siRNA’s effects, we decided that sufficient controls were in place to continue with viral 
challenge assays. 
Figure 3-16: MTT assay for RNAi-related cytotoxicity 
TZM-bl cells were treated with HDAC inhibitor Trichostatin A (TSA) at various concentrations as a 
positive control and transfected with the siRNA-derived shRNAs, siRNA pools and their respective 
controls. Mitochondrial Reductase activity was measured as solubilised formazan production 
(absorbance at 570 nm) relative to background absorbance (655 nm). Data were normalised to the 
mean of the untreated samples (n=3, SEM). ANOVA with Dunnett’s post-test comparisons with the 
untreated control (dashed lines) or with Mock and siHBV (solid lines): ns (p > 0.05), ** (p < 0.01). 
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3.10 The effect of SPTBN1 and SP110 knockdown on HIV-1 replication 
 
3.10.1 Single-round challenge of transfected cells with pseudovirus 
An initial screen was set up in TZM-bl cells after 72 hours of gene knockdown by 
shRNAs (Figure 3-17) and siRNAs (Figure 3-18, pg 82) targeting SPTBN1 and SP110, as 
well as their respective controls (Section 2.13.1). As shown in Figure 3-17a, the control 
shRNAs shLTR and shTat (targeting the viral LTR promoter and Tat transactivator-
encoding genes) and shHTATSF-2 and shLEDGF (targeting verified HIV-1 host factors, 
HTATSF1 (Section 1.2.6) and LEDGF (Section 1.2.4)) inhibit the virus to their respective 
expected levels. shLEDGF does not show significant viral inhibition as incomplete gene 
knockdown ensures sufficient gene product remains for HIV-1 to replicate unhindered 
(Vandekerckhove et al., 2006).  
The effects of shRNA-mediated knockdown on pseudovirus infection shown in 
Figure 3-17b are not statistically significant. This was confirmed by additional statistical 
analysis excluding the variable samples shSP110-B and shSP110-C (data not shown). 
This result is not surprising considering the weaker knockdown efficacy of the shRNAs 
compared to the siRNA pools. For this reason, the shRNAs were not used in the 
subsequent viral challenge assay. The challenge assay described above included 
samples transfected with siRNA (Figure 3-18). As the siRNA- and shRNA-treated cells 
were part of the same experiment, the shRNA controls (Figure 3-17a) provided support for 
the validity of the siRNA challenge data in the absence of corresponding siRNA controls. 
In contrast to the shRNA-treated cells, the data in Figure 3-18 show a significant decrease 
in viral activity when SPTBN1 is knocked down, though only at the highest siRNA 
concentration (100 nM). There was a significant difference between the untransfected 
Virus Control samples and those treated with the non-specific control siRNA targeting 
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HBV. This indicates some repressive effect of the siRNA transfection procedure on virus 
replication and/or on cell viability, as indicated by the MTT assay (Figure 3-16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-17: Changes in pseudovirus activity in cells transfected with shRNA 
a) TZM-bl cells were transfected with shRNA controls and infected 72 hours later with HIV-1 
pseudovirus (expressing a Subtype C envelope). Forty-eight hours later, LTR-Luciferase activity 
was measured relative to background Renilla Luciferase. Virus Control and No Virus control wells 
were not transfected and only assayed for LTR-Luciferase activity. All data were normalised to non-
specific shRNA control, shHBx, and analyzed by ANOVA with Dunnett’s post-test comparison (n=3, 
SEM): ns (p > 0.05), * (p < 0.05), ** (p < 0.01). b) The same experiment as in a) showing the 
shRNA data. 
 
b 
a 
b 
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Figure 3-18: Changes in pseudovirus activity in cells transfected with siRNAs 
TZM-bl cells were transfected with siRNA SMARTpools (at 100 nM and 50 nM concentrations) and 
siHBV control. After 72 hours of knockdown, cells were infected with pseudovirus (except for No 
Virus control wells).  Forty-eight hours later, LTR-Luciferase activity was measured. All data (n=3, 
SEM) normalised to siHBV. ANOVA with Dunnett’s post-test comparison with siHBV: ns (p > 0.05), 
** (P < 0.01). 
 
3.10.2 Two-part challenge of transfected cells with replication-competent virus 
After the initial screen for the requirement of each gene for pseudovirus activity, 
siRNA-transfected cells were challenged with fully replicating virus. The assay was set up 
in two parts (Figure 3-19) to mimic as closely as possible the experiments carried out by 
Brass et al. (2008). The virus used, HIV-1p81A-4 (derived from the molecular clone p81A-4) 
is capable of a full round of replication, producing assembled virions (during Part 1) that 
can infect fresh cells in a second round of infection (Part 2) (Sections 2.11 and 2.13.2). As 
shown in Figure 3-19b, only SPTBN1 was shown to have a significant effect on viral 
infection. This effect was only seen at the highest siRNA concentration (100 nM) and 
supports the pseudovirus challenge data (Figure 3-18). In addition, the gene appears to 
be required during a later stage of infection as only the Part 2 data shows a statistically 
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significant (P < 0.01) effect. However the sample means in Part 1 and 2 follow the same 
trend (compare Figure 3-19a and b). SP110 knockdown did not negatively affect TZM-bl 
cell infection by HIV-1p81A-4 (during either Part 1 or 2). This also supports the data from the 
pseudovirus challenge assay. Thus, in summary, SPTBN1 knockdown decreases HIV-1 
replication by 60-75% (P < 0.01), seemingly during the late stage of infection. While Brass 
et al. (2008) showed a similar decrease in viral activity (76%), they indicated an early-
stage role for SPTBN1. In addition, this study found no indication for SP110 as a HIV-1 
host factor, while Brass et al. showed that SP110 knockdown caused a 84% virus 
reduction during the later stages of the viral lifecycle. 
 
 
Figure 3-19: Changes in HIV-1
p81A-4
 activity in cells transfected with siRNAs  
a) TZM-bl cells transfected with siRNA SMARTpools targeting SPTBN1 and SP110, challenged 
with HIV-1
p81A-4
 72 hours post-transfection, and assayed for LTR-Luciferase activity 48 hours later 
(Part 1). b) Fresh TZM-bl cells infected with viral supernatant from Part 1 cells and assayed for 
LTR-Luciferase activity 20 hours later (Part 2). All data (n=3, SEM) normalised to siHBV. ANOVA 
with Dunnett’s post-test comparison with siHBV: ns (p > 0.05), * (P < 0.05). 
  
b a 
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CHAPTER 4 : DISCUSSION 
 
4.1 The possible roles of SPTBN1 in HIV-1 replication 
 
This study has shown that SPTBN1, but not SP110, is required for infection and 
early-stage replication of a pseudovirus expressing Subtype C envelope in TZM-bl 
reporter cells. An early role in viral replication is supported by Brass et al. (2008) who 
showed viral suppression of 76% during Part 1 of their assay by 2 individual siRNAs. In 
contrast, this study’s subsequent challenge assay with fully replicating virus showed a 
greater requirement during the later stages (post-translation up to assembly and budding 
of new virions). An important difference between this study and that published by Brass et 
al. (2008) is that Part 1 of their study was assessed by p24 assay (i.e. from viral entry to 
Gag translation), while this study measured LTR-Luciferase activity (which covers viral 
entry to Tat-induced transcription and reporter translation). Thus post-transcriptional 
modifications, export and translation of viral transcripts (apart from Tat and Rev) is not 
included in this study’s Part 1. A ―late-stage‖ classification in this study could translate into 
an ―early-stage‖ role in terms of Brass et al.’s delineation of the lifecycle. In addition, the 
Part 2 data of Brass et al. (2008) was normalized to the number of Part 1 donor cells. This 
was not possible in this study and could affect the correlation between Part 1 and 2 
samples. In spite of the above complications, the detection of this gene in all three 
challenge assays merits some discussion on its potential role(s) in HIV-1 replication. 
As mentioned in Section 1.6.1.1, spectrins crosslink actin, organize 
transmembrane proteins and regulate stability and shape of the plasma membrane. β-
spectrins interact with a wide array of membrane proteins to form a junctional complex 
and a major attachment site for the cytoskeleton to the cell membrane (Mouro-Chanteloup 
et al., 2003; Nicolas et al., 2003). These interactions occur via direct binding of various 
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forms of phospholipids (Diakowski et al., 1999). In addition, spectrins may bind calmodulin 
to cause calcium-dependant movement of the cytoskeleton at the membrane. As 
described in Sections 1.2.1, 1.2.3 and 1.2.10, multiple associations occur between the 
cytoskeleton and HIV-1 during both entry and exit from the cell, as well as during 
trafficking to and from the nucleus [reviewed by (Naghavi and Goff 2007)]. Thus, both 
early and late roles for SPTBN1 in HIV-1 replication are plausible. 
 
4.2 SP110 and HIV-1 replication  
 
SP110 was not detected as a host factor in either of the two screens performed 
here (in spite of almost-complete knockdown in the same cell line used by Brass et al., 
(2008). As mentioned in Section 1.6.1.5, this gene is recruited by EBV and stabilizes A. 
phagocytophilium gene expression. Thus a possible role in HIV-1 replication is not 
unlikely. As a retinoic acid receptor transcriptional co-activator, with a C-terminal region 
that is homologous to the Transcription Intermediary Factor 1 (TIF1) family of proteins, it’s 
most likely role would be during viral transcription (i.e. Part 1). In contrast, Brass et al. 
(2008) found only a post-Gag translation requirement for SP110.  
SP110 is also induced by the Interferon response (Regad and Chelbi-Alix 2001). 
This innate immune pathway functions to inactivate viral replication. In response, several 
viruses, including HIV-1 (Gunnery et al., 1990; Martinand et al., 1999) have evolved 
means to inhibit this cellular process.  Possibly, HIV-1 interacts with SP110 to further 
regulate this response. Apart from these factors, high SP110 expression is restricted to 
peripheral blood leukocytes (PBLs) and the spleen. Although its expression in HeLa and 
293T cells could be detected by qRT-PCR in this study, this gene’s involvement in the 
Interferon response, specifically during HIV-1 infection, may only be active in immune 
cells (e.g. PBLs (peripheral blood leukocytes), which interestingly are also the natural 
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targets of HIV-1). Thus, the inconclusive data reported for this gene in this study and by 
Brass et al. (2008) highlights the risks of using cellular models that do not represent the 
biological context of the process being studied. 
 
4.3 Comparison of viruses used in this study and by Brass et al. 
(2008) 
 
As TZM-bl reporter cells and siRNA SMARTpools were used in both studies, the 
discrepancy in results seems to reflect differences between the viruses. As the 
CAP210.2.00.E8 pseudovirus and HIV-IIIB (HTLV-IIIB/H9 from Dr Robert Gallo, NARRRP 
Catalogue Reagent 398, used by Brass et al., 2008) data agree on an early requirement 
for SPTBN1, while the HIV-1p81A-4 data indicate a later stage of involvement, we would 
expect the pseudovirus and HIV-IIIB to have common properties (particularly regarding 
cellular entry) that differ from those of HIV-1p81A-4. In contrast, HIV-IIIB is T-cell tropic (i.e. 
using CXCR4 as entry co-receptor) while both the Env-pseudotyped virus and HIV-1p81A-4 
are macrophage-tropic (i.e. using CCR5 co-receptor), the latter due to the insertion of a 
BaL strain V3 loop region into the envelope of NL4-3 virus (Chesebro et al., 1992). 
Moreover, HIV-IIIB and HIV-1p81A-4 are both Subtype B viruses while the pseudovirus has 
a Subtype C envelope. Thus these aspects of the viruses do not account for the results. 
Other differences between the viruses include the fact that the lab-adapted strain of HIV-
IIIB used by Brass et al. (2008) is deficient for the viral accessory genes nef and vpu, 
while a molecular clone (HXBc2, Genbank accession number K03455) derived from this 
strain encodes a truncated form of Vpr. It is interesting that the pseudovirus in this study is 
also lacking vpu, while HIV-1p81A-4 has an intact genome, except for the V1-V3 region 
substitution that changes its cell tropism. Since a Vpu-deficiency is common to the 
pseudovirus and HIV-IIIB, this loss-of-function may explain the pattern of results obtained.  
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Vpu has several functions in viral pathogenesis [recently reviewed by (Nomaguchi 
et al., 2008)]. Briefly, Vpu is required for virus maturation and release (Klimkait et al., 
1990). Deletion of vpu was shown to cause retention of virus at the plasma membrane, as 
a result of host Tetherin that is normally degraded by Vpu (Neil et al., 2008), and 
increased cytopathic effects (Iwatani et al., 1997). These cytopathic effects were found to 
result from association between virions / envelope protein with abnormally high levels of 
surface CD4 receptor, which is normally degraded by Vpu (Willey et al., 1992). Down-
regulation of CD4 has several functions, one being to prevent superinfection of infected 
cells (Wildum et al., 2006). Loss of these functions may have had significant implications 
on the pseudovirus data obtained in this study and the findings of Brass et al. (2008). 
While their study reported no change in CD4 surface expression after Rab6 gene 
knockdown, they did not take into account the effect of HIV-IIIB infection on CD4 levels. 
Tetherin-mediated membrane retention of virus (in the absence of Vpu) could mask a late-
acting function of SPTBN1 (and other membrane proteins) in aiding the release of virus 
particles. Alternatively, superinfection (resulting from increased CD4 levels) would place a 
greater burden on viral entry pathways, possibly making an early requirement for SPTBN1 
more pronounced than during a Vpu-regulated infection.  
As Nef also functions in down-regulating CD4 surface expression, the lack of both 
vpu and nef in HIV-IIIB may explain the stronger requirement for SPTBN1 observed by 
Brass et al. (2008). Nef also directly interacts with the Actin cytoskeleton to aid post-fusion 
trafficking (Campbell et al., 2004). Thus the loss of a putative SPTBN1 function at the 
membrane during entry may not be as debilitating in the presence of Nef (as observed in 
the pseudovirus data). Finally, cytopathic effects induced by vpu deletion could have 
diverse effects on cellular functions, making the interpretation of any one gene’s role in 
cellular or viral processes inaccurate.  
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4.4  Gene selection 
The criteria comprising the selection process used in this study to compile a list of 
individual genes representing both the early and late stages of the HIV lifecycle are 
logically and biologically sound. However, as three of the five selected genes could not be 
fully studied (PRDM14 because of low expression levels in the cell lines used; KIAA1012 
and SP110 because of target mRNA inaccessibility to the shRNAs) in viral challenge 
assays, their status as HDFs is inconclusive. Such obstacles may be prevented in future 
studies by using online databases such as the NCBI Gene Expression Omnibus (GEO) 
Dataset that provides sequence- and microarray-based expression data in a range of 
cellular types. Moreover, bioinformatic measures of target site accessibility should be 
incorporated into the shRNA design process (see Section 4.6.2) or genes selected for 
which effective RNAi effecters (at the mRNA or protein level) have been published. 
 
4.5 Broader perspectives 
 
4.5.1 Large-scale lentiviral shRNA transduction of T-cells 
A recent study by Yeung et al. (2009) used a lentiviral shRNA library to transduce 
Jurkat T-cells before infection with full-length NL4-3 virus. Such a study is far more 
valuable in representing a natural T-cell infection than siRNA screens in HeLa or 293T 
cells using lab-adapted viral strains. This study (Yeung et al., 2009) identified 252 host 
genes whose knockdown did not affect T-cell viability (over 3 weeks of selection) and that 
protected the cell from lytic viral replication. The candidates identified by Yeung et al. 
(2009) have great potential as future drug targets since cytotoxic effects resulting from 
long-term knockdown has already been ruled out, while the ability of each gene to 
completely protect the cell from virus-induced lysis (over 4 weeks of infection) has also 
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been shown. In addition, reversal of viral suppression could be achieved by reconstituting 
the inhibited gene product (for three genes), thus proving the direct and specific effects of 
the knockdown. A disadvantage of such an experiment is the incomplete genome 
coverage resulting from incomplete transduction efficiency. Also, Yeung et al. (2009) 
acknowledge several factors that can result in false negative and false positive results. 
However, by repeating such a screen several times, both coverage and accuracy can be 
improved. Moreover, by repeating such a screen in primary T-cells and macrophages (that 
are refractory to siRNA transfection but not lentiviral transduction), a shortlist of 
candidates can be assembled that can be confirmed by detailed studies of specific viral 
processes.  
On comparing their data with the three siRNA genomic screen datasets (Brass et 
al., 2008; Konig et al., 2008; Zhou et al., 2008), Yeung et al. found that their 252 genes 
were mostly distinct. However, the cellular pathways used by HIV-1 seem to be conserved 
across the studies. This is interesting, considering the differences in cell lines, viral 
strains, study design and detection assays used. They suggest that further study of these 
common cellular pathways may be more informative than focusing on individual genes 
identified. This confirms the need for using microarray analyzes of total gene expression 
profile changes, as well as robust and powerful bioinformatic algorithms that take into 
account protein interactions and molecular pathway networks in order to detect overlaps 
and patterns that might easily be missed when dealing with such large datasets. This 
study has shown that there are many reasons for which study of an individual gene might 
be discontinued. By studying the interacting proteins and functional gene networks of such 
a gene in parallel, such obstacles would have little impact on the investigative potential of 
the study. In addition, the results would be more robust and informative, with data on 
multiple interacting genes providing a biological context that does not exist in single gene 
studies.  
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4.5.2 Alternative techniques for characterizing the viral/cellular interactome 
The task of documenting the viral/cellular interactome is vast and complex. By 
combining the data obtained from a wide variety of approaches, there is a greater 
likelihood that the final picture will be a true reflection of such a dynamic process. 
Moreover, because these interactions are dynamic, using only two time-points for 
measurements (as used in this study and in all four genomic RNAi screens mentioned) 
would not detect subtle and transient changes. Thus kinetic analyzes of several viral 
markers (for example, LTR-expression, p24-Gag levels, CD4 receptor levels and total viral 
load) over time would be more informative.  
Several novel technologies have been developed for high-throughput analysis of 
protein interactions that are useful in biochemically validating the interaction data from 
standard yeast-two-hybrid (Y2H) screens. These technologies [reviewed by (Bailer and 
Haas 2009)] include: nucleic acid programmable protein arrays, NAPPA (Ramachandran 
et al., 2004), that transcribe and translate DNA printed on array chips for co-
immunoprecipitation (CoIP) assays; luminescence-based mammalian interactome 
mapping, LUMIER (Barrios-Rodiles et al., 2005), that uses luciferase-fusion proteins to 
detect protein interactions; protein fragment complementation assays, PCA (Nyfeler et al., 
2005), based on the reconstitution of a fluorescent protein when its domains (fused to the 
proteins of interest) interact and finally, mammalian protein-protein interaction trapping, 
MAPPIT (Eyckerman et al., 2001), to detect the transcriptional activity of an endogenous 
reporter gene that is activated by a signaling cascade when the proteins of interest (fused 
to the membrane receptor and signal molecule, respectively) interact.  
Other approaches to mapping the viral/cellular interactome include microarray 
analyzes of HIV-induced changes in the host transcriptome and proteome (Geiss et al., 
2000), shotgun liquid chromatography-tandem mass spectrometry (Chan et al., 2009), as 
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well as high-resolution microscopy techniques. The many applications of the latter are 
particularly exciting for viral research (Arhel et al., 2006; Brandenburg et al., 2007). 
PALM/STORM (photoactivation localization microscopy/stochastic optical reconstruction 
microscopy) combines super-resolution microscopy with superior algorithms for visualizing 
molecules at the nanometer scale and detecting individual fluorescent signals in three 
dimensions over time (Bates et al., 2007; Huang et al., 2008). In addition, single particle 
tracking and new molecular beacons have been used to study RNA localization and 
trafficking as effectively as the GFP reporter allows protein visualization (Bratu et al., 
2003; Mhlanga et al., 2005). The application of such technologies to future studies of viral 
replication and infection will enable the real-time detection of individual reporter signals in 
single live cells. This will greatly reduce the inaccuracies of previous experiments where 
averaged static signals across cell populations were used, potentially masking multiple 
subtle variations that can now be more fully explored. 
 
4.6 Factors of RNAi experiments highlighted by this study 
 
4.6.1 Primer design in PCR-based cloning of shRNAs 
The variable ease with which each shRNA could be cloned (using the two-step 
PCR approach) may be because of specific sequence combinations that make hairpin 
formation thermodynamically more favorable than template/primer binding. The second-
round PCR reverse primers were designed to bind the loop region as well as part of the 
sense strand of the first-round product, allowing hairpin formation to occur in both the 
primer and the template. In retrospect, the original primer design suggested by 
(Castanotto et al., 2002), using reverse primers that are complementary to each other 
over the loop region only, would have avoided this hairpin formation. The comparatively 
greater success at cloning the siRNA-based shRNAs (using single-round PCR with full-
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length primers, where the template did not contain hairpin-forming sequences) gives 
support for using this approach in future, as no optimization or additional reagents was 
required for efficient PCR amplification.  
 
4.6.2 Target mRNA accessibility to the RNAi machinery 
The ability of the original set of shRNAs to knock down Luciferase reporter targets 
by at least 75% (with most affording over 90% knockdown) indicates efficient Dicer 
processing of the guide strand and RISC activation. In addition, the fact that a non-
targeting shRNA showed no effect on each reporter target supports this knockdown as 
being sequence-specific. The fact that such efficiently processed and highly functional 
shRNAs had no significant effect on their endogenous mRNA targets (excepting 
shSP110-2) is likely to be a result of the inherent properties of the target mRNA. Both 
bioinformatic modeling and experimental studies have shown that the local secondary 
structure of target mRNAs affects the biological activity of siRNAs by preventing loaded 
RISCs from accessing the site (Bohula et al., 2003; Kretschmer-Kazemi Far and Sczakiel 
2003; Overhoff et al., 2005). Indeed, one way in which HIV-1 can evade RNAi is by 
altering its secondary structure to hinder target site accessibility, which in turn lowers the 
stability of the siRNA/target duplex (Westerhout et al., 2005). Moreover, a bioinformatic 
analysis of 100 siRNAs and 101 shRNAs targeted to 103 endogenous human genes 
(Shao et al., 2007) predicted that siRNA/shRNA efficacy could be improved by 40% just 
by ensuring target accessibility. Shao et al. (2007) described a measure of target 
structural accessibility (termed ΔGdisruption) that was found to be the most important 
predictor of RNAi efficacy. Such factors would be given more attention in future shRNA 
designs. 
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4.6.3 The importance of reliable reference genes and controls in qRT-PCR assays 
Target site accessibility cannot be predicted by assays like the Dual Luciferase 
Reporter Assay used in this study. The oligodeoxyribonucleotide/RNase H method has 
been used effectively to give a direct indication of target accessibility (Scherr and Rossi 
1998; Lee et al., 2002), though it cannot measure overall knockdown efficacy. A simpler 
alternative to assess the RNAi activity on the endogenous mRNA is to use qRT-PCR 
(used here to address the second objective of the study). This technique (if set up 
correctly) is both sensitive and accurate, allowing the detection of changes in RNA levels 
over a large dynamic range. 
The qRT-PCR data obtained in this study clearly shows the importance of having 
the correct controls in place. In this study, several negative and positive controls were 
tested: the no-template and negative-RT controls, target plasmid standards, as well as 
melting curve analysis, all served to ensure that the correct template (cDNA) was being 
amplified during each assay, with no contamination and with the same efficiency. Apart 
from these, two different housekeeping genes (β-actin and GAPDH) were compared for 
their reliability as references for normalizing mRNA levels. β-actin and GAPDH have been 
used as single reference genes in more than 90% of studies (Vandesompele et al., 2002). 
In spite of this, several studies on the reliability of commonly used housekeeping genes 
have shown that neither are in fact optimal reference genes (Zhong and Simons 1999; 
Selvey et al., 2001; Glare et al., 2002; Watson et al., 2007). Their expression varies 
across several tissue types tested and are affected by cell cycle activation (Radonic et al., 
2004). This is of concern as the requirement for a reference gene in mRNA detection is 
that the gene’s expression is as constant as biologically possible, without being affected 
by experimental procedures.   
In this study, where RNA was amplified by qRT-PCR from two cell lines, β-actin 
consistently proved to be more reliable than GAPDH, with the data normalized to β-actin 
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showing very little variation between replicate samples and assays. The suitability of β-
actin is further supported by the fact that the knockdown efficacies of the positive control 
shRNAs (that were previously determined by qRT-PCR) matched the data obtained in this 
study. The only discrepancy observed (for shTat) is due to differences in experimental 
setup, with the weaker knockdown observed here being attributable to the far higher 
target concentration (expressed from a plasmid) than was present when originally tested 
(expressed endogenously from a stable cell line). Moreover, the levels of LTR-driven 
reporter gene expression in the absence of Tat are so low that any knockdown would not 
be detected in comparison to the decrease detected when Tat was added. 
 
4.6.4 Off-target effects and the benefits of Dharmacon’s ON-TARGETplus 
SMARTpool technology 
An important aspect of any RNAi study is non-specific or off-target effects. The 
only comprehensive way to rule this out is to use microarrays to assess changes in the 
gene expression profile before and after RNAi treatment. As this option was not feasible in 
this project, non-specific control shRNAs (targeting the HBV genome and a host gene, 
lacZ) and a control siRNA (also targeting HBV) were tested for their effects against each 
of the genes studied. Once their reliability had been ascertained, these were included in 
every qRT-PCR assay to indicate whether knockdown effects were shRNA/siRNA-specific 
or not. Finally, the online BLAST tool was useful in screening each shRNA for non-specific 
matches between the guide sequence and other human gene sequences.  
Several aspects of Dharmacon’s ON-TARGETplus SMARTpool technology ensure 
specific silencing by the siRNAs used in this study. Firstly, chemical modifications in both 
strands (Jackson et al., 2006; Chen et al., 2008) serve to ensure that the antisense 
(guide) strand is processed and loaded into RISC and to stabilize target specificity. 
Secondly, the effect of pooling not only increases knockdown efficacy but also minimizes 
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off-target silencing by decreasing the concentration of each individual siRNA. Seed region 
filters and seed frequency analyzes (Birmingham et al., 2006; Anderson et al., 2008) have 
also been incorporated into the design of each siRNA to prevent miRNA-like off-target 
silencing of genes with seed sequence matches in their 3’-UTRs. Finally, microarray 
analyzes of the number of genes’ expression affected by these siRNAs (Anderson et al., 
2008) show a marked decrease in off-target effects.  
The SMARTselection™ design algorithm, combined with the dual-strand 
modifications and pooling, not only decrease off-target silencing but are also responsible 
for the impressive knockdown efficacy of the siRNAs. The increase in knockdown of both 
genes at the lowest concentration (5 nM - Figure 3-11) is unexpected. A possible 
explanation is that the siRNA/lipid charge ratio at such a low concentration favours 
lipoplex formation (lipid molecules complexed with DNA or RNA), enhancing transfection 
and thus knockdown efficacy. The comparatively weaker knockdown efficacy of the 
shRNAs derived from the siRNA pools is unsurprising. Not only is the pooling effect lost, 
as well as the chemical modifications that enhanced both specificity and efficiency in the 
SMARTpools, but potential variability in Dicer cleavage sites (Vermeulen et al., 2005) 
could produce guides sequences of slightly different lengths, affecting the ultimate seed 
sequence of the guide and thus its targets for knockdown. While shRNAs provide stabler, 
longer-term silencing, with Dicer processing increasing the efficiency of RISC loading (Kim 
et al., 2005; Siolas et al., 2005), the siRNA ON-TARGETplus SMARTpool technology 
provides more potent knockdown with fewer off-target effects, which was important for 
achieving the viral knockdown objective of the study. 
 
4.6.5 siRNA-related cytotoxicity 
The third aim of this project was to confirm that no significant toxicity was induced 
in the treated cells. Trypan-blue exclusion (the classical standard for measuring the 
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proportion of viable cells in a sample) detects only late apoptotic and necrotic cells where 
the plasma membrane is sufficiently damaged to allow uptake of the dye, whereas the 
MTT assay used in this study can detect apoptotic cells and distinguish them from viable 
and dead cells (Feng et al., 2002). The MTT assay assesses metabolic activity (and thus 
cell viability) by measuring mitochondrial enzyme activity and cytoplasmic NADH 
reduction. It is important to ensure that the cells to be tested have a uniform baseline 
metabolic rate. The cells tested in this study were healthy, proliferating well and not 
subjected to any extreme environmental changes before the test. They were seeded 
uniformly from one population and transfected in the same way as during previous 
knockdown assays.  The only observed toxicity (relating to siRNA transfection) may be 
related to siRNA-induced activation of the innate immune response when certain 
sequence motifs are recognized by Toll-like Receptor 7/8 (Hornung et al., 2005; Judge et 
al., 2005). This ultimately leads to sequence-independent suppression of protein synthesis 
and enhanced mRNA degradation through the activation of many host defense genes 
(Kariko et al., 2004). However, this is unlikely as siHBV has previously tested negative for 
Interferon induction (data not shown) while the design and construction of the 
SMARTpools ensures that such motifs are excluded while including chemical 
modifications that can avoid such an effect (Sioud 2008).  
Alternatively off-target silencing may have down-regulated essential gene 
functions. As described previously, several preventative measures serve to significantly 
decrease the number of off-target effects in the ON-TARGETplus SMARTpool siRNAs. 
Another possibility is that the targeted genes’ loss of function is responsible for the 
toxicity. In spite of the care taken during selection of these genes, very few of the protein 
interactions and molecular pathway interactions of the selected genes have been 
described. As with any study where relatively unknown human genes are targeted, in-
depth characterization of the gene in several cell lines would need to be done and more 
sensitive techniques than the MTT assay used to assess the exact cellular system that is 
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affected by the knockdown. However, in light of the fact that both siRNA pools and the 
siRNA control affected cell viability to a similar degree suggests a more general cause of 
toxicity.  
The transfection procedure is a likely candidate for siRNA-associated toxicity. One 
study, comparing a number of commercially available cationic liposome/lipid-based 
systems used for siRNA delivery, found that the doses required for maximum transfection 
efficiency and target knockdown also caused non-specific down-regulation of cellular 
protein expression (Spagnou et al., 2004). One of these transfection reagents is widely 
used in RNAi studies because of its high transfection efficiencies across a broad range of 
cells. In contrast, the siRNA transfection reagent used in this study (DharmaFECT 4) 
claims to have very low toxicity. Alamar blue viability assays on transfected cells 
(matching the exact conditions used in this study excepting the cell line) indicated 80% 
viability post-transfection (data unpublished, Dharmacon). The alamar blue assay is 
comparable in sensitivity (if not slightly more sensitive) to the MTT assay used here 
(Hamid et al., 2004).  
The only remaining explanation for the observed toxicity is that the untransfected, 
untreated control sample wells contained more cells than the siRNA-transfected wells 
because of cells lifting off during the two changes of culture medium in the latter. For the 
shRNA-transfected wells, the transfection mix was added directly to the medium, which is 
less disruptive to the cell monolayer. This explanation is supported by the difference in 
LTR-activity observed between the Virus Control and siHBV-treated samples in the viral 
challenge assays (Figure 3-18 for an example). In summary, it is unlikely that the siRNA 
transfection conditions are cytotoxic, with the data probably reflecting unequal baseline 
signals as a result of the transfection process.  
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4.6.6 Delivery of RNAi effecters to a T-cell line by electroporation and lipid-based 
reagents 
Another objective of this study was to determine whether shRNAs or siRNAs could 
be delivered to a T-cell line (that is permissive to natural infection by HIV) using reagents 
and tools available to us. Unfortunately, electroporation is clearly too harsh a delivery 
technique, with insufficient cells remaining for several of the tested protocols. If delivery of 
the RNAi effectors significantly affects cell viability (altering several cellular pathways’ 
normal functioning), this would severely limit our ability to accurately detect these 
pathways’ interactions with HIV. Apart from the adverse effects on viability, the delivery 
efficiency of the protocols tested here was also disappointing. In contrast, the 
DharmaFECT 4 and ESCORT-V transfection reagents showed better delivery (of siRNA 
and DNA, respectively) with no visible effects on cell viability. However, delivery was still 
inadequate for achieving the knockdown potential of the RNAi effecters. To infer the 
involvement of a gene product in viral replication very good knockdown of gene 
expression must be achieved and thus highly efficient delivery of the RNAi effecters is an 
absolute requirement.  
 
4.6.7 Alternative delivery methods 
Two alternatives to the delivery methods tested in this study are nucleofection and 
lentiviral transduction. Both have been reported to be successfully applied (Schroers et 
al., 2002; Zhou et al., 2003; Maasho et al., 2004; Anderson et al., 2007; ter Brake et al., 
2008), however they are considerably expensive. Generation of recombinant lentiviral 
vectors is also time-consuming and requires some experience.  
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4.6.7.1 Nucleofection 
Nucleofection™ is an adaptation of electroporation that delivers any nucleic acid 
directly to the nucleus (and cytoplasm) without requiring cells to be dividing. This 
technique, developed by the Amaxa biotechnology company (Lonza, Cologne, Germany), 
specializes in delivery to difficult-to-transfect cell types, including primary cells, stem cells, 
suspension cells and non-dividing cells. Nucleofection™ uses both electrical parameters 
(which can only be used on the Nucleofector™ device) and a buffer specially formulated 
for each cell type. The company’s website (www.lonzabio.com) has reports of 5 
independent researchers that have successfully transfected SupT1 cells using their 
technology, with delivery ranging from 30 to 65% and 75-98% cell viability. This technique 
is promising for transient transfection as it is simple and rapid, with a cell-type specific 
buffer and existing protocols that have been proven to work. However, in the HIV-1 gene 
therapy setting stable transfection of cells is important, thus limiting the application of this 
technique. 
 
4.6.7.2 Lentiviral transduction 
Lentiviral transduction has been developing for many years and has been used in 
a wide variety of settings including delivery of potential gene therapies to inhibit HIV-1 
[reviewed by (Escors and Breckpot 2010)]. Lentiviral vectors are attractive for gene 
therapy because stable integration of the transgene into the genome occurs, allowing 
permanent knockdown of targeted genes. Moreover, as with nucleofection, transduction of 
non-dividing, primary and stem cells is possible (Hamilton et al., 2009). Finally, these 
vectors have low immunogenic properties, making them useful for long-term challenge 
assays to detect viral resistance and changes in replication kinetics over time [reviewed 
by (Nayak and Herzog 2009)].  
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Their great potential in the gene therapy field is illustrated by a triple-therapy 
vector comprising a TAR decoy, a ribozyme targeted to CCR5 and a shRNA against 
rev/tat. This gene therapy has proved to be both safe and highly effective against HIV-1 in 
T-cells/PBMCs (peripheral blood mononuclear cells) (Li et al., 2003), hematopoietic stem 
cells, HSCs (Li et al., 2005) and in SCID-hu (severe combined immune deficient human) 
mouse-derived T-cells (Anderson et al., 2007). Effective delivery of this vector to the 
HSCs is particularly exciting, as these cells give rise to the lymphocytes and other cells of 
the humoral immune system, many of which are targets of HIV-1 infection. This therapy 
has been approved by the FDA for participation in two planned human clinical trials.  
The drawback of using any integrating viral vector is the risk of insertional 
mutagenesis occurring - a concern enhanced after three X-SCID (X-linked severe 
combined immunodeficiency) patients developed leukemia during a gene therapy trial due 
to onco-retroviral vector integration adjacent to a proto-oncogene promoter (Hacein-Bey-
Abina et al., 2003). Since then most studies use lentiviral vectors, as they tend to integrate 
distally from promoters in introns, lowering the oncogenic risk (Wu et al., 2003) or non-
integrating lentiviral vectors [reviewed by (Philpott and Thrasher 2007)] that remove this 
risk entirely while retaining their high transduction efficiency (particularly in non-dividing 
cells). Lentiviral vectors have been extensively developed for increased safety (Pauwels 
et al., 2009). However, in spite of these safety precautions there is always a chance that 
recombination between the vector and wildtype virus may occur, potentially mobilizing the 
vector and rendering it replication-competent. However, this risk may be used to our 
advantage by ensuring that the vector is spread to every cell that becomes infected 
(Morris and Rossi 2004).  
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4.6.7.3 Other viral delivery vectors 
Apart from lentiviral vectors, other popular viral vectors have been developed from 
Adenovirus (AdV), and Adeno-associated virus (AAV). AdV vectors (usually derived from 
serotypes 2 or 5) have a broad tissue-tropism [reviewed by (Lipiec et al., 2009)], can 
transduce quiescent and proliferating cells and rapidly induce strong transgene 
expression – important in infectious disease settings. Vector toxicity and immunogenicity 
(leading to rapid clearance of transduced cells) has been overcome by the generation of 
―gutless‖ AdV vectors, from which all adenovirus coding sequences (excepting the 
inverted terminal repeats, ITRs, and packaging signal, ψ) are deleted (McCaffrey et al., 
2008).  
AAVs have long-term in vivo stability, up to 6 years (Bankiewicz et al., 2006) in 
spite of mostly remaining episomal (i.e. non-integrating), which lowers concerns of 
insertional mutagenesis. The drawback of slow onset of transgene expression by single-
stranged AAVs was overcome by generation of self-complementary (sc) double-stranded 
AAVs that reach maximal expression within several days (McCarty et al., 2003; Wang et 
al., 2003). The maximum insert size of scAAV vectors (~2.2 Kb), while being prohibitive 
for most applications, is ideal for expression of RNAi triggers like shRNAs. 
In brief, while cloning and packaging high-titer viral vector preparations is a 
relatively lengthy process requiring specific resources and skills, the many developments 
and options in this field allow highly efficient transgene delivery to almost any target cell 
desired, allowing stable expression with few side effects. Moreover, while there are 
significant concerns relating to safety of these vectors, these continue to be addressed in 
each new generation of vector development. As a result, viral vectors are the most 
promising and widely used vectors for delivery of gene therapies.  
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CHAPTER 5 : CONCLUSIONS 
 
In summary, this study has verified that SPTBN1 is required for HIV-1 replication in 
a HeLa-derived cell line. However, unlike Brass et al. (2008), we have shown a later (post-
transcriptional) stage of involvement. In addition, SP110 (implicated by Brass et al. (2008) 
as a late-acting HDF) does not appear to have any involvement in the viral lifecycle. 
These discrepancies between our findings and those of Brass et al. (2008) may reflect the 
absence of several important viral accessory genes from the virus used in the latter study. 
As both studies used a HeLa-derived reporter cell line rather than CD4+ T-cells, the need 
for using physiologically representative viral and cellular models when using RNAi to study 
virus-host interactions has been highlighted. Moreover, a set of viral markers that 
represent the viral replication cycle should be measured over several time-points, to 
ensure that experiments are comprehensive and maximally informative.  
This study has accentuated several factors regarding RNAi-based knockdown 
experiments. Firstly, accessibility of the mRNA target site to RNAi activity is essential. 
Secondly, off-target knockdown effects, as well as cytotoxicity arising from the RNAi 
process, the transfection conditions or target knockdown must be carefully considered. 
Thirdly, while qRT-PCR is an immensely sensitive and powerful technique, it can give 
misleading results if reliable reference genes and controls are not used. Finally, while T-
cells appear to be refractory to efficient transfection by lipid-based reagents and 
electroporation, advances in viral delivery systems, as well as the development of newer 
approaches (like Nucleofection), have made RNAi-based research in difficult-to-transfect 
cells possible.  
Future prospects are promising as there have been major advances in our ability 
to directly visualize any host/viral molecular interaction in high resolution and in real-time 
within single live cells. These technologies are continually improving, enhancing our 
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understanding of the complex and dynamic processes that occur during a cellular HIV-1 
infection. By complementing existing approaches to confirm and characterize the 
hundreds of newly identified candidate host factors, the goal of developing novel effective 
antiviral therapies will be more easily reached. 
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APPENDIX A: Sequence information 
 
* These sequences were the intended targets but were not actually targeted due to incorrect 
insertion of the sense (anti-guide) sequence in the position of the guide sequence during design of 
shRNAs shSPTBN-2 and -3.  
 
 
 
Table A-1: Genomic location of shRNA target sequences 
Gene targeted RNAi effecter Transcript code Target location 
SPTBN1 
 
shSPTBN-1 
 
NM_003128.2 (transcript variant 1, TV1) 
NM_178313.2 (transcript variant 2, TV2) 
4864-4884 
4961-4981 
 
shSPTBN-2 
 
shSPTBN-3 
 
 
TV1 
TV2 
TV1 
TV2 
 
6121-6141* 
6218-6238* 
1896-1916* 
1993-2013* 
 
TMED2 
 
 
 
shTMED-1 
shTMED-2 
shTMED-3 
 
NM_006815.3 
 
 
 
584-604 
153-173 
162-182 
 
KIAA1012 
 
 
 
shKIAA-1 
shKIAA-2 
shKIAA-3 
 
NM_014939.3 
 
 
 
4394-4414 
536-556 
1151-1171 
 
PRDM14 
 
 
 
shPRDM-1 
shPRDM-2 
shPRDM-3 
 
NM_024504.2 
 
 
 
303-323 
1544-1564 
691-711 
 
SP110 
 
 
 
shSP110-1 
 
shSP110-2 
shSP110-3 
NM_004509.3 (TV1) 
NM_080424.2 (TV3) 
TV1 +  NM_004510.3(TV2) + TV3 
TV1 + TV2 + TV3 
2162-2182 
2234-2254 
348-368 
471-491 
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Table A-2: Genomic location of siRNA-derived shRNA target sequences 
Gene targeted RNAi effecter Transcript code Target location 
SPTBN1 
 
 
 
 
 
 
 
 
shSPTBN-A 
 
shSPTBN-B 
 
shSPTBN-C 
 
shSPTBN-D 
 
 
NM_003128.2 (transcript variant 1, TV1) 
NM_178313.2 (transcript variant 2, TV2) 
TV1 
TV2 
TV1 
TV2 
TV1 
TV2 
 
5239-5257 
5336-5354 
1664-1682 
1761-1779 
4146-4164 
4243-4261 
5876-5894 
5973-5991 
 
SP110 
 
 
 
 
 
 
shSP110-A 
 
 
shSP110-B 
shSP110-C 
shSP110-D 
 
NM_004509.3 (TV1) 
NM_004510.3 (TV2) 
NM_080424.2 (TV3) 
TV1 + TV2 + TV3 
TV1 + TV2 + TV3 
TV1 + TV2 + TV3 
 
1530-1548 
 
 
499-517 
1714-1732 
1204-1222 
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Table A-3: Primer sequences used in two-step PCR-amplification of shRNA expression 
cassettes for SPTBN1, TMED2 and KIAA1012 
Universal U6F GGATCCGATTCAAGGTCGGGCAGGAAGAGGGCCT                                                
SPTBN_1 R1 CTTTTGGGTCAGGAGAGATGTGTCAATGCGAGGCGGTGTTTCGTCCTTTCCACAA  
SPTBN_1 R2 AAAAAACCTCGCATTGACGACATCTTTTGGGTCAGGAGAGATG 
SPTBN_2 R1 ATTATGGGTCAGGTAATGCACGTAGTTAGAGTCGCGGTGTTTCGTCCTTTCCACAA 
SPTBN_2 R2 AAAAAACGACTTTAACTACGTGCATTATGGGTCAGGTAATGCA 
SPTBN_3 R1 TGATTGGGTCAGGATCAGAACTCTGTTATGATCGCGGTGTTTCGTCCTTTCCACAA 
SPTBN_3 R2 AAAAAATAGTCTTGAGACAATACTAGCTGGGTCUGGATCAGAA 
TMED_1 R1 CACAATGGGTCAGGTTGTGTTGTCGTTGATGGCTCGGTGTTTCGTCCTTTCCACAA 
 TMED_1 R2 AAAAAAGAGCCATCAACGACAACACAATGGGTCAGGTTGTGTT 
 TMED_2 R1 TATTTTGGGTCAGGACATAGCACGAGACCGTGGCCGGTGTTTCGTCCTTTCCACAA 
 TMED_2 R2 AAAAAAGGCCACGGTCTCGGGCTATTTTGGGTCAGGACATAG 
 TMED_3 R1 GCATTGGGTCAGGATGCTAACGAGATAGCACGAGCGGTGTTTCGTCCTTTCCACAA 
 TMED_3 R2 AAAAAACTCGGGCTATTTCGTTAGCATTGGGTCAGGATGCTAA 
 KIAA_1 R1 TAGTTTGGGTCAGGAACTATGACATCTACATCAGCGGTGTTTCGTCCTTTCCACAA 
 KIAA_1 R2 AAAAAAGCTGATGTAGATGTCATAGTTTGGGTCAGGAACTAT 
 KIAA_2 R1 CGTATGGGTCAGGTACGTGAAGTTGATTATTAGGCGGTGTTTCGTCCTTTCCACAA 
 KIAA_2 R2 AAAAAACCTAATAATCAACTTCACGTATGGGTCAGGTACGTGA 
 KIAA_3 R1 CTGATTGGGTCAGGTGAAGTTATAGTACAAGAGCCGGTGTTTCGTCCTTTCCACAA 
 KIAA_3 R2 AAAAAACGATCATAACAGAGTTCTGATTGGGTCAGGTGAAGT 
 
Key: Bold: BamHI; Italic: EcoRI; Bold Italic: Loop; Red: Guide sequence; Blue: U6 promoter priming; 
Underlined: Termination signal 
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Table A-4: Primer sequences used in two-step PCR-amplification of shRNA 
expression cassettes for PRDM14 and SP110 
 
PRDM_1 R1 AGAATGGGTCAGGTTCTGTAGTGTCCATAGGACGCGGTGTTTCGTCCTTTCCACAA  
 
PRDM_1 R2 AAAAAACGTCCTATGGACACTACAGAATGGGTCAGGTTCTGTA  
 
PRDM_2 R1 TGTTTGGGTCAGGAACATGAAGAATGTGGATCCGCGGTGTTTCGTCCTTTCCACAA  
 
PRDM_2 R2 AAAAAACGGATCCACATTCTTCATGTTTGGGTCAGGAACATGA  
 
PRDM_3 R1 TTATTTGGGTCAGGAATAACTGAGAGGTCCTCAGCGGTGTTTCGTCCTTTCCACAA  
 
PRDM_3 R2 AAAAAAGCTGAGGACCTCCCAGTTATTTGGGTCAGGAATAAC  
 
SP110_1 R1 CCATATGGGTCAGGTATGGTTGCGAGACATCAGGCGGTGTTTCGTCCTTTCCACAA  
 
SP110_1 R2 AAAAAAGCCTGATGTTTCGCAACCATATGGGTCAGGTATGGT  
 
SP110_2 R1 TCATTGGGTCAGGATGATGGAGTTGTCTAGGAGGCGGTGTTTCGTCCTTTCCACAA  
 
SP110_2 R2 AAAAAACCTCCTAGACAACTCCATCATTGGGTCAGGATGATGGAGT  
 
SP110_3 R1 CATTTGGGTCAGGAATGTCACCAGAAGAGACAGGCGGTGTTTCGTCCTTTCCACAA  
 
SP110_3 R2 AAAAAACCTGTCTCTTCTGGTGACATTTGGGTCAGGAATGTCA  
Key: Bold: BamHI; Italic: EcoRI; Bold Italic: Loop; Red: Guide sequence; Blue: U6 promoter priming; 
Underlined: Termination signal 
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Key: Orange: BamHI; Purple: XhoI; Dark Red: NotI; Green: NheI; Bold: Overlapping restriction 
sites; Bold Italic: Loop; Red: Guide sequence; Blue: U6 promoter priming; Underlined: Termination 
signal; R: Purine (A or G); Y: Pyrimidine (C or T) 
 
 
 
Table A-5: Primer sequences used in single-round PCR-amplification of siRNA-derived 
shRNA expression cassettes 
Universal U6F 5′ - GGATCCTCGAGCGGCCGCTAGCAAGGTCGGGCAGGAAGAGGGCC - 3′                                                 
SPTBN_A R 
5’ – AAAAAAGCCTGAARGTGAGCGCATTATTGGGTCAGGATAATACGCTCACTTTCAGGC 
GGTGTTTCGTCCTTTCCACAA – 3’ 
SPTBN_B R 
 
5’ – AAAAAACCGCATACGAGGAGCGTGTATTGGGTCAGGATATACGCTCCTCGTATGCGGC 
GGTGTTTCGTCCTTTCCACAA – 3’ 
SPTBN_C R 
 
5’ – AAAAAAGGACATGTCTTACGATGAATTTGGGTCAGGAATCCATCGTAAGACATGTCC 
GGTGTTTCGTCCTTTCCACAA – 3’ 
SPTBN_D R 
5’ – AAAAAAGTGACAAGGCCGACGATATATTGGGTCAGGATACATCGTCGGCCTTGTCAC 
GGTGTTTCGTCCTTTCCACAA – 3’ 
SP110_A R 
 
5’ – AAAAAAGGAGAARGATATCTGTTCATTTTGGGTCAGGAATGAACAGATATCTTTCTCC 
GGTGTTTCGTCCTTTCCACAA – 3’ 
SP110_B R 
 
5’ – AAAAAACRAATTAACCTGCGTGAATATTGGGTCAGGATACTCACGCAGGTTAATTTGC 
GGTGTTTCGTCCTTTCCACAA – 3’ 
SP110_C R 
 
5’ – AAAAAAGAGGATGGAACTTGGTTAATTTGGGTCAGGAATCAACCAAGTTCCATCCTC 
GGTGTTTCGTCCTTTCCACAA – 3’ 
SP110_D R 
5’ – AAAAAAGAAGATGACTCAACTTGTATTTGGGTCAGGAACACAAGTTGAGTCATCTTC 
GGTGTTTCGTCCTTTCCACAA – 3’ 
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            Key: Underlined: XhoI site; Bold: EcoRV; Bold, italic: NotI 
 
 
 
Table A-6: shRNA Target Oligonucleotide Sequences 
SPTBN1  F1 5’ - TCGAGATATCCCTCGCATTGACGACATCTTTCGACT - 3’ 
SPTBN1  F2 5’ - TTAACTACGTGCATTACGATCATAACAGAGTTCTGATGC - 3’ 
SPTBN1  R1 5’ - GTTAAAGTCGAAAGATGTCGTCAATGCGAGGGATATC - 3’ 
SPTBN1  R2 5’ - GGCCGCATCAGAACTCTGTTATGATCGTAATGCACGTA - 3’ 
TMED2  F1 5’ - TCGAGATATCGAGCCATCAACGACAACACAAGGCCA - 3’ 
TMED2  F2 5’ - CGGTCTCGGGCTATTTCTCGGGCTATTTCGTTAGCATGC - 3’ 
TMED2  R1 5’ - GACCGTGGCCTTGTGTTGTCGTTGATGGCTCGATATC - 3’ 
TMED2  R2 5’ - GGCCGCATGCTAACGAAATAGCCCGAGAAATAGCCCGA - 3’ 
KIAA1012  F1 5’ - TCGAGATATCGCTGATGTAGATGTCATAGTTCCTAA - 3’ 
KIAA1012  F2 5’ - TAATCAACTTCACGTAGGCCCTTGTACTATAACTTCAGC - 3’ 
KIAA1012  R1 5’ - GATTATTAGGAACTATGACATCTACATCAGCGATATC - 3’ 
KIAA1012  R2 5’ - GGCCGCTGAAGTTATAGTACAAGGGCCTACGTGAAGTT - 3’ 
PRDM14  F1 5’ - TCGAGATATCCGTCCTATGGACACTACAGAACGGAT - 3’ 
PRDM14  F2 5’ - CCACATTCTTCATGTTGCTGAGGACCTCCCAGTTATTGC - 3’ 
PRDM14  R1 5’ - TGTGGATCCGTTCTGTAGTGTCCATAGGACGGATATC - 3’ 
PRDM14  R2 5’ - GGCCGCAATAACTGGGAGGTCCTCAGCAACATGAAGAA - 3’ 
SP110  F1 5’ - TCGAGATATCGCCTGATTTCTCGCAACCATACCTCC - 3’ 
SP110  F2 5’ - TAGACAACTCCATCATCCTGTCTCTTCTGGTGACATTGC - 3’ 
SP110  R1 5’ - GTCTAGGAGGTATGGTTGCGAGAAATCAGGCGATATC - 3’ 
SP110  R2 5’ - GGCCGCAATGTCACCAGAAGAGACAGGATGATGGAGTT - 3’ 
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Table A-7: qRT-PCR primers 
GENE PRIMER SEQUENCE (5’-3’) 
GAPDH 
Forward (F) CAT GAG AAG TAT GAC AAC AGC CT 
Reverse (R) AGT CCT TCC ACG ATA CCA AAG T 
β-ACTIN 
F AGG TCA TCA CCA TTG GCA ATG AG 
R TCT TTG CGG ATG TCC ACG TCA 
SPTBN1 
F CCT CTG ATC GTA AAG CCA AGA C 
R CCA CTC GTG TTT CCG ATT GAG 
TMED2 
F AGC TCA CCA GAA CAA GCT AGA 
R GTC GTT GAT GGC TCT GTG TAT T 
KIAA1012 
F ACT TTC GGT GGT AAT ACT GCT G 
R GAA GCT GAT GAT ATG AGT GCT GT 
PRDM14 
F CAG GAC AAG GTG TGC TAC CC 
R GCT GCC GGA AAG GTT GGA A 
SP110 
F TCG GAA TGA GGA TGG AAC TTG G 
R CAG AGC AAA AGT CCA CTC TTC AG 
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1
 This represents the antisense sequence (guide) of the siRNA and was labeled at the 3’ end with 
the Cy3 fluorescent dye. The sense sequence is as follows: 5’-ACCUUGAAGCAUACUUCAAdTdT-
3’ (d: deoxy). 
 
 
 
 
 
 
 
Table A-8: Control siRNA/shRNAs and target primers 
siRNA/shRNA GUIDE SEQUENCE (5’-3’) 
TARGET Q-PCR PRIMERS (5’-3’) 
 
siHBV:  UUGAAGUAUGCCUCAAGGUCdG
1
 
shHBx-5: CAG AGG TGA AGC GAA GTG CAC ACG G 
shHBx-10:  CCA AGG CAC AGC TTG GAG GCT TGA A 
N/A 
shHTATSF-2: TTG CGG TAG AAC TAG ATG CGC 
shLEDGF: TCG CTT CCT CAT GCT GTC T 
HTATSF1 F: AGT GGG ACC TGG ACA AAA AGG 
HTATSF1 R: GTT CCG GGG CTT TTT CTT GTG 
LEDGF: N/A 
shLTR: TCT GAG GGA TCT CTA GTT ACT T 
shTat: GCT CTT CGT CGC TGT CTC CGC 
Firefly Luc F: (EcoRI site in bold) 
ATT AGA ATT CAT GGA AGA CGC CAA AAA C  
Firefly Luc R: (HindIII site in bold) 
ATT AGG GCC CAC TAG TAA GCT TAC CAC ATT  
TGT AGA GGT TTT AC  
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APPENDIX B: Experimental procedures 
 
1) Ethanol/EDTA precipitation 
After addition of 2.5 µl 125 mM EDTA and 30 µl of absolute ethanol, the reaction was 
incubated for 15 minutes in the dark at room temperature. Centrifugation at 12 000 × 
g for 15 minutes ensued, after which the supernatant was discarded. Finally, 30 µl of 
70% ethanol was added before centrifugation at 12 000 × g for 10 minutes, after 
which the supernatant was again discarded. 
 
2) Bacterial cell culturing 
Using aseptic technique and working near a gas flame, a scraping of frozen bacterial 
cells (e.g. DH5α E. coli cells) were inoculated into Luria Bertani (LB) broth (10 g/L 
bactro-tryptone, 5 g/L yeast extract, 5 g/L sodium chloride in distilled water and 
autoclaved), such that the final volume did not exceed 1/10th of the flask’s volume. 
The flask was incubated overnight (approximately 16 hours or until growth was in the 
log phase) at 37°C in a shaking incubator. To control for contamination, a flask was 
inoculated as described above but with 1 × ampicillin: any turbidity after overnight 
culture indicated growth of contaminants (i.e. ampicillin-resistant bacteria or fungi). 
 
3) Agar bacterial plates 
Agar plates were made by adding 1% w/v agar to LB broth (see Bacterial cell 
culturing (section 2)) and autoclaving. After cooling (without setting), 100 µg/ml 
ampicillin was added if necessary and 30-50 ml agar poured into each sterile bacterial 
plate (Greiner Bio-One, GmbH, Kremsmunster, Austria) using aseptic technique near 
a gas flame. After setting, the plates were stored at 4°C. 
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4) Chemically competent bacterial cells 
A 1 in 50 dilution of overnight bacterial culture in fresh LB broth (see Bacterial cell 
culturing (section 2)) was made and allowed to incubate at 37°C with moderate 
shaking. During incubation, the transformation buffer (100 mM CaCl2, 10 mM PIPES 
HCl, 15% v/v Glycerol) was allowed to thaw on ice. After two hours, growth was 
arrested by placing the cultures on ice for five minutes.  The cultured cells were then 
pelleted by centrifugation at 1200 × g for 15 minutes. Working aseptically and on ice, 
the supernatant was discarded and the pellet gently resuspended in 1 ml of 
transformation buffer. The volume was then made up to 20 ml with transformation 
buffer and incubated on ice for 30 minutes. Thereafter, the cells were pelleted by 
centrifugation at 500 – 700 × g for 10 minutes. The supernatant was carefully 
removed, the pellet gently resuspended in 1.5 – 2 ml transformation buffer and 
aliquots of 100 µl stored at -70°C. 
 
5) Small-scale preparations of plasmid DNA 
Bacterial cells transformed with plasmid DNA were cultured overnight (12-16 hours) in 
4 ml LB (see Bacterial cell culturing (section 2)) at 37⁰C before DNA purification using 
the  High Pure Plasmid Isolation kit (Roche, Mannheim, Germany). The culture was 
pelleted at 13 000 × g for 30 seconds and the pellet resuspended in 250 µl 
Suspension Buffer/RNase (50 mM Tris-HCl, 10 mM EDTA, pH 8, 0.1 mg/ml RNase 
A). Thereafter, 250 µl Lysis Buffer was added, mixed gently and incubated for five 
minutes at room temperature. Next 350 µl chilled Binding Buffer was added, gently 
mixed and incubated for 5 minutes on ice before centrifugation at 13 000 × g for 10 
minutes. The supernatant containing the DNA was transferred to a High Pure filter 
tube, centrifuged at 13 000 × g for one minute and the flow-through discarded. The 
resin/filter binding the DNA was washed of contaminants using 700 µl Wash Buffer II 
and centrifuged at 13 000 × g for one minute and an additional minute after discarding 
the flow-through. Finally the pure DNA was eluted by applying 100 µl Elution Buffer to 
the centre of the filter and centrifuging after one minute at 13 000 × g for a minute. 
The quantity and quality of the DNA was then measured at 260 nm relative to 280 nm 
using the NanoDrop™ 1000 spectrophotometer (Thermo Scientific). 
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6) Bulk preparations of plasmid DNA 
A scraping was taken from a 60% glycerol stock of bacterial cells transformed with the 
desired plasmid and used to inoculate 200 ml of LB supplemented with 100 µg/ml 
ampicillin for overnight culture. After approximately 16 hours of growth, the cells were 
pelleted by centrifugation at 3 040 × g for 30 minutes. During the centrifugation step, 
Qiagen HiSpeed Maxi Tips (one for each plasmid preparation) were equilibrated by 
filling with dH2O, followed by 20 ml equilibration buffer (QBT) (750 mM NaCl, 50 mM 
MOPS (pH 7.0), 15% v/v isopropanol, 0.15% v/v Triton® X-100) and allowing to empty 
by gravity flow through the resin into a waste container. After centrifugation, the 
supernatant was discarded and the pellet gently resuspended in 10 ml chilled 
resuspension buffer (P1) (50 mM Tris-chloride (pH 8.0), 10 mM EDTA, 100 µg/ml 
RNase A). The cells were lysed by addition of 10 ml lysis buffer (P2) (200 mM NaOH, 
1% w/v SDS), mixed by inversion and incubated for 5 minutes at room temperature. 
Thereafter, 10 ml chilled neutralization buffer (P3) (3 M potassium acetate, pH 5.5) 
was added, mixed by inversion and incubated for 5 minutes on ice. Centrifugation at 3 
040 × g for 20 minutes followed, after which the supernatant (free of cellular debris) 
was carefully poured into the equilibrated HiSpeed (Qiagen) tips and allowed to filter 
through the resin. The low salt and pH conditions allow the DNA to bind to the anion-
exchange resin. The HiSpeed tips were washed with 60 ml wash buffer (QC) (1 M 
NaCl, 50 mM MOPS (pH 7.0), 15% v/v isopropanol). The DNA was then eluted into a 
clean tube containing 10 ml isopropanol by addition of 15 ml elution buffer (QF) (1.25 
M NaCl, 50 mM Tris-chloride (pH 8.5), 15% v/v isopropanol), mixed and stored at -
20°C overnight. The following day, the precipitated DNA was pelleted (by 
centrifugation at      10 000 × g for 1 hour), washed by resuspension in 70% v/v 
ethanol and again centrifuged for 15 minutes. The final pellet was air-dried before 
resuspension in 200 µl dH2O. 
 
7) Mammalian cell culture 
All mammalian cell culture (including transfections) was done in a separate tissue 
culture room using sterile techniques. Handling of cultures was performed inside a 
biological laminar flow cabinet, decontaminated with Virkon® disinfectant and 70% 
ethanol, before incubation in sterile incubators fitted with HEPA (high efficiency 
particulate air) filters, warmed to 37 °C and ventilated with 5% CO2 gas. 
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i. Passage of 116, HEK293 and 293T cells 
When cells reached 80% confluency (i.e. ~80% of the culture vessel’s surface area is 
covered with an even monolayer of cells) they were passaged. This involved lifting 
the adherent cells from the surface of the culture vessel by gently washing with pre-
warmed phosphate buffered saline, PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.76 mM KH2PO4, pH 7.4) supplemented with 0.01% w/v EDTA. Once all 
the cells were in suspension a fraction of the volume (generally one quarter) was 
returned to the culture vessel (or transferred to a fresh one) and the appropriate 
culture volume made up with fresh warmed complete medium. 
 
ii. Passage of TZM-bl cells 
These cells were also passaged at 80% confluency. After removing culture medium, 
the cells were gently rinsed of residual serum with pre-warmed PBS/EDTA, being 
careful not to lift off any cells, and the rinse fluid discarded. After rinsing, sufficient 
0.25% Trypsin / 1 mM EDTA (GIBCO, Invitrogen, CA, USA) was added to cover the 
monolayer of cells. The cells were returned to the 37 °C incubator for 4 minutes or 
until the cells easily lifted from the culture vessel surface. Thereafter, fresh medium 
was added to the cell suspension (at a 3 : 1 volume ratio of medium to Trypsin), 
before returning one quarter to the culture vessel with fresh warmed complete 
medium. 
 
iii. Passage of SupT1 cells 
Unlike the 116 and TZM-bl adherent cell lines, SupT1 cells grow in suspension and 
were passaged when cell density reached ~5 × 105 cells/ml. The cell suspension was 
pelleted by centrifugation at 500 × g for 5 minutes, after which the supernatant was 
removed and the pelleted cells washed by resuspending in 1 × PBS (no EDTA 
added). The washed cells were again pelleted by centrifugation and resuspended in 
PBS. Thereafter 1/10th of the cell suspension was returned to the culture flask with 
fresh warmed complete medium. 
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8) Cell counting with a haemocytometer 
Cells were resuspended in PBS (4-5 ml) and a 50 µl sample diluted 1:2 with Trypan-
blue. After gently mixing, the sample was loaded by capillary action into both 
chambers of a haemocytometer (Hausser Scientific, Horsham, PA) covered with a 22 
× 26 mm glass coverslip (Marienfeld, Germany). After focusing on the grid under a 
light microscope, the number of white cells in four quadrants and the centre square 
were counted. The total number of cells was divided by the number of quadrants 
counted (i.e. 5), multiplied by the dilution factor (i.e. 2) and by 104. This calculation 
gives the approximate number of cells per ml and can be used to calculate the 
dilutions needed to seed the required number of cells per well. 
 
9) Algorithm for TCID50 calculation 
The Spearman-Kärber formula for calculating 50% tissue culture infectious dose 
(TCID50) is given as: 
M = xk + d[0.5 - (1/n) (r)] 
where xk is the dose of the highest dilution, r is the sum of negative responses, d is 
the spacing between dilutions and n represents the number of wells per dilution 
(Schmidt and Emmons 1989).  
 
Example of TCID50 calculation 
The following viral dilutions were used in triplicate: 4-2; 4-3; 4-4; 4-5; 4-6; 4-7; 4-8. There 
are 9 negative responses out of the 21 total responses (i.e. nine samples’ means are 
statistically significant (P < 0.05) from the mean of the No Virus control). The volume 
per well is 200 µl. 
Then:  xk = 8 (because 4-8 was the highest dilution); r = 9; d = 1 and n = 3 
Thus: M = 8 + 1[0.5 – (1/3)(9)] = -5.5 
The 50% endpoint is 4M, thus 10x = 4-5.5  
Thus the titre, x, is 3.31 TCID50s per 200 µl. 
The TCID50/ml is the above value multiplied by 5:  1.02 × 104 / ml 
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10) Electroporation protocols (two tables) 
 
Table B-1: Preset electroporation protocols 
 
 
 
 
 
 
 
 
 
 
PROTOCOL Preset – Mammalian 11 (Jurkat) 
Volume (µl) 400 200 100 
Number of 
Cells 
1 × 105 
Buffer OptiMEM DMEM OptiMEM DMEM OptiMEM DMEM 
DNA (ng) 40 
Cuvette size 
(cm) 
0.4 0.2 
Temperature 
(⁰C) 
25 (room temperature) 
Outgrowth 2 ml medium (10% FBS) 
500 µl medium (10% 
FBS) 
Waveform Exponential 
Voltage (V) 140 
Capacitance 
(µF) 
1000 
Number of 
pulses 
Single 
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Table B-2: Electroporation protocols from the literature 
a (Melkonyan et al., 1996); b (Beerens et al., 2000); c (Maroun et al., 2006); d (Chow and 
Gawler 1999; Jason et al., 2004); e (Chu et al., 1987; Baum et al., 1994; Eksioglu-Demiralp et 
al., 2003).  
 
11) Safety precautions when handling Ethidium Bromide 
Avoid inhalation or ingestion, as well as contact with the eyes or skin. Use gloves, 
separate pipettes and glassware and dispose of waste appropriately. This dye 
intercalates into nucleic acid bases and may be mutagenic and thus carcinogenic. 
PROTOCOL 1
a 2b 3c 4d 5e 
Volume (µl) 300 400 200 250 
Number of 
Cells 
7 × 106 5 × 106 2 × 106 1 × 106 2 × 106 
Buffer 
DMEM 
+ 10% 
FBS 
DMEM 
+ 10% 
FBS + 
1.25% 
DMSO 
GenePulser 
Phosphate-
buffered 
sucrose 
OptiMEM 
HEPES-
buffered 
dextrose 
DNA (µg) 30 2 5 25 5 
Cuvette size 
(cm) 
0.2 0.4 0.2 0.4 
Temperature 
(⁰C) 
25 (room temperature) 0 (ice) 
Outgrowth 
10 ml 
DMEM 
+ 10% 
FBS 
10 ml 
DMEM 
+ 10% 
FBS + 
1.25% 
DMSO 
500,000 
fresh cells 
in 27.5 ml 
medium 
1 ml DMEM + 10% FBS 
Waveform Exponential Square Exponential 
Voltage (V) 250 100 250 
Capacitance 
(µF) 
960 N/A 950 900 
Number of 
pulses 
Single 10 Single 
Pulse 
duration 
(ms) 
N/A 2 N/A 
Pulse 
interval (ms) 
N/A 100 N/A 
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APPENDIX C: Selection of genes 
 
This appendix contains tables listing the genes that were excluded or selected during 
selection of the genes to be studied. The title of each table describes each stage of the 
process, where Part 1 and 2 refers to the early and late stages, respectively, of the HIV-1 
lifecycle as defined by Brass et al. (2008). In addition, the tables themselves are adapted 
from Supplementary Table 2 published by Brass et al. (2008). The original table of genes 
was successively sorted according to criteria explained in Section 3-1. 
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Table C-1: Genes that decreased HIV-1 activity by 75% or more 
Symbol
SMARTpools, percent versus 
controls (part one, p24, or part 
two, RLU)
Symbol
SMARTpools, 
percent versus 
controls (part 
one, p24, or 
part two, RLU)
KIAA1012 11% p24 FAM76B 20% RLU
ATP6V0A1 12% RLU NDUFB7 20% RLU
FLJ90680 12% RLU NMT1 20% RLU
STAC2 12% RLU ADAM10 21% p24
ZNF512B 13% RLU RICS 22% p24
CXorf50 14% RLU EDNRA 22% RLU
DIMT1L 15% p24 MPHOSPH6  22% RLU
ASXL2 15% RLU
OST48 
(DDOST) 
22% RLU
DDX55 15% RLU PDIA6 22% RLU
CXCR4 16% p24 C3orf56 23% p24
CACNG1 16% RLU TNPO3 23% p24
FLJ10154 16% RLU ATG16L2 23% RLU
SP110 16% RLU JHDM1D 23% RLU
GABARA
PL2 
(ATG8)
17% RLU
DKFZp686O24
166
24% p24
STT3A 17% RLU SPTBN1 24% p24
NUP107 18% p24 WNT1 24% p24
THOC2 18% p24 LOC285550 24% RLU
TMED2 18% p24 PPP2R2A 24% RLU
SPCS3 18% RLU C8orf14 25% p24
TUBAL3 18% RLU GCN5L2 25% p24
C20orf174 19% p24 TIMM8A 25% RLU
C9orf131 19% RLU UBQLN4 25% RLU
PRDM14 19% RLU
AGBL5 20% p24
PNRC1 20% p24
Genes that decreased HIV activity by 75% or more
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  Table C-2: Genes that scored with two or more siRNAs in Part 1 (left) and Part 2 
(right) 
 
 
 
 
 
 
 
 
 
 
Symbol
p24 siRNAs 
(part one)
Symbol
Beta-gal siRNAs 
(scored in part 
two only)
KIAA1012 4 DDX55 3
DIMT1L 4 PRDM14 3
TNPO3 4 NMT1 3
TMED2 3 OST48 (DDOST) 3
SPTBN1 3 DKFZp686O24166 2
WNT1 3 ATP6V0A1 2
C8orf14 3 FLJ90680 2
CXCR4 2 STAC2 2
NUP107 2 CXorf50 2
AGBL5 2 FLJ10154 2
ADAM10 2 SP110 2
RICS 2 STT3A 2
SPCS3 2
EDNRA 2
PDIA6 2
ATG16L2 2
PPP2R2A 2
TIMM8A 2
2 or more siRNAs in Part 1 2 or more siRNAs in Part 2
Symbol
p24 siRNAs 
(part one)
Symbol
Beta-g l siRNAs 
(scored in part 
two only)
KIAA1012 4 DDX55 3
DIMT1L 4 PRDM14 3
TNPO3 4 NMT1 3
TMED2 3 OST48 (DDOST) 3
SPTBN1 3 DKFZp686O24166 2
WNT1 3 ATP6V0A1 2
C8orf14 3 FLJ9068 2
CXCR4 2 STAC2 2
NUP107 2 CXorf50 2
AGBL5 2 FLJ10154 2
ADAM10 2 SP110 2
RICS 2 STT3A 2
SPC 3 2
EDNRA 2
PDIA6 2
ATG16L2 2
PPP2R2A 2
TIMM8A 2
2 or more siRNAs in Part 1 2 or more siRNAs in Part 2
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Table C-3: Part 1 genes excluded due to important cellular functions 
Symbol UniProt function
OST48 (DDOST) 
Essential subunit of N-oligosaccharyl transferase enzyme which catalyzes 
the transfer of a high mannose oligosaccharide to an asparagine residue 
within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains.
ATP6V0A1
Required for assembly and activity of the vacuolar ATPase. Potential role 
in differential targeting and regulation of the enzyme for a specific 
organelle (By similarity).
STT3A
Component of the N-oligosaccharyl transferase enzyme which catalyzes 
the transfer of a high mannose oligosaccharide from a lipid-linked 
oligosaccharide donor to an asparagine residue within an Asn-X-Ser/Thr 
consensus motif in nascent polypeptide chains. N-glycosylation occurrs 
cotranslational and the complex associates with the Sec61 complex at 
the channel-forming translocon complex that mediates protein 
translocation across the endoplasmic reticulum (ER). SST3A seems to be 
involved in complex substrate specificity (By similarity).
SPCS3
Component of the microsomal signal peptidase complex which removes 
signal peptides from nascent proteins as they are translocated into the 
lumen of the endoplasmic reticulum (By similarity).
EDNRA
Receptor for endothelin-1. Mediates its action by association with G 
proteins that activate a phosphatidylinositol- calcium second messenger 
system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> 
ET3.
TIMM8A
Mitochondrial intermembrane chaperone that participates in the import 
and insertion of some multi-pass transmembrane proteins into the 
mitochondrial inner membrane. Also required for the transfer of beta-
barrel precursors from the TOM complex to the sorting and assembly 
machinery (SAM complex) of the outer membrane. Acts as a chaperone-
like protein that protects the hydrophobic precursors from aggregation 
and guide them through the mitochondrial intermembrane space. The 
TIMM8-TIMM13 complex mediates the import of proteins such as 
TIMM23, SLC25A12/ARALAR1 and SLC25A13/ARALAR2, while the 
predominant TIMM9-TIMM10 70 kDa complex mediates the import of 
much more proteins. Probably necessary for normal neurologic 
development.
Part 2 genes excluded due to important cellular functions
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 Table C-4: Final Part 1 gene selection 
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             Table C-5: Part 2 genes excluded due to important cellular functions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symbol Homologs
FLJ90680
STAC2
Stac2 (Mus musculus); Stac2_predicted (Rattus 
norvegicus); STAC2 (Canis lupus familiaris); STAC2 
(Homo sapiens)
CXorf50 CXorf50 (Homo sapiens); LOC653687 (Homo sapiens)
FLJ10154
9430010O03Rik (Mus musculus); FLJ10154 (Homo 
sapiens)
SP110
Sp110 (Rattus norvegicus); Sp110 (Mus musculus); 
SP110 (Pan troglodytes); SP110 (Homo sapiens)
PRDM14
Prdm14 (Mus musculus); LOC563151 (Danio rerio); 
PRDM14 (Canis lupus familiaris); LOC464224 (Pan 
troglodytes); PRDM14 (Homo sapiens)
ATG16L2
Atg16l2 (Mus musculus); LOC100007282 (Danio 
rerio); ATG16L2 (Canis lupus familiaris); ATG16L2 
(Homo sapiens)
DKFZp686O24166
Part 2 genes with 5 or fewer homologs
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Table C-1: Part 2 genes with five or fewer homologs 
Symbol UniProt function
DIMT1L
Specifically dimethylates two adjacent adenosines in the loop of 
a conserved hairpin near the 3'-end of 18S rRNA in the 40S 
particle (By similarity).
WNT1
Ligand for members of the frizzled family of seven 
transmembrane receptors. Probable developmental protein. May 
be a signaling molecule important in CNS development. Is likely 
to signal over only few cell diameters.
CXCR4
Receptor for the C-X-C chemokine CXCL12/SDF-1. Transduces a 
signal by increasing the intracellular calcium ions level. Involved 
in haematopoiesis and in cardiac ventricular septum formation. 
Plays also an essential role in vascularization of the 
gastrointestinal tract, probably by regulating vascular branching 
and/or remodeling processes in endothelial cells. Could be 
involved in cerebellar development. In the CNS, could mediate 
hippocampal-neuron survival. Acts as a coreceptor (CD4 being 
the primary receptor) for HIV-1 X4 isolates and as a primary 
receptor for some HIV-2 isolates. Promotes Env-mediated fusion 
of the virus.
NUP107
Essential component of nuclear pore complex. Required for the 
assembly of peripheral proteins into the nuclear pore complex.
ADAM10
Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-
|-Val-77' to its mature soluble form. Responsible for the 
proteolytic release of several other cell-surface proteins, 
including heparin-binding epidermal growth-like factor, ephrin-
A2 and for constitutive and regulated alpha-secretase cleavage 
of amyloid precursor protein (APP). Contributes to the normal 
cleavage of the cellular prion protein. Involved in the cleavage 
of the adhesion molecule L1 at the cell surface and in released 
membrane vesicles, suggesting a vesicle-based protease 
activity. Controls also the proteolytic processing of Notch and 
mediates lateral inhibition during neurogenesis (By similarity).
TNPO3
Seems to function in nuclear protein import as nuclear transport 
receptor. In vitro, mediates the nuclear import of splicing factor 
SR proteins SFRS1 and SFRS2, by recognizing phosphorylated 
RS domains.
Part 1 genes excluded due to important cellular functions
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Table C-2: Final Part 2 gene selection 
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